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Synopsis 
 1
A comprehensive summary of the work to be incorporated in the thesis 
entitled “Analysis of the Pharmaceuticals by Chromatographic Techniques” has 
been presented in two parts as follows. 
  
PART - [A]:  APPLICATION OF THE CHROMATOGRAPHY FOR THE 
SEPARATION OF ISOMERS OF SOME 
PHARMACEUTICALS. 
PART - [B]:  APPLICATION OF THE CHROMATOGRAPHY FOR THE 
IMPURITY PROFILING OF ACTIVE PHARMACEUTICAL 
INGRADIENT. 
 
Aim of Work 
 
The objective of the work is to study the use of chromatographic techniques 
for the analysis of pharmaceuticals for different applications. Pharmaceutical drugs 
are very specific in their action therefore, it is very essential to have analytical 
methodology for the separation of isomers, impurities and degradants from the desired 
substance. 
 
Experimental Approach  
 
  Development of Analytical Method                
Selection of mobile phase    
Selection of stationary phase 
Selection of column temperature and flow rate 
Selection of wave-length for detection 
Injection volume / Concentration 
Selection of diluent   
 
  Validation of Analytical Method 
System suitability/Specificity study  
Linearity study  
Precision & Intermediate precision study 
Accuracy/Recovery study 
Synopsis 
 2
Robustness study 
Solution stability study 
Limit of detection and limit of quantification 
 
PART - [A]:  APPLICATION OF THE CHROMATOGRAPHY FOR THE 
SEPARATION OF ISOMERS OF SOME 
PHARMACEUTICALS. 
 
The research work undertaken in these studies mainly addresses liquid 
chromatographic separation of different types of isomers, such as, enantiomers, 
diastereomers and E/Z isomers.  It covers method development and its validation as 
per ICH guidelines for pharmaceutical compounds.   
 
Section-I : HPLC Separation of Enantiomers of Duloxetine Hydrochloride 
 
Duloxetine (Fig. 1), [(S)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) 
propanamine] is an antidepressant drug. Duloxetine is a potent and balanced dual re-
uptake inhibitor of serotonin ( 5-hydroxytryptamine, 5-HT) and norepinephrine(NE). 
Its pharmacological effects are mainly due to (S)-enantiomer while the (R)-
enantiomer is considered to be inactive. 
 
 
S
H
N
O
 
 
 
 
 
Fig. 1 :  Chemical Structure of S(+)-Duloxetine 
Synopsis 
 3
Developed Chromatographic Parameters  
 
Mobile phase: - Sodium acetate buffer (pH 3.8; 10 mM)-acetonitrile (93:07, v v) 
Column: - Chiral-AGP (150 mm   4.0 mm, 5  m) 
Flow rate: - 1 mL/min 
Column temperature: - 20° C 
Wavelength: - 220 nm 
Injection volume: - 5 µL       
Diluent: - Mobile phase  
 
 The developed method has been validated as per ICH guideline. Interestingly, 
distomer was eluted prior to eutomer in the developed method.  The proposed method 
was found to be suitable, precise, linear, accurate and robust for the quantitative 
determination of (R)-enantiomer in bulk drug.  
 
Section-II: HPLC Separation of Two Diastereomers of 2-[4-
(Methylsulfonyl)Phenyl]-3-(3(R)-oxocyclopentyl)Propanoic Acid 
 
The title compound, 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-
oxocyclopentyl)propanoic acid (Fig. 2) has novel skeleton and is an interesting 
molecule for generation of pharmacologically active compounds. This study 
examines the efficiency of crystallization induced resolution and monitors chiral 
enrichment/separation of two diastereomers.  
 
  
 
 
S
OH
OO
OH3C
O
Fig. 2 :  Chemical Structure of 2-[4-(methylsulfonyl)phenyl]-3-  
(3(R)-oxocyclopentyl)propanoic acid 
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Developed Chromatographic Parameters 
  
Mobile phase: - 0.05 % Triflouroacetic acid in water-Acetonitrile (85:15, v/v)         
Column: - J’sphere-ODS-H80 (150 mm   4.6 mm, 4  m, YMC make, Japan) 
Flow rate: - 1 mL/min 
Column temperature: - 30° C 
Wavelength: - 228 nm 
Injection volume: - 5 µL       
Diluent: - Mobile phase 
 
The developed procedure has been evaluated over the system suitability, peak 
homogeneity, precision, limit of detection, limit of quantification, robustness and 
solution stability in order to ascertain the stability of the analytical method. It has 
been proved that proposed method is linear, precise, suitable and robust for its 
intended use. 
 
Section-III: HPLC Separation of E/Z isomers of Acrivastine 
 
Acrivastine is a second generation H1-receptor antagonist antihistamine and 
works by blocking H1 histamine receptors. It is chemically, (E)-3-{6-[(E)-1-(4-
methylphenyl)-3-pyrrolidin-1-yl-prop-1-enyl]pyridin-2-yl}prop-2-enoic acid (Fig. 3). 
The current method , which may be further optimized is discussed below. 
 
 
N
NHO
O
 
 
 
 
 
Fig. 3:  Chemical Structure of Acrivastine 
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Chromatographic Parameters  
 
Mobile phase: - 0.05 % Triflouroacetic acid in water-Acetonitrile (72:28, v/v)         
Column: - Cosmosil packed column, 5C18-PAQ (250 x 4.6, 5µm) 
Flow rate: - 1.0 mL/min 
Wavelength: - 229 nm 
Injection volume: - 5 µL 
       
The method has been validated as per ICH guideline. The proposed method 
was found to be rapid, precise, linear, accurate and robust for the quantitative 
determination of undesired Z-isomer in bulk drug. 
 
PART - [B]:  APPLICATION OF THE CHROMATOGRAPHY FOR THE 
IMPURITY PROFILING OF ACTIVE PHARMACEUTICAL 
INGRADIENT. 
  
Impurity profiling constitutes a fascinating science in pharmaceutical 
industries. One encounters several adjectives eg. known, unknown,  specified, 
unspecified, polymeric, organic volatile, metallic, inorganic, fibrous, polymorphic, 
etc. linked with the world of impurities. There are significant regulatory and IP 
consequences also linked with the world of impurities. 
 The research work undertaken in these studies mainly addresses use of 
chromatographic for the organic impurity profiling of API. Method development and 
validation for the determination of process related impurities is presented in section-I 
while formation, isolation and characterization of degradant impurities are discussed 
in section-II for drug substance.   
 
Section-I : A UPLC Method For The Determination of Process-Related 
Impurities in Azathioprine 
 
Azathioprine (Fig. 4) is the nitro imidazole derivatives of 6-mercaptopurine. It 
is an immunosuppressive drug co-administered with cyclosporine and corticoids to 
prevent rejection after transplantation. 
 
Synopsis 
 6
 
N
NNH
N
S
N
N
CH3
O2N
 
 
 
 
 Chromatographic Parameters  
 
Mobile phase: - (A) 0.05 % Triflouroacetic acid in water : (B) Acetonitrile  
Gradient Program: Time/B (%) : 1/3, 3.5/60, 4/60, 4.1/3, 5/3  
Column: - Acquity UPLC BEH C18 (100 mm   2.1 mm, 1.7  m) 
Flow rate: - 0.35 mL/min 
Wavelength: - 220 nm 
Injection volume: - 1 µL       
Diluent: - 0.1 % Ammonia in methanol  
 
 The developed method has been validated for the process-related impurities. 
Validation parameters such as, specificity, precision, accuracy, linearity, limit of 
detection and limit of quantification have been studied. The proposed method was 
found to be useful for rapid monitoring of impurities during process development.  
 
 
 
 
 
Fig. 4:  Chemical Structure of Azathioprine 
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Section-II :Isolation and Characterization of Degradation products of 
Pioglitazone Hydrochloride 
 
Pioglitazone hydrochloride (Fig. 5), is an oral anti-hyperglycemic agent which 
acts primarily by decreasing insulin resistance. It is used in the treatment of type-II 
diabetes. 
 
N O
S
NH
O
OHCl  
 
 
 
 
Stress Testing  
 
Acid degradation  
Base degradation 
Peroxide degradation  
Thermal degradation  
Photolytic degradation 
 
 Stress testing has been monitored by HPLC. The significant degradation was 
observed under base treatment. The major degradation products were isolated by 
preparative HPLC and characterized by spectroscopic teqchniques such as, Mass, 
NMR (1H and 13C), IR and UV. 
 
Fig. 5:  Chemical Structure of Pioglitazone hydrochloride 
Introduction 
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1.0 Analysis of Pharmaceuticals 
 
Pharmaceutical analysis simply means analysis of a pharmaceutical(s). 
Webster’s dictionary defines a pharmaceutical as a medicinal drug. It is generally 
known that a pharmaceutical is a chemical entity of therapeutic interest. In an ideal 
world, the need for analysis of pharmaceuticals should be driven by the desire to 
assure the quality of a drug substance and product. However, in the real world the 
need for pharmaceutical analysis is driven largely by regulatory requirements. This 
stems from the fact that regulatory considerations loom large when a commercial 
product does not meet its purported quality. A dose examination of new drug 
development quality can not be tested into the drug; it has to be built into it. This 
means that a great deal of consideration has to go in from the very start, when NCE is 
developed to assure that it has the proposed structure, crystal form and stereo 
chemical structure. Additionally, it is critical that it meet high quality standards 
necessary for a product that is to be administrated to humans. 
 The pharmaceutical industry in under increased scrutiny from the government 
and public interest groups to contain costs and get consistently deliver to market safe, 
efficacious drugs that fulfill unmet medical needs. Analytical chemistry has played a 
major role in the changes facing the pharmaceutical industry today. Traditionally, 
viewed as a service organization, the analytical department has become a significant 
partner in the drug development process. Indeed, the demand for analytical data has 
become a critical path activity for the selection of candidate molecules for full 
development. The science and technology utilized today coupled with new regulation 
that are now binding, have made pharmaceutical analysis much more complicated 
compared to what it has as little as fifteen years ago.  
The number of drugs introduced into the market is increasing every year. 
These drugs may be either new entities or partial structural modification of the 
existing one. Very often there is a time lag from the date of introduction of a drug into 
the market to the date of its inclusion in pharmacopoeias. This happens because of the 
possible uncertainties in the continuous and wider usage of these drugs, reports of 
new toxicities (resulting in their withdrawal from the market), development of patient 
resistance and introduction of better drugs by competitors. Under these conditions, 
standards and analytical procedures for these drugs may not be available in the 
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pharmacopoeias. It becomes necessary, therefore to develop newer analytical methods 
for such drugs. 
Also quality is important in every product or service but it is vital in medicines 
as it involves life. Quality control is a concept, which strives to produce a perfect 
product by series of measures designed to prevent and eliminate errors at different 
stage of production. The decision to release or reject a product is based on one or 
more type of control action. With the growth of pharmaceutical industry during last 
several years, there has been rapid progress in the field of pharmaceutical analysis 
involving complex instrumentation. 
The drugs is very specific in  their action, other than drug itself, anything 
present in bulk is consider as a impurity of that drug. It may be undesired enantiomer, 
undesired diastereomer, undesired geometric isomer, related substances, degradant, 
residual solvents, inorganic substances and any contaminant. Therefore, to control 
quality of the drug and to support process research, we needs reliable analytical 
methods for the separation and determination of all this different kinds of impurities.  
 
2.0 Chromatography 
When discussing chromatography, the first question usually asked refers to the 
name and its meaning. In other words: What is chromatography? 
            Tswett in his basic papers published in 1906 [1, 2] gave a very pragmatic 
definition: he simply stated that the method in which different components of a 
mixture are separated on an adsorbent column in a flowing system is a 
“chromatographic method.” The authors of the first books on chromatography (e.g., 
Zechmeister and Cholnoky [3] and Strain [4]) did not try to exactly define the 
technique either. The first detailed definition we could find was given by Zechmeister  
in his second book: :The term ‘chromatography’ designates those processes which 
allow the resolution of solute mixtures by selective fixation and liberation on a solid 
surface of a support , with the aid of a fluid streaming in a definite direction .” 
As is true with technique in science, chromatography was not developed at a 
certain instant, on a single day of the calendar. In fact, “chromatography “ actually 
exists in nature: the composition of fluids –liquids and gases-migrating underground 
through clay, soil , and other sediments can often be explained by a “chromatographic 
separation “ during migration. 
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Chromatography is now more than 105 years old. It was originally developed 
as a technique for the separation of plant pigments, which, according to present day 
terminology, would be termed liquid-solid (adsorption) chromatography. For the first 
20 years, may be a dozen or even fewer people utilize the new technique. The real 
upswing in the use of chromatography started in the 1930s and, in less than a decade, 
chromatography became an important laboratory technique. During this period new 
variants, such as thin-layer and ion-ex-change chromatography and electrophoresis 
also came into existence. The 1940s saw the invention of partition chromatography 
and the development of paper chromatography, another important variant of liquid 
chromatography, and, finally, gas chromatography, albeit first in the gas –solid form. 
The early 1950s brought about the development of gas-liquid partition 
chromatography, which by 1955, started an evolution hitherto unparalleled in 
laboratory techniques. Other important results originating in the 1950s are the 
utilization of ion-exchange chromatography for the analysis of amino acids, the 
development of the theory of chromatography as a differential migration process, and, 
by the end of the decade, gel filtration technique. Finally, by the middle of the 1960a 
the knowledge accumulated in the previous two decades in general chromatographic 
theory and in the practice of liquid and gas chromatography initiated the 
modernization of liquid chromatography, which, by the end of the 1960s the started 
another exponential development rapidly “catching up “ gas chromatography. 
Chromatography, in its various forms, is also a very versatile technique. It can 
be carried out in a column or on a plate, and the sample may equally be a solid, a 
liquid, or a gas. Present-day instruments used in chromatographic techniques are 
highly sophisticated, with automated controls and data handling. 
 
3.0 High Performance Liquid Chromatography (HPLC) 
HPLC was introduced to pharmaceutical analysis not long after its discovery 
in the late 1960s. By now it has developed into a generally applicable analytical 
method providing rapid and versatile separation possibilities that meet the increasing 
requirements for purity testing of bulk pharmaceuticals and pharmaceutical products. 
It is also suitable for the determination of drugs in biological and environmental 
samples. It provides a number of highly selective variants to resolve almost every type 
of separation problem: on the basis of this, HPLC and related techniques can be 
regarded as the most importance of HPLC can be characterized by the very high 
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number of books devoted to this subject. The most important ones published in the 
last decade [5-11] with emphasis of pharmaceutical and biomedical applications [12-
16] are listed. 
       In the beginning, major attempts were first made to develop highly efficient 
systems leading to a dramatic improvement in column technology using micro- 
particulate packing and to an optimized design of column hardware resulting in 
extremely low extra-column peak dispersion through the column. In the later stage, 
development of selective stationary phases was attempted. The fundamentally 
important steps in creating highly selective phase systems include rigorous control of 
surface chemistry and adjustment of the final stationary phase properties by 
appropriate mobile phase selection, leading to specific solute-surface interactions and 
suppressing undesired interactions. Similarly, significant advances in the 
instrumentation to further improve separation selectivity (detection, raw data 
manipulation, etc.) and efficiency (injection techniques, extra-column peak 
broadening, etc.) have been made. The high level of HPLC instrumentation regarding 
speed, accuracy, precision and reliability meets the special requirements of purity 
tests in pharmaceutical analysis. 
 
3.1 Instrumentation of HPLC 
 
The basic components of HPLC are pumping system, sample introduction 
device, chromatographic column, detector and data handling device  [17-21]. A 
schematic diagram of HPLC equipment is shown in Fig. 1 [22]. 
 
 
 
Fig. 1 : Schematic diagram of HPLC equipment 
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3.1.1 Pumping System 
 The HPLC pump is very important component of the system. It delivers the 
constant flow of the mobile phase. Its performance directly affects retention time, 
reproducibility and detector sensitivity. There are mainly, three types of pumps are 
used in HPLC to propel the liquid mobile phase through the system are as under 
Displacement pump: It produces a flow that tends to independent of viscosity 
and backpressure and also output is pulse free. But it possesses limited capacity  (250 
ml).  
Reciprocating pump: It has small internal volume (35 to 400 µl), their high 
output pressure (up to 10,000 psi) and their constant flow rates. But it produces a 
pulsed flow. 
Pneumatic or constant pressure pump: They are pulse free, suffer from 
limited capacity as well as a dependence of flow rate on solvent viscosity and column 
backpressure. They are limited to pressure less than 2000 psi. 
There are two type of pumping systems mode are used: isocratic and gradient. 
Isocratic: In the system, the things are kept constant throughout the run. In the 
case of pumping of mobile phase, the mobile phase composition is kept constant 
throughout the run. The nominal flow rate accuracy required is ± 1 % of the set flow    
Gradient: There is some change purposely incorporated during the particular 
sample run to achieve a better or/and faster separation. In case of pumping mobile 
phase, the composition of mobile phase is continuously varied during the particular 
run. The gradient accuracy of  ± 1 % of the step gradient composition is typical. 
 
3.1.2 Sample Introducing Device  
 It is not possible to use direct syringe injection on column like GC, as the inlet 
pressure in LC is too high. Insertion of the sample onto the pressurized column must 
be as a narrow plug so that the peak broadening attributable to this step is negligible. 
The injection system itself should have no dead (void) volume. There are three 
important ways of introducing the sample into injection port. 
Loop injection: In which, a fixed amount of volume is introduced by making 
use of fixed volume loop injector. 
Valve injection: In which, a variable volume is introduced by making use of 
an injection valve. 
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On column injection: In which, a variable volume is introduced by means of a 
syringe through a septum. 
 
3.1.3 Chromatographic Column 
 Column is a heart of chromatography. The column is usually made up of 
heavy glass or stainless steel tubing to withstand high pressure. The columns are 
usually 10-30 cm long and 4-10 mm inside diameter containing stationary phase at 
particle diameter of 25 µm or less.  
The packing used in modern HPLC column consists of small, rigid particles 
having a narrow particle size distribution. There are three main types of column 
packing in HPLC. 
Porous, polymeric beds: Porous, polymeric beds based on styrene divinyl 
benzene co-polymers used doe ion exchange and size exclusion chromatography. For 
analytical purpose these have now been replaced by silica based, packing which are 
more efficient and more stable. 
Porous layer beds: Consisting of a thin shell (1-3 µm) of silica or modified 
silica on an spherical inert core (e.g. Glass). After the development of totally porous 
micro particulate packings, these have not been used in HPLC. 
Totally Porous silica particles (dia. < 10 µm): These packing have widely 
been used for analytical HPLC in recent years. Particles of diameter > 20 µm are 
usually dry packed. While particles of diameter < 20 µm are slurry packed in which 
particles are suspended on a suitable solvent and the slurry so obtained is driven into 
the column under pressure. 
 
3.1.4 Detector 
 The function of the detector in HPLC is to monitor the mobile phase as it 
merges from the column. There are several detectors available in the market. However 
UV-Visible detector, photo diode array detector, fluorescence detector, 
conductometric and coulometric detector are more commonly used. The new ELSD 
detector is proving to be important detector, while the MS detector is outstanding. 
Detectors are usually of two types: 
Bulk property detectors: It compares overall changes in a physical property of 
the mobile phase with and without an eluting solute e.g. refractive index, dielectric 
constant or density. 
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Solute property detectors: It responds to a physical property of the solute, 
which is not exhibited by the pure mobile phase e.g. UV absorbance, fluorescence or 
diffusion current. 
 
4.0 Ultra Performance Liquid Chromatography (UPLC) 
Increasing demand for greater pharmaceutical analysis throughput promoted 
the testing of the Ultra Performance Liquid Chromatography. This system claims to 
provide faster analysis through the use of a novel separation material of a very fine 
particle size (1.7 µm) and unique core chemistry. 
 The UPLC System is up to nine times faster, has up to twice the peak 
resolution, and is up to three times more sensitive than traditional HPLC. Combine 
UPLC System with mass spectrometry systems to satisfy regulatory detection limits 
and significantly increase the throughput of laboratory. 
UPLC takes advantage of technological strides made in particle chemistry 
performance, system optimization, detector design and data processing and control. 
This new category of analytical separation science retains the practically and 
principles of HPLC while increasing the overall interlaced attributes of speed, 
sensitivity and resolution. The picture of UPLC is shown in Fig. 2. 
The UPLC system has been holistically designed to match the performance 
needs of innovative column chemistries with robust hardware, easy-to-use software. 
  Small, pressure-tolerant particles  
  High-pressure fluidic modules  
  Minimized system volume  
  Negligible carryover  
  Reduced cycle times  
  Last response detectors  
  Integrated system software and diagnostics 
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Fig. 2: Waters ACQUITY UPLC system 
 
The UPLC system’s high-pressure fluidics optimizes flow rates to make the 
most of small particle technology. The UPLC system’s sample-handling design is 
designed to ensure exceptionally low carryover and reduced cycle time. And when 
interfaced with the sample organizer, it increases unattended sample capacity by ten 
times. High-speed detectors, both optical and mass, contribute to increased sensitivity 
and help manage the heightened speed and resolution requirements of UPLC. The 
both MassLynx™ and Empower™ software support data management capabilities. 
 
5.0 Method Development 
A variety of patterns have been used to develop analytical separations. The 
discussion here is limited to conventional chromatographic approaches. These 
approaches are advanced and often based on intuitive judgment and the knowledge of 
the chromatographer. Where as individual approaches may exhibit considerable 
diversity, method development often follows the series of steps summarized below. 
Before starting the method development, it is needed to review what is known 
about the sample. The aim of method development should also define at separation 
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stage. The important information about sample of interest, which may help in method 
development strategy, there are nature of sample, number of components present, 
chemical structure, molecular weight, pKa value, solubility and sample type (ionic or 
non-ioinic). 
The choice of the mode of HPLC method should be made principally from the 
properties of the sample to be analyzed such as, molecular weight (MW), polarity and 
solubility. 
After selecting mode of HPLC, the choice of the column (stationary phase) 
should be made after thorough consideration of mode of chromatography, column-to-
column variability, and a number of other considerations. The silica particles may be 
acquired in a variety of sizes, shapes, and degrees of porosity. In addition, various 
functional groups or polymeric layers can easily be attached to the silica surface, 
extending the usefulness of these particles for applications to any specific HPLC 
method. Sufficient time is also allowed for column equilibration before starting the 
analysis. 
The selection of mobile phase is very important parameter in HPLC method 
development as changing the mobile phase altars the selectivity. When selecting 
organic solvents for use in mobile phases, various physical and chemical properties of 
the solvent should be considered. Selected solvent should have low viscosity, 
compatible with the detection system, easily available in pure form, and low 
flammability and toxicity, if possible. UV cutoff values of solvents are also important 
consideration from the stand point of detection. The term polarity concerns the ability 
of a sample or solvent molecule to interact by combination of dispersion, dipole, 
hydrogen boding, and dielectric interactions. The combination of these four 
intermolecular attractive forces constitutes the solvent polarity.  
Application of reagents such as buffers, ion-pairing reagents, or other 
modifiers (such as triethylamine) to the mobile phase is known to improve 
reproducibility, selectivity, or peak shape. Buffers are used primarily to regulate the 
pH and the acid-base equilibrium of the solute in the mobile phase. They may also be 
utilized to affect the retention times of ionizable compounds. The buffer capacity 
should be at maximum and should not vary in the pH range of 2 to 8 commonly used 
in HPLC. The buffers should be soluble, stable, inert to analytes and compatible to the 
detector. 
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By employing gradient elution mode, required % of the organic phase can be 
estimated rapidly. For aqueous sample mixtures, the best way to start is with gradient 
reversed phase chromatography. Gradient run can be started with 5 to 10% organic 
phase (acetonitile or methanol) in the mobile phase and can be increased up to 90% 
within 30 to 40 minutes. Separation can then be optimized by changing the initial 
mobile phase composition and the slope of the gradient according to the 
chromatogram obtained from the preliminary run.  
For each samples, good analytical results should be obtained by careful 
selection of the wavelength used for detection. This choice requires known UV 
spectra of the sample. If analyte standard is available, its UV spectra can be measured 
prior to HPLC method development. Alternatively, PDA detector permits the 
acquisition of UV spectra for all sample components during method development. 
The wavelength selected for detection should provide acceptable response by the 
various components in the sample and no interference of baseline noise. Alternatively, 
relative response factor can be determined if two components do not have similar 
absorbance at single wavelength. In most cases HPLC method development is carried 
out with UV detector. Alterative detectors are required when sample have low or no 
UV absorbance. 
Diluent for test preparation shall be selected at initial stage of development on 
the basis of solubility of the drug. However, optimization of the diluent is based on its 
extraction efficiency, effect on peak symmetry, peak interference in estimation and 
stability of analyte in diluent. Test concentration and injection volume shall be set 
according to suitability with extraction process and detector response. Wherever it is 
necessary to filter the test preparation, filter compatibility shall be check for selection 
of proper type of filter. 
Unfortunately, theoretical predictions of mobile phase and stationary phase 
interactions with a given set of sample components are not always accurate, but they 
do help to narrow down the choices for method development. The separation scientist 
must usually perform a series of trial and error experiments with different mobile 
phase compositions until a satisfactory separation is achieved. 
The parameters that are affected by the changes in chromatographic conditions 
are: resolution (Rs) capacity factor (k’), selectivity ( ), column efficiency (N) and 
peak asymmetry factor (As). 
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? Resolution (Rs): 
 The resolution of a column provides a quantitative measure of its ability to 
separate two analyses.  Column resolution is defined as  
 
     2 (t2-t1) 
       Rs = ------------ 
     W1+W2 
Where, 
  t1 and t2 are retention times of the first and second adjacent bands.  
 W1 and W2 are baseline at bandwidth of the peaks 
 Resolution for a given stationary phase can be improved by lengthening the 
column, thus increasing the number of plates.  Resolution can be estimated in three 
ways. 
  Calculation based on above equation 
  Comparison with standard resolution curves 
  Calculations based on the valley between the two bands. 
Resolution can be expressed in terms of three factors (k, a and N) 
 
  1       (α-1)      k 
Rs =     ---  x ------ x ------ x  N1/2 
   4        α         1+k 
Where, 
 k – Average retention factor for the two bands 
 N - Number of plates making up column 
 α – Selectivity factor 
 
? Capacity factor (k): 
 It is the measure of the how well the sample molecule is retained by the 
column during and isocratic separation 
    tR-t0 
k = --------- 
   t0 
    Where,  
    tR   -  band retention time 
    tO    -  column dead volume 
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? Selectivity ( ): 
It measures relative retention of two components.  Selectivity is found of 
chromatographic surface (column), melting point and temperature 
     
    α = -----       =  --------- 
Where, 
V1, V2 – retention volume 
V0 –void volume   
? Column efficiency (N): 
 It is called as number of theoretical plates.  It indicates good column and 
system performance.  It measure the band separation of a peak when band spread is 
smaller, the number of theoretical plate is higher. 
 
Column performance can be defines in terms of values of N 
N = 16 (tR/W)2 or 3500L (cm) dp (µm) 
HETP = L/N 
L-length of the column packing (cm) 
 
Efficiency of column can be expressed by 
  HETP = H = A + B/µ + Cµ  
Where, 
  H = plate height in centimeters 
µ = linear velocity of mobile phase in cm/sec 
A = Multipath effect (Eddy diffusion) 
B/µ  = Longitudinal diffusion 
Cµ  = Mass transfer 
 
? Peak asymmetry  
 Peak asymmetry and symmetry can result in inaccurate plate number, 
imprecise quantitation, decrease in detection limits and poor retention reproducibility 
It is calculated by 
 
k'2 
k’1 
V2-Vo 
V1-V0 
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     W0.05 
T =  -------- 
     2 f 
 
Where,  
 W0.05 =  is the width of peak at 5 % peak height 
f = distance at 5 % height from leading edge of peak to distance of peak 
maximum as measured at 5 % height. 
The increased peak asymmetry value 1.5 the sign that the column should be changed. 
6.0 Method Validation 
Validation is an act of proving that any procedure, process, equipment, 
material, activity or system performs as expected under given set of conditions and 
also give the required accuracy, precision, sensitivity, ruggedness, etc. 
When extended to an analytical procedure, the analytical method validation is 
the process of demonstrating that analytical procedures are suitable for their intended 
use. More specifically, analytical method validation is a matter of establishing 
documented evidence that provides a high degree of assurance that the specified 
method will consistently provide accurate test results that evaluate a product against 
its defined specification and quality attributes [23]. The U.S. Federal register states 
that, “validation data must be available to establish that the analytical procedures used 
in testing meet proper standards of accuracy and reliability [24].” All analytical 
procedures require some form of validation, regardless of whether the method is used 
for stability, in-process analysis, release, or acceptance testing. 
  Literature survey revealed that method validation has received considerable 
attention of industrial committees and regulatory agencies. The U.S. FDA  cGMP [25] 
states for validation for the test methods employed by the firm. The U.S. FDA has 
also proposed industry guidance for Analytical Procedures and Methods Validation 
[26]. ISO/IEC 17025 includes a chapter on the validation of methods [27] with list 
validation parameters. The ICH [28] has developed a consensus text on the validation 
of analytical procedures. It has also developed guidance on detailed methodology 
[29]. The U.S. EPA prepared guidance for method’s development and validation for 
the Resource Conservation and Recovery Act (RCRA) [30]. The AOAC, the EPA and 
other scientific organizations provide methods that are validated through multi-
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laboratory studies. The USP has published specific guidelines for method validation 
for compound evaluation [31]. The WHO published validation guidelines under the 
title, ‘Validation of analytical procedures used in the examination of pharmaceutical 
materials’ in the 32nd report of the WHO expert committee on ‘specifications for 
pharmaceutical preparations.’ 
There were papers published by representatives of the pharmaceutical and 
chemical industry on the validation of analytical methods. Hokanson [32, 33] applied 
the life cycle approach, developed for computerized systems, to the validation and 
revalidation of methods. Green [34] gave a practical guide for analytical method 
validation, with a description of a set of minimum requirements for a method. 
Wegscheider [35] has published procedures for method validation with a special focus 
on calibration, recovery experiments, method comparison and investigation of 
ruggedness. Seno et al.[36] have described how analytical methods are validated in a 
Japanese QC laboratory. The AOAC [37] has developed a Peer-Verified Methods 
validation program with detailed guidelines on exactly which parameters should be 
validated. Winslow and Meyer [38] recommend the definition and application of a 
master plan for validating analytical methods. J. Breaux and colleagues have 
published a study on analytical methods development and validation [39]. 
 
6.1 Advantages of Analytical Method Validation 
? The biggest advantage of method validation is that it builds a degree of 
confidence, not only for the developer but also to the user. 
? Although the validation exercise may appear costly and time consuming, it results 
inexpensive, eliminates frustrating repetitions and leads to better time 
management in the end. 
? Minor changes in the conditions such as reagent supplier or grade, analytical setup 
are unavoidable due to obvious reasons but the method validation absorbs the 
shock of such conditions and pays for more than invested on the process. 
 
6.2 Validation Terminology and Definitions 
It is important to define the terms used in regulatory guidelines when 
discussing method validation. Following parameters are generally validated for the 
analytical method to prove its validity for intended use. 
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Accuracy: 
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. Method accuracy is the agreement between the 
difference in the measured analyte concentrations of fortified and unfortified samples, 
the fortification procedure is called spiking. 
 
Precision: 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements from multiple sampling of the same homogeneous 
sample under prescribed conditions. Precision may be considered at three levels: 
Repeatability, intermediate precision, and reproducibility. 
 
Repeatability:  
Repeatability expresses the precision under the same operating conditions over 
a short interval of time. 
 
Intermediate Precision: 
Intermediate precision expresses within laboratories’ variations: Different 
days, different analysts, different equipment, etc. 
 
Reproducibility:   
Reproducibility expresses the precision between laboratories. 
 
Specificity:  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. 
  
Detection Limit: 
The detection limit of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily quantitated as an 
exact value, 
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Quantitation Limit:  
The quantitation limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be quantitatively determined with suitable 
precision and accuracy. 
 
Linearity: 
The linearity of an analytical procedure is its ability (within a given range) to 
obtain test results which are directly proportional to the concentration (amount) of the 
analyte in the sample. 
 
Range: 
The range of an analytical procedure is the interval between the upper and 
lower concentration (amounts) of the analyte in the sample (including these 
concentrations) for which it has been shown that the analytical procedure has a 
suitable level of precision, accuracy, and linearity. 
  
Robustness:  
The robustness of an analytical procedure is the measure of its capacity to 
remain unaffected by small, bur deliberate, variations in method parameters and 
provides an indication of its reliability during normal usage. 
 
Ruggedness: 
The degree of reproducibility of test results obtained by the analysis of the 
same samples under a variety of normal test conditions, such as different labs, 
different analysts, and different lots of reagents. Ruggedness is a measure of 
reproducibility of test results under normal, expected operational conditions from 
laboratory to laboratory and from analyst to analyst. See intermediate precision. 
 
Sensitivity:  
The sensitivity of an analytical method is equal to the slope of the calibration 
line in a linear system. 
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7.0 Isomerization 
Isomerism was first noticed in 1827, when Friedrich Woehler prepared cyanic 
acid and noted that although its elemental composition was identical to fulminic acid 
(prepared by Justus von Liebig the previous year), its properties were quite different. 
This finding challenged the prevailing chemical understanding of the time, which held 
that chemical compounds could be different only when they had different elemental 
compositions. After additional discoveries of the same sort were made, such as 
Woehler's 1828 discovery that urea had the same atomic composition as the 
chemically distinct ammonium cyanate, Jöns Jakob Berzelius introduced the term 
isomerism to describe the phenomenon. In 1849, Louis Pasteur separated tiny crystals 
of tartaric acid into their two mirror-image forms. The individual molecules of each 
were the left and right optical stereoisomers, solutions of which rotate the plane of 
polarized light in opposite directions. 
In chemistry, isomers are compounds with the same molecular formula but 
different structural formulas. The word is derived from the Greek ισοµερης, isomerès; 
isos = "equal", méros = "part". There are many different classes of isomers, like 
stereoisomers, enantiomers, geometrical isomers, etc. (see chart below). Isomers do 
not necessarily share similar properties, unless they also have the same functional 
groups. There are two main forms of isomerism: structural isomerism and 
stereoisomerism (spatial isomerism). 
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In structural isomers, the atoms and functional groups are joined together in 
different ways. This group includes chain isomerism whereby hydrocarbon chains 
have variable amounts of branching; position isomerism which deals with the position 
of a functional group on a chain; and functional group isomerism in which one 
functional group is split up into different ones. 
In skeletal isomers the main carbon chain is different between the two 
isomers. This type of isomerism is most identifiable in secondary and tertiary alcohol 
isomers. 
Tautomers are structural isomers of the same chemical substance that 
spontaneously interconvert with each other, even when pure. They have different 
chemical properties, and consequently, distinct reactions characteristic to each form 
are observed. If the interconversion reaction is fast enough, tautomers cannot be 
isolated from each other. An example is when they differ by the position of a proton, 
such as in keto/enol tautomerism, where the proton is alternately on the carbon or 
oxygen. 
In stereoisomers the bond structure is the same, but the geometrical 
positioning of atoms and functional groups in space differs. This class includes 
enantiomers where different isomers are non-superimposable mirror-images of each 
other, and diastereomers when they are not. Diastereomerism is again subdivided into 
"cis-trans isomers"", which have restricted rotation whithin the molecule (typically 
isomers containing a double bond) and "conformational isomers" (conformers), which 
can rotate about one or more single bonds whithin the molecule. Note that although 
conformers can be referred to as diastereomers, they are not stable diastereomers, 
since bonds in conformers can be rotated to make them mirror images. 
An obsolete term for "cis-trans isomerism" is "geometric isomers".  
For compounds with more than two substituents E-Z notation is used in stead of cis 
and trans. If possible, E and Z (written in italic type) is also preferred in compounds 
with two substituents. 
In octahedral coordination compounds fac- (with facial ligands) and mer- 
(with meridional ligands) isomers occur. 
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8.0 Chirality and Drug Development 
Although the optical isomers of a recemic drug can exhibit different 
pharmacological    activities in living systems [40-48], bioactive synthetic 
compounds, which comprise most of the chiral drugs, are administered as recemates 
[49]. Obviously, the more chiral centers present in a drug molecule, the more complex 
the situation. To ensure the optimum therapeutic effect, it would seem to be 
convenient to administer the eutomer. However, applying a single enantiomer to 
humans does not necessarily prevent side effects or tissue/organ damage, since, for 
example, the formation of harmful metabolites, as well as chiral inversion or 
racemization, can occur in vivo. To protect patients from unwanted and harmful 
enantiomers [40] and side effects, the possibility of a different action of the individual 
enantiomers with regard to pharmacology and toxicology had to be taken into 
account. The quality of the stereoisomer is served by chromatographic techniques, 
such as HPLC, GC, SFC, CEC and TLC. 
Among the chromatographic techniques, HPLC remains the best modality 
owing to several advantages. High speed, sensitivity, and reproducible results make 
HPLC the method of choice in almost all laboratories. Moreover, HPLC can be used 
successfully at the preparative scale. There is no serious limitation of this technique. 
About 90% of the work in chiral resolution has been achieved by means of the HPLC 
mode of chromatography. Almost all the chiral selectors are available in the form of 
HPLC columns, owing to the wide range of applications of HPLC in chiral resolution 
[44-48]. A variety of mobile phases including normal, reversed, and new polar 
organic phases are used in HPLC. The composition of the mobile phases may be 
changed by the addition of various aqueous and non-aqueous solvents. A number of 
parameters are used in the optimization of the chiral resolution. 
 
9.0 Impurities 
During the manufacturing process, whether by chemical synthesis, extraction, 
cell culture/fermentation, recovery from natural sources, or any combination of these 
processes, impurities may arise. There is an ever increasing interest in impurities 
present in API’s. Recently, not only purity profile but also impurity profile has 
become essential as per various regulatory requirements. Impurities are extraneous 
compounds that are not the drug substance (API), but arise during the synthesis, 
extraction, purification, or storage of the drug. Understanding the origin, control, and 
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measurement of impurities is critical to the production of high-quality drug 
substances. 
In addition to guidances from the local authorities of many countries, a series 
of guidances developed in recent years by the Expert Working Group of the 
International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use, commonly known as ICH, have been 
increasingly accepted by the pharmaceutical community. 
Impurities present in excess of 0.1% should be identified and quantified by 
selective methods. It is essential to know the structure of these impurities in the bulk 
drug in order to alter the reaction condition and to reduce the quantity of impurity to 
an acceptable level. Isolation, identification and quantification of impurities help us in 
various ways, to obtain a pure drug substance with less toxicity and, safety in drug 
therapy. Quantitative determination of these impurities could be used as a method for 
the quality control and validation of drug substances. Regulatory authorities such as 
US FDA, CGMP, TGA (Therapeutic Good Administration, Australia), and MCA 
(Medical Control Agency, UK) insist on the impurity profiling of drugs. 
 
9.1 Origin of impurities 
Impurities generally fall into three main categories: process impurities, 
degradation impurities, and contaminant impurities. Additionally, enantiomers and 
polymorphs may be considered impurities under some circumstances. 
Process impurities arise during the manufacture of the drug substance. 
Degradation impurities arise during the storage of the drug substance.  
Contaminant impurities are not drug related but are inadvertently introduced 
during processing or storage, and are not part of the synthesis, extraction, or 
fermentation process. Impurities that cause the greatest concern are those that are 
toxic, defined by the US Pharmacopeia (USP) as impurities that have significant 
undesirable biological activity [50]. 
 
9.2 Process Impurities  
These include inorganic impurities, organic impurities and residual solvents. 
Organic impurities may be unwanted by-products of a chemical synthesis. They may 
arise by many different routes, for example, by the reaction of an intermediate with 
the solvent rather than the desired substrate, by cyclization in the wrong direction. 
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Organic impurities can also arise from impurities in the starting materials, for 
example, traces of propylamine in butylamine may lead to the propyl analog of the 
drug substance or they may be reagents used during the reaction. Unreacted starting 
materials and intermediates may also be present as impurities in the drug substances. 
In some cases, enzymes are used during a chemical synthesis. These materials may be 
present in the drug substance as impurities. Very frequently, batches of drug 
substance made by different synthetic routes will contain different impurities. 
In a chemical synthesis, the unwanted compounds that are not removed during 
the synthetic or purification steps will become impurities. In a similar fashion, the 
extraction, purification, and later synthetic steps for natural, fermentation, or 
recombinant products may also give rise to such impurities. Biotechnological 
processes may give rise to impurities such as media components and host cell 
proteins. For animal and plant sources, the manufacturing process begins with the 
organ, fluid, or tissue of the animal or the whole plant or part of the plant. 
Understanding the source of the impurity will make it easier to devise a means of 
eliminating the impurity, thus resulting in a drug substance of improved quality. 
Inorganic impurities include water, salts from buffers, reagents, ligands, 
catalysts, heavy metals, or other residual metals, and inorganic compounds used in 
processing, such as filter aids and charcoal. Inorganic impurities can also arise by 
leaching from equipment as a result of the unit manufacturing process.     
Residual solvents are considered a subset of organic impurities. Solvents used 
to create a solution or suspension during the manufacturing process may not be 
completely eliminated in the course of manufacture. Solvents used later in the 
synthesis are more likely to be present in the drug substance, although solvents that 
have low volatility may persist from earlier steps.      
 
9.3 Degradation Impurities 
Normally, degradants are chemical breakdown compounds of the drug 
substance formed during storage. In rare cases, degradants are formed when the drug 
substance chemically interacts with other compounds or contaminants. In addition, 
degradants may also be formed by physical degradation, for example, aggregates of 
proteinaceous material, dimmers, trimers, and so forth, of synthetic compounds, 
polymorphs of synthetic compounds. Degradants may be chemically identical to 
process impurities. However, the levels of degradants will increase during storage, 
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while the levels of process impurities will remain constant. The rate of increase of 
degradants resulting from storage is dependant on the chemical nature of the drug 
substance. An understanding of the potential degradation pathways of the drug 
substance will lead to optimization of the storage conditions and will result in less 
impurities. 
 
9.4 Contamination Impurities 
Contamination impurities are unexpected adulterating compounds found in the 
drug substance. Current manufacturing technology has reduced many of the 
contaminant impurities observed in drugs prepared decades ago. For example, heavy 
metals like lead that leached from pipes or manufacturing/storage tanks gave rise to 
the commonly used limit test for heavy metals in the drug substance. Current pipes 
and tanks are primarily stainless steel or glass-lined to reduce this concern, although 
the type of material is ultimately dependent on the nature of the reactions, the nature 
of the drug substance, and the nature of the manufacturing unit operations. Other 
contaminants could be, but not likely agents sprayed to improve the environment in 
the manufacturing plant or accidental droppings like human hair or paint chips from 
walls. Disinfectants such as mono-, di-, or trichloroacetic acids or chloramines may be 
present. 
 
9.5 Control of Drug Substance Impurities 
In theory, all impurities should be eliminated. In practice, it is generally not 
economically feasible to totally eliminate all impurities. However, the levels of all 
impurities should be controlled to provide a consistent product. In most cases, only 
low levels of impurities should be allowed, but in rare cases, even quite high levels of 
impurities are tolerated. 
Generally, the reaction conditions are adjusted to reduce the amounts of by-
products produced during each step of the reaction. The reaction conditions are tightly 
controlled to prevent varying levels of impurities, or even new impurities, from 
arising. High-quality starting materials may also lead to lower amounts of impurities 
in the final product when starting material impurities are carried through to drug 
substance impurities. Similarly, the use of high-quality reagents may help avoid the 
generation of unwanted by-products. Other options to reduce these impurities are the 
introduction of additional intermediate or final purification steps. 
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1. Introduction  
 
The separation of enantiomers is an important area in the pharmaceutical 
industry. The reasons for the separation and quantitation of enantiomers in a racemic 
mixture are being addressed by the regulatory agencies of the USA, Japan and the 
European Economic Community [1-5]. The physiological environment within a living 
organism is chiral, therefore, chiral discrimination has been an issue in the 
development and use of pharmaceutical drugs. The enantiomers of chiral drugs often 
exhibit different pharmacological properties, and more and more chiral drugs are 
being developed as single isomers to avoid the use of larger doses or the risk of toxic 
effects [1, 6]. Determination of enantiomeric purity, or enantiomeric excess (ee), is of 
special importance in the control of the purity of chiral synthetic materials and chiral 
pharmaceuticals. Fast, simple and rugged stereoselective analytical methods to control 
the enantiomers are urgently needed. In the recent years, research has been intensified 
to understand the aspects of the molecular mechanism for stereoselective biological 
activities of the chiral molecules. The development of analytical methods for the 
assessment of enantiomeric purity is extremely challenging due to the fact that 
enantiomers possess virtually identical properties [7]. 
In the present study Duloxetine hydrochloride, an anti-depression drug has 
been selected. Depression is a chronic, debilitating mental disease affecting more than 
10% of the general population [8–12]. Traditional tricyclic antidepressants (TCAs) 
increase the synaptic availability of norepinephrine (NE) [13, 14]. However, 
conventional tricyclic antidepressants have a relatively high affinity for a broad range 
of receptors, including adrenergic, muscarinic and histaminergic receptors [15]. This 
low selectivity causes a wide range of adverse side effects that contribute to low 
compliance among patients. The introduction of the selective serotonin reuptake 
inhibitors (SSRIs), which have a more favourable side effect profile, shifted the 
emphasis toward a potential crucial role of serotonergic dysfunction in affective 
disorders.  
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1.1 Drug Profile 
 
1.1.1 Description  
Duloxetine (Fig.1), [(S)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) 
propanamine] is an antidepressant drug. It is a potent and balanced dual re-uptake 
inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE). Its 
pharmacological effects are mainly due to (S)-enantiomer while the (R)-enantiomer is 
considered to be inactive. Its molecular formula is C18H19NOS having molecular 
weight 333.88 g/mole. 
 
S
H
N
O
 
Fig. 1:  Chemical Structure of S(+)-Duloxetine 
 
 
1.1.2 Mechanism of Action 
 
Duloxetine belongs to a family of drugs called serotonin-norepinephrine 
reuptake inhibitors (SNRIs). Other members of this family include venlafaxine 
(Effexor XR, Effexor) and sibutramine (Meridia, Reductil). Although the exact 
mechanism of duloxetine is not precisely known, its actions are believed to be related 
to its effect on the levels of the neurotransmitters serotonin and norepinephrine in the 
central nervous system. Duloxetine weakly inhibits dopamine reuptake and has no 
significant affinity for histaminergic, dopaminergic, cholinergic or adrenergic 
receptors [16]. 
  Lab studies have shown that duloxetine is a strong inhibitor of serotonin and 
norepinephrine reuptake by brain cells. This action would theoretically raise levels of 
serotonin and norepinephrine in the spaces between brain cells (called "synapses"). 
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Increased levels of serotonin and norepinephrine in the synapses is believed to 
alleviate the symptoms of depression and anxiety.  
 
1.1.3 Clinical Use 
Duloxetine is a prescription drug for treatment of anxiety, depression, 
fibromyalgia, and diabetic neuropathy [17]. 
Major Depressive Disorder (MDD): For MDD, duloxetine is taken at a total 
dose of 40 mg daily (given as 20 mg twice daily) to 60 mg maximum daily (either 60 
mg once daily or 30 mg twice daily). Treatment of MDD remains a challenge, and a 
recent study has shown that many recently-approved antidepressants (bupropion, 
duloxetine, mirtazapine, and venlafaxine) offer comparable success rates [18].  
Diabetic Peripheral Neuropathic Pain: For diabetic peripheral neuropathic 
pain, duloxetine is taken at a total dose of 60 mg daily given once a day. The drug 
does not appear to prevent nerve damage; rather, its effects seem to be based on its 
activity at serotonin and norepinephrine receptors in mediating pain. It tends to 
increase blood glucose to a small extent, but also tends to improve patients' reported 
quality of life [19]. 
Generalized Anxiety Disorder (GAD): For GAD, duloxetine is taken at a 
total dose of 60 mg once daily. Duloxetine offers improvements in GAD symptoms as 
well as improvements in reported well-being and quality of life[20].  
 
1.1.4 Pharmacokinetic 
The Applicant has appropriately described the non-clinical pharmacokinetics 
properties for duloxetine. A number of studies concerning the absorption, distribution, 
metabolism, and excretion of duloxetine in mice, rats, and dogs have been performed. 
Rats might be suggested to be the most appropriate species for toxicology 
studies since major biotransformation pathways for duloxetine, in female rats as in 
man, were similar. However, mice and dogs are also valuable since exposure to 
specific human circulating metabolites could be seen in their plasma. Duloxetine was 
well absorbed in the mentioned species, and absorption was maximum at the 
duodenum. It did not show evidence of accumulation when duration of exposure 
increased. Duloxetine presented high protein binding across all species. Although it is 
not widely distributed it crosses the blood-brain barrier, undergoes placental transfer 
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and is excreted into milk. Duloxetine is extensively metabolised, primarily by the 
liver. The pharmacokinetics for duloxetine is summerized in Table 1.  
 
Table 1: Summary of Pharmacokinetics for Duloxetine 
Absorption 
Well absorbed. 
After oral administration: 
tmax = 1.5 h in mice, rats, dogs and monkeys 
tmax =6 h in humans; with food tmax delayed to 10 hrs 
(variable) 
Bioavailability 
Rat approximately 21%. 
Dog approximately 5%. 
Human approximately 50% (32%-80%) 
Dose proportionality 
Linear kinetics was seen in mice and rats. In dogs, linear 
kinetics was observed at low daily doses (< 30 mg/kg). 
Non-linear at and above daily doses of 30 mg/kg in dog. 
Non-linear kinetics in humans 
Terminal plasma half-life 
Mouse: 2.1 h, radioactivity half life: 27 h 
Rat: 1.5 h, radioactivity half life: 122 hrs 
Dog: 4 h, radioactivity half life: 93 h 
Monkey: 3.5 h, radioactivity half life: 91 h 
Human: 12.1 h, radioactivity half life: 120 h 
Distribution 
High protein binding (93.6%-97.3% in all species). 
Not widely distributed but crosses the blood-brain barrier. 
Distribution over placenta and excreted into milk. 
Metabolism 
Rapid and extensive metabolism. Some differences related 
to the metabolic profile and exposure exists between 
animals species and humans. 
Excretion 
Mice, rats and dogs: main route via faeces (46%-77%). 
Monkey: main route via urine (58%) 
Human: main route via urine (72%) 
Biliary excretion in rats, dogs. 
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1.1.5 Dosage 
Oral dose for adults:  
Major Depressive Disorder: Initial: 40-60 mg/day; dose may be divided (ie, 20 
or 30 mg twice daily) or given as a single daily dose of 60 mg; maintenance: 60 mg 
once daily; for doses >60 mg/day, titrate dose in increments of 30 mg/day over 1 
week as tolerated to a maximum dose: 120 mg/day. Note: Doses >60 mg/day have not 
been demonstrated to be more effective.  
 
1.1.6 Side Effects 
The most common side effects observed with duloxetine use are: 
Nausea, Vomiting, Constipation, Diarrhea, Dry mouth, Dyspepsia (indigestion), 
Loose stools, Fatigue, Asthenia (feelings of weakness), Fever, Nasopharyngitis 
(common cold symptoms), Decreased appetite, Anorexia (loss of appetite), Muscle 
cramp, Myalgia (muscle aches), Somnolence (sleepiness), Headache, Dizziness, 
Tremor, Insomnia, Frequent daytime urination (pollakiuria), Erectile dysfunction, 
Cough, Sore throat and Increased sweating. 
 
1.1.7 Risks and Precautions 
As with many other antidepressants, person taking duloxetine may develop 
suicidal thoughts, especially when the drug is first started or when the dose is changed 
[21]. 
 
1.1.8 Drug Interactions 
Since the liver enzymes CYP1A2 and CYP2D6 are responsible for duloxetine 
metabolism, concurrent use of CYP1A2 inhibitors (such as fluvoxamine and 
quinolone antibiotics) and CYP2D6 inhibitors (such as paroxetine, fluoxetine, and 
quinidine) with duloxetine is to be avoided.  
Duloxetine must not to be used with any MAO inhibitors (MAOIs) nor with 
any anti-migraine medications called triptans.  
 
1.1.9 International Brand Names 
  Ariclaim (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, 
NL, NO, PT, RU, SE, TR)  
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  Cymbalta (AR, AT, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, 
ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MX, MY, NI, NL, NO, 
PA, PE, PH, PT, RU, SE, SG, SV, TH, TR, TW)  
  Delok (IN)  
  Duxetin (UY)  
  Xeristar (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, 
NL, NO, PT, RU, SE, TR)  
  Yentreve (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IL, 
IT, MX, NL, NO, PT, RU, SE, TR, TW)  
 
1.2 Chiral AGP Column 
 
Chromtech Ltd. make Chiral-AGP column contains human alpha-acid 
glycoprotein as a stationary phase. The alpha-acid glycoprotein is a protein based 
chiral stationary phase (CSP). Proteins CSP's are defined as Type V CSP's where 
separations rely on a combination of hydrophobic and polar interactions. 
Human alpha-acid glycoprotein (shown in Fig. 2) is a polypeptide with 181 
amino acid residues and 40 sialic acid residues. It has an acidic character, its iso-
electricpoint being 2.7. It is very stable protein having two disulphide bridges. It may 
be covalently bonded to silica to produce a reverse-phase column. A very wide range 
of molecules have been separated using AGP columns. The AGP column can be used 
for the resolution of an extremely broad range of chiral compound. Such as a amines 
(primary, secondary, tertiary and quaternary ammonium.), acids, esters, sulphoxides, 
amides, alcohols etc. The enantioselectivity and the retention can easily be regulated 
by the pH of the mobile phase, the buffers concentration and the nature and the 
concentration of the organic modifier. 
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 Fig. 2: Schematic drawing of alpha-acid glycoprotein (AGP) 
 
Typical mobile phases are phosphate buffer pH 4-7 with a low percentage of 
organic modifier. The first choice of modifier is IPA. If this doesn't produce a 
separation then Acetonitrile, Ethanol, Methanol or THF should be tried. Changing the 
modifier, results in a temporary change in the protein structure. Column loading is of 
vital importance. Changing the pH has a critical effect on the selectivity, especially 
for amines. The most important tool in the method development is the pH, the reason 
is that by changing the pH the net charge of the chiral selectors as well as the charge 
of the solute can be changed, which affect the way the analytes interacts with the 
chiral selectors. AGP has a low isoelectric point of 2.7, this means that using column 
at pH 2.7 gives a net charge of zero of the chiral stationary phase, increasing the pH 
from 2.7 to 7 means that the degree of net negative charge of the chiral selectors 
increases. The charge distribution, at different pH is shown in Fig. 3. This gives the 
prerequisites for ionic binding of positively charge solutes resulting in a high affinity 
and high retention of the solute, a change of the net charge of the chiral selectors 
strongly affects the interaction between the solutes and the chiral stationary phase. It 
has been demonstrated that ionic binding of amines to the AGP column is a very 
important type of interaction for retention of this category of compounds. The solutes 
are also retained by hydrophobic interaction and hydrogen bonding. The relative 
influence of the different types of binding forces depends of the natures of the solute. 
A good starting point for amines is 10 mM sodium acetate buffer at pH 4.5, for acids 
10mM phosphate at pH 7.0 would be a good choice. 
 
Carbohydrate Unit 
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Increasing net negative charge of AGP at higher pH 
 
   Fig. 3: Net charge of AGP at different pH 
Charged modifiers may be used when organic modifiers have failed. These 
result in a permanent change in the protein structure and should be used with caution. 
They include Butyric acid, Octanoic acid, Decanoic acid, Dimethyloctylamine. 
Ethylene Glycol, 1-, 2- butanol and Sodium chloride, have also been used. 
Temperature affects the separation, as temperature increases the retention time and 
separation factors decrease. 
For a compound to be resolved on an AGP column it requires the following 
properties: 
1. Ring close to chiral centre  
2. At least one hydrogen bonding site  
3. The distance between the ring and the H-bonding site should not be greater 
than 3 atoms (unless there is more than one).  
AGP columns may be regenerated by washing with 25% aqueous IPA 
 
 
 
 
 
 
pH:2.0 pH:7.0 
IP
Part-A Section-I 
41 
2. Literature Review 
 
The literature reviews regarding duloxetine suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation 
and in various biological fluids. Analytical methods for the determination of the 
impurities and enantiomeric purity were also reported.  
A literature survey revealed that a few HPLC methods were reported for 
determination of duloxetine in bulk drug, pharmaceutical formulation and other 
biological fluids [22-26]. Only a few enantioselective chromatographic separation 
methods for duloxetine and its (R)-enantiomer have been described in the literature. 
Chiral separations have been mainly focused on capillary electrophoreses with 
modified cyclodextrins [27-30]. 
Jing Yang, Xiumei Lu, Yujin Bi, Feng Qin and Famei Li have reported 
HPLC method for determining the duloxetine and its (R)-enantiomer using 
hydroxypropyl- -cyclodextrin as chiral selector with resolution 1.3, analysis time 
about 60 min, and a vancomycin chiral stationary phase with resolution of isomers 
1.7, analysis time approximately 20 min. The developed method was applied for 
enantiomeric purity of duloxetine bulk drug substance and can be used for the quality 
control of duloxetine, as well as in subsequent pharmacological studies [31]. 
V. P. Rane and D. B. Shinde have reported development and validation of 
chiral LC method for the enantiomeric separation of duloxetine on amylose based 
stationary phase. The analyte was chromatographed on Chiralpak AD-H column by 
isocratic elution with hexane-ethanol-diethyl amine (80:20:0.2, v/v/v) at a flow rate of 
1.0 mL/min. The resolution was found to be not less than 2.8 in optimized method. 
The developed method can be used for the determination of (R)-enantiomer during 
quality control of the duloxetine. Authors have also tried chiral-AGP column using 
mobile phase ammonium acetate buffer (pH 3.5; 10 mM)-ethanol (65:35, v/v) but 
they could not achieved enantiomeric separation of duloxetine on chiral-AGP column 
[32]. 
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3. Aim of Present Work 
 
As per preceding discussion in the literature review, a few chromatographic 
methods are reported for the enantiomeric separation of the duloxetine hydrochloride. 
So far to our present knowledge, there is no validated, simple, rapid and accurate 
reverse phase chiral HPLC method for the determination of (R)-enantiomer in 
duloxetine hydrochloride was available as well as no successful report on AGP 
column in literature. In day-to-day routine laboratory activities, most of the HPLC 
methods are in reverse phase. It is tedious to convert HPLC instrument from reverse 
phase to normal phase and from normal phase to reverse phase for single analysis. 
Therefore, our aim is to develop simple, rapid and accurate reverse phase HPLC 
method on Chiral AGP column, which can be used comfortably in day-to–day 
activities.      
Our work deals with the systematic method development studies such as, 
effect of organic modifier, effect of pH of buffer, effect of concentration of buffer and 
effect of column temperature. This work also deals with the validation of the 
developed method for the determination of the (R)-enantiomer in duloxetine 
hydrochloride. The developed method is recommended for routine monitoring of 
process development and quality control analysis. 
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4. Experimental 
 
4.1 Chemicals  
Duloxetine and its (R)-enantiomer were kindly supplied by Process Research 
Department of Cadila Healthcare Limited, Ankleshwar, India. HPLC grade 
acetonitrile was purchased from S.D.Fine, India. Analytical Reagent grade sodium 
acetate and acetic acid were purchased from Qualigens. HPLC grade water was 
obtained from Milli-Q water purification system. 
 
4.2 Instrumentation 
A Agilent 1100 series (Germany) HPLC system equipped with degasser auto 
sampler, auto injector, thermostatic compartment and photo diode array detector was 
utilized for method development and validation. The out put signal was monitored 
and processed using Agilent Chemstation software. 
 
4.3 Mobile Phase Preparation 
The mobile phase was sodium acetate buffer (pH 3.8; 10 mM)-acetonitrile 
(93:07, v/v). The buffer solution was prepared by dissolving 0.82 g sodium acetate in 
water and diluted up to the mark in 1000 mL volumetric flask with the water. pH was 
set 3.8 by glacial acetic acid. The buffer solution was filtered through a 0.45µm nylon 
membrane (Millipore Pvt. Ltd. Banglore, India). The final mobile phase was prepared 
by mixing 930 mL of buffer solution and 70 mL of acetonitrile in 1000 mL mobile 
phase bottle and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.4 Diluent Preparation  
Mobile phase used as a diluent. 
 
4.5 Sample Preparation  
Stock solution of (R)-enantiomer (100 µg/mL) and duloxetine (4 mg/mL) were 
prepared by dissolving the appropriate amount of the substances in mobile phase. The 
analyte concentration of duloxetine was fixed as 0.4 mg/mL. Working solution was 
also prepared in mobile phase. 
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4.6 Chromatographic Conditions  
The chiral column used for the separation was 150 mm x 4.0 mm, Chiral-AGP 
(Chromtech make) packed with 5 µm particles. The mobile phase was sodium acetate 
buffer (pH 3.8; 10 mM)-acetonitrile (93:07, v/v). The flow rate was set at 1.0 mL/min. 
The column was maintained at 20° C, and the detection was carried out at a 
wavelength of 220 nm. The injection volume was 5  L. 
 
4.7 Method Validation 
4.7.1 System Suitability  
The racemic mixture containing equal quantity of (R)-enantiomer and 
duloxetine was injected in the equilibrated chromatographic system. The system 
suitability parameters such as, resolution (Rs), symmetry (S), retention factor (k), 
separation factor ( ) and efficiencies (N) were obtained.   
 
4.7.2 Precision 
Precision of the method is the degree of agreement among the individual test 
results when the procedure is applied repeatedly to multiple sampling of a 
homogenous sample. The precision of the method was checked by analyzing six 
replicate samples of duloxetine (at 0.4 mg/mL) spiked with 0.5 % of (R)-enantiomer 
and calculating the percentage relative standard deviation of retention time and peak 
area. The intermediate precision was also evaluated at different day by performing six 
successive injections. 
 
4.7.3 Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and Limit of quantification (LOQ) were determined 
at a signal-to-noise ratio of 3 and 10. LOD and LOQ were achieved by injecting a 
series of dilute solutions of (R)-enantiomer. 
The precision of the developed method for (R)-enantiomer at LOQ was 
checked by analyzing six test solutions of (R)-enantiomer prepared at the LOQ level 
and calculating the percentage relative standard deviation of retention time and peak 
area. The accuracy of the method was checked for (R)-enantiomer at LOQ level by 
analyzing three replicate samples of duloxetine spiked with (R)-enantiomer at LOQ 
level and calculating the percentage relative standard deviation.   
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4.7.4 Linearity of (R)-enantiomer  
Detector response linearity was assessed by preparing calibration sample 
solutions of (R)-enantiomer covering from 400 ng/mL to 3000 ng/mL (400, 1000, 
1500. 2000, and 3000 ng/mL), in mobile phase from (R)-enantiomer stock solution. 
The regression curve was obtained by plotting peak area versus concentration, using 
the least squares method. Linearity was checked for three consecutive days in the 
same concentration range from the same stock solution. The percentage relative 
standard deviation of the slope and Y-intercept of the calibration curve was 
calculated.  
 
4.7.5 Accuracy  
The standard addition and recovery experiments were conducted to 
demonstrate accuracy of the method. The study was carried out in triplicate for the 
determination of recovery of (R)-enantiomer at 0.4, 0.5 and 0.6 % of the Duloxetine 
target analyte concentration. The recovery of (R)-enantiomer was calculated from the 
slope and Y-intercept value range of 400-3000 ng/mL (slope and Y-intercept values 
obtained in the linearity study).   
 
4.7.6 Robustness 
The robustness of a method was determined by altering experimental 
conditions and chromatographic resolution between Duloxetine and (R)-enantiomer 
was evaluated. To study the effect of flow rate, pH of buffer, concentration of buffer 
and column temperature on the resolution of enantiomers, it was changed by varying 
0.1 units,  0.1 units, -2 to +2 mM and –1 to +1 °C respectively, while the other 
chromatographic parameters were held constant as stated in section 2.4. 
 
4.7.7 Solution stability  
Stability of Duloxetine in solution at analyte concentration was studied by 
keeping the solution in tightly capped volumetric flask at room temperature on a 
laboratory bench for 3 days. Content of (R)-enantiomer  was checked for 6, 12, 24 and 
48 h.    
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5. Result and Discussion 
 
5.1 Development and Optimization of the HPLC Method 
The aim of this study is to separate the enantiomers of duloxetine 
hydrochloride with optimum resolution within short time using Chiral-AGP column. 
The racemic sample solution was used for the method development. The wavelength 
of the detection was set 220 nm based on the UV spectra of duloxetine (Fig. 4) 
 
 
nm200 225 250 275 300 325 350 375  
         Fig. 4: UV spectra of Duloxetine 
 
Duloxetine is a weak base (secondary amine) in nature. Therefore, to separate 
the pair of enantiomers on Chiral AGP column, it is better to work at acidic pH range, 
which was also evidenced by experiment at pH: 7.0 (Fig. 5) and pH: 4.5 (Fig. 6).  
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         Fig. 5: 10 mM Phosphate (Na2HPO4) buffer (pH: 7.0) : IPA [90:10] 
                   Flow: 0.8mL/min, 220nm, 30°C column temp.  
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Fig. 6:10mM Sodium Acetate buffer pH : 4.5:IPA [90:10] 
            Flow: 0.8 mL/min, 30°C column temp. 
 
The mobile phase parameters affecting the retention and resolution of the 
duloxetine enantiomers on the Chiral-AGP column are; the type and concentration of 
organic modifier, pH and concentration of the buffer, and column temperature. Each 
of these parameters were studied to evaluate their influence on the separation of the 
duloxetine enantiomers. The systematic experimental strategy was applied to develop 
and optimize the enantiomeric separation of duloxetine on the Chiral-AGP column.   
 
5.1.1 Effect of Organic Modifier 
Two organic modifiers, acetonitrile and isopropyl alcohol in the range of 5-10 
% were tried with sodium acetate buffer (pH 4.5; 10 mM) as a mobile phase at a flow 
rate of 0.8 mL/min. It can be seen from the Fig. 7 that, when the percentage of organic 
modifier decreased from 10 to 5 retention and resolution were increased. Thus, less 
retention and high enatioselectivity were observed for 7 % concentration of organic 
modifier. The optimum resolution and good peak shape was found on using 
acetonitrile as compared to isopropyl alcohol at equivalent volume based mobile 
phase composition. 
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        Fig. 7: Chromatograms of different organic modifier compositions 
 
5.1.2 Effect of pH of Buffer 
An important factor in chiral chromatography is the pH of the buffer that 
effects the binding affinity of both chiral selector and the analyte. The pH, mobile 
phase has shown to have strong influence on the retention and enatioselectivity of 
basic, acidic and non-protolytic compounds [33].  
The effect of pH of the buffer was investigated on the resolution and retention 
of enantiomers of duloxetine. The other chromatographic parameters; buffer 
concentration (10 mM), acetonitrile (7 %), column temperature (30° C), flow rate (1.0 
mL/min) and wavelength (220 nm) were maintained constant, while pH of the buffer 
was scanned from 3.2 to 5.2. The plot of the pH versus retention factor (Fig. 8) was 
drawn to understand the effect of pH on the retention and separation of the 
enantiomers of duloxetine. 
 
Part-A Section-I 
49 
0
5
10
15
20
25
30
3.2 3.5 3.8 4 4.2 4.4 4.5 4.8 5.2
pH
k
k1
k2
 
 Fig. 8: Effect of pH of buffer (Plot of pH versus retention factor, k) 
 
 It can be seen from the Fig. 8 that as the pH was raised from 3.2 to 5.2, 
retention of the enantiomers increased. Resolution and selectivity also increased with 
higher mobile phase pH, however, baseline separation within short time, peak shape 
and adequate resolution were optimal at a pH 3.8 and 4.0. Few of the representative 
chromatograms of the effect of pH are shown in Fig. 9, 10, 11 and 12. The selectivity 
and resolution between the two enantiomers at different buffer pH values are 
presented in Table 2. 
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Fig. 9: 10mM Sodium phosphate (NaH2PO4) buffer pH: 3.2:ACN [93:07] 
             Flow: 1.0 mL/min 
 
 
 
 
Part-A Section-I 
50 
 
min10 20 30 40 50 
mAU    
0 
2 
4 
6 
8 
10 
12 
14 
 30.905
 38.870
Rs = 2.99
 
Fig. 10: 10 mM Sodium Acetate(CH3COONa) buffer pH : 5.2:ACN [93:07] 
             Flow: 1.0 mL/min 
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Fig. 11: 10 mM Sodium Acetate(CH3COONa) buffer pH : 4.0:ACN [93:07] 
             Flow: 1.0 mL/min 
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Fig. 12: 10 mM Sodium Acetate(CH3COONa) buffer pH : 3.8:ACN [93:07] 
             Flow: 1.0 mL/min 
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Table 2: Selectivity and Resolution Between Both the Enantiomers at 
Different pH Value of the Buffer. 
Buffer pH 
Retention factor (k) Selectivity 
( ) 
Resolution 
(Rs) (R)-enantiomer 
 
Duloxetine 
3.2 0.84 1.06 1.26 1.24 
3.5 1.37 1.75 1.28 1.70 
3.8 1.37 2.19 1.60 2.11 
4.0 2.54 3.32 1.31 2.34 
4.2 3.89 5.03 1.29 2.34 
4.4 5.09 6.53 1.28 2.45 
4.5 6.65 8.50 1.28 2.41 
4.8 11.51 15.10 1.31 3.20 
5.2 19.23 24.44 1.27 2.99 
 
5.1.3 Effect of Concentration of Buffer 
Effect of concentration of sodium acetate buffer in the range of 5-25 mM was 
investigated. While the other chromatographic parameters; pH of the buffer (pH 4.0), 
acetonitrile (7%), column temperature (30° C), flow rate (1.0 mL/min) and 
wavelength (220 nm) were maintained constant. The results of selectivity and 
resolution between both the enantiomers at different mobile phase buffer 
concentration are summarized in Table 3. 
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Table 3: Selectivity and Resolution Between Both the Enantiomers at 
Different Mobile Phase Buffer Concentration. 
Buffer 
concentration 
(mM) 
Retention factor (k) Selectivity 
( ) 
Resolution 
(Rs) (R)-enantiomer 
 
Duloxetine 
5 2.36 3.03 1.28 1.96 
10 2.54 3.32 1.31 2.34 
15 2.82 3.63 1.29 2.24 
20 2.76 3.54 1.28 2.22 
 
 
It can be seen that the optimum resolution and retention were achieved at the 
10 mM concentration of sodium acetate buffer. The chromatograms obtained for 
different concentration of sodium acetate buffer are shown in Fig. 13, 14, 15 and 16. 
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Fig. 13: Chromatogram of 5 mM buffer concentration 
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Fig. 14: Chromatogram of 10 mM buffer concentration 
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Fig. 15: Chromatogram of 15 mM buffer concentration 
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Fig. 16: Chromatogram of 20 mM buffer concentration 
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5.1.4 Effect of Column Temperature 
Column temperature has been reported to influence enantiomer retention, 
enantioselectivity and resolution [33, 34]. The effect of column temperature was 
studied from 20° C to 40° C with 5° C interval. While other chromatographic 
parameters; mobile phase consisting of sodium acetate buffer (pH 4.0; 10 mM)-
acetonitrile (93:07, v/v), flow rate (1.0 mL/min) and wavelength (220 nm) were 
maintained constant. The plot of the column temperature versus retention factor (Fig. 
17) was drawn to understand the effect of column temperature on the retention and 
separation of the enantiomers of duloxetine. 
It can be seen from the Fig. 17 that retention and selectivity decreased with 
increasing column temperature. Few of the representative chromatograms of the effect 
of column temperature are presented in Fig. 18, 19 and 20. The selectivity and 
resolution between the two enantiomers at different column temperature values are 
summerized in Table 4. The resolution between two enantiomers also increased as 
column temperature decreased (Table 4). 
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Fig. 17: Effect of column temperature (Plot of column temperature 
versus retention factor, k) 
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Fig. 18: Chromatogram of 40° C column temperature 
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Fig. 19: Chromatogram of 30° C column temperature 
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Fig. 20: Chromatogram of 20° C column temperature 
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 Table 4: Selectivity and Resolution Between Both the Enantiomers at Different 
Column Temperature. 
Column 
temperature 
(°C) 
Retention factor (k) Selectivity 
( ) 
Resolution 
(Rs) (R)-enantiomer 
 
Duloxetine 
20 2.73 5.23 1.40 2.69 
25 3.25 4.38 1.35 2.50 
30 2.55 3.33 1.31 2.34 
35 2.49 3.08 1.24 1.92 
40 2.16 2.55 1.18 1.56 
 
In the frame of the optimization process the temperature dependency of 
retention and enantioselectivity was also studied by plotting Van’t Hoff plot of ln   
versus 1/T for the temperature range 20 to 40° C (Fig. 21). 
 
 
 
 
 
 
 
 
Fig. 21: Van’t Hoff Plot for the separation of duloxetine enantiomers 
 
The apparent enantioselectivity ( ) can be expressed by the Gibbs Hemholtz 
equation: 
  ( G) = RTln         (1) 
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where - ( G) is the difference in the Gibbs free energy between 
diastereomeric complexes formed upon interaction with the chiral selector and the 
individual enantiomers of a racemic analyte.  
Eq. 1 can be expressed as, 
 
ln  =  -  ( H)/RT +   ( S)/R      (2) 
where   ( H) and  ( S) are the enthalpy and entropy differences respectively, 
between the two enantiomers when they interact with the stationary phase. R is the 
gas constant (8.314 J/mol K) and T is absolute temperature. 
The Van’t Hoff plot (Fig. 21) showed linear relation with correlation 
coefficient greater than 0.995. It suggests that correlation thermodynamic parameters 
and retention mechanism are temperature independent. The slope (- ( H)/R) and 
intercept ( ( S)/R) were used to calculate  ( H) and  ( S). The obtained values of 
 ( H) was – 6501.61 J/mol,  ( S) was – 19.34 J/mol and  ( G) was – 834.99 J/mol 
(at 20° C). The negative value of  ( G) was due to contribution of negative  ( H) 
value. Therefore, it can be said that transfer of solute from the mobile phase to 
stationary phase and the separation are enthalpically driven.      
 
5.1.5 Optimum Separation 
The influence of each chromatographic parameter was systematically studied. 
The optimal parameters from all the studies have been taken to finalize the condition 
of the method. The study on effect of organic modifier suggested that acetonitrile is 
good as a organic modifier. The study on effect of buffer pH concluded that pH 
should be 3.8 or 4.0. The study on the concentration of buffer said that 10 mM is the 
ideal concentration. The study on effect of column temperature showed that resolution 
is higher at 20° C. The optimized separation for the enantiomers of duloxetine on 
Chiral-AGP column is shown in Fig. 22. Which was achieved using mobile phase 
consisting of sodium acetate buffer (pH 3.8; 10 mM)-acetonitrile (93:07, v/v). The 
flow rate was 1.0 mL/min. Column temperature was maintained 20° C. The 
enantiomers were baseline resolved with a runtime less than 8 min. Interestingly, 
distomer was eluted prior to eutomer in the developed method.   
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Fig. 22: 10 mM Sodium Acetate (CH3COONa) buffer pH : 3.8:ACN [93:07] 
               Flow: 1.0 mL/min, (Racemic in Mobile Phase), T = 20° C 
 
5.2 Results of Method Validation 
 
5.2.1 Results of System Suitability 
The system suitability results summarized in Table 5, which showed that 
resolution between both the enantiomers was not less than 2.2. Peak purity of both the 
enantiomers was not less than 0.999/990 using PDA detector. Report of peak purity is 
presented in Fig. 23. 
 
   Table 5: System Suitability Data 
System suitability parameters (R)-enantiomer 
(n =3) 
Duloxetine 
(n=3) 
Retention factor (k) 2.37 3.33 
Resolution (Rs) 2.38  
Symmetry (S) 0.80 0.79 
Selectivity ( )  1.41 
 
 
 
 
 
Part-A Section-I 
59 
 
  (a)     (b) 
Fig. 23: Peak purity report of (a) (R)-enantiomer and (b) Duloxetine 
 
5.2.2 Results of Precision 
In the precision study, the percentage relative standard deviation (RSD) was 
less than 0.05 % for the retention time and 0.5 % for the peak area of both the 
enantiomers indicating good precision of the method. Data of precision study are 
summarized in Table 6. In the intermediate precision study, results showed that RSD 
values were in the same order of magnitude than those obtained for repeatability and 
data are presented in Table 7.  
 
        Table 6: Result of Precision Study 
Precision Data 
Sr. No 
(R)-enantiomer Duloxetine 
RT Area RT Area 
1 5.133 62.32 6.224 15731.20 
2 5.133 62.35 6.225 15757.10 
3 5.131 62.61 6.221 15794.60 
4 5.133 62.12 6.224 15732.50 
5 5.131 62.62 6.221 15747.00 
6 5.133 62.06 6.223 15743.70 
Average 5.13 62.35 6.22 15751.02 
SD 0.0010 0.2351 0.0017 23.4169 
% RSD 0.02 0.38 0.03 0.15 
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       Table 7: Results of Intermediate Precision Study 
Intermediate Precision Data 
Sr. No 
(R)-enantiomer Duloxetine 
RT Area RT Area 
1 5.181 63.95 6.291 15985.00 
2 5.179 64.55 6.287 16010.70 
3 5.18 63.87 6.288 15982.60 
4 5.179 64.24 6.289 15996.00 
5 5.186 64.84 6.293 16020.60 
6 5.183 64.57 6.293 15997.10 
Average 5.18 64.34 6.29 15998.67 
SD 0.0027 0.3798 0.0026 14.6993 
% RSD 0.05 0.59 0.04 0.09 
 
5.2.3 Result of Limit of Detection and Limit of Quantification 
The LOD and LOQ concentration were estimated to be 150 and 400 ng/mL for 
(R)-enantiomer, when the signal-to-noise ratio of 3 and 10 were used as the criteria. 
The method precision for (R)-enantiomer at LOQ was 1.4  % RSD (Table 8). The 
recovery of (R)-enantiomer at LOQ was 93 % in the spiked Duloxetine samples. It 
can be said that LOQ value of the (R)-enantiomer is quite law than the specification 
limit. The method is precise and accurate at LOQ level. 
 
              Table 8: Results of Precision study at LOQ level 
Sr. No 
(R)-enantiomer at LOQ level 
RT Area 
1 5.195 9.85 
2 5.196 9.74 
3 5.192 9.54 
4 5.192 9.63 
5 5.194 9.64 
6 5.189 9.47 
Average 5.19 9.65 
SD 0.0025 0.1351 
% RSD 0.05 1.40 
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5.2.4 Result of Linearity of (R)-enantiomer 
The described method was linear in the range of 400-3000 ng/mL for (R)-
enantiomer. The calibration curve was drawn by plotting the peak area verses its 
corresponding concentration with a correlation coefficient of  0.999. The equation of 
the calibration curve for (R)-enantiomer was y = 31.402x – 3.4162. Linearity was 
checked for (R)-enantiomer over the same concentration range for three consecutive 
days (Fig. 24, 25 and 26). The percentage relative standard deviation of the slope and 
Y-intercept of the calibration curve were 0.25 and 4.4, respectively. The data are 
summarized in Table 9. It can be observed that method is linear within the studied 
range. 
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Fig. 24: Linearity of (R)-enantiomer (400 to 3000 ng/mL), for Day 1 
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Fig. 25: Linearity of (R)-enantiomer (400 to 3000 ng/mL), for Day 2 
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   Fig. 26: Linearity of (R)-enantiomer (400 to 3000 ng/mL), for Day 3 
 
              Table 9: Results of Linearity Study 
Linearity 
Equation of Calibration curve 
Slope Intercept 
Day 1 31.488 3.5777 
Day 2 31.383 3.3877 
Day 3 31.335 3.2832 
Average 31.402 3.4162 
SD 0.0782 0.1493 
% RSD 0.2492 4.3705 
 
5.2.5 Result of Accuracy Study 
In order to determine the accuracy of the method standard addition and 
recovery experiments were conducted in triplicate at 0.4, 0.50 and 0.6 % of analyte 
concentration, i.e. 1600, 2000 and 2400 ng/mL of (R)-enantiomer. Recovery was 
calculated from slope and Y-intercept of the calibration curve obtained in linearity 
study. The data are presented in Table 10. It can be seen from the data that method is 
very accurate for the determination of the (R)-enantiomer in bulk drug. 
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Table 10: Recovery Results of (R)-enantiomer in Bulk Sample 
Added (ng) Recovered (ng) % Recovery % RSD 
1600 1676 104.7 1.7 
2000 2098 104.9 0.7 
2400 2495 103.9 0.5 
n = 3 determinations 
 
5.2.6 Result of Robustness Study 
The chromatographic resolution between both enantiomers was used to 
evaluate the method robustness under modified conditions. Sufficient resolution 
between Duloxetine and (R)-enantiomer was obtained under all separation conditions 
tested, which was demonstrated sufficient robustness. Results are summarized in 
Table 11. It can be seen from the data that method is robust for its intended use. 
 
    Table 11: Results of Robustness Study 
Parameter Resolution between two 
enantiomers 
Flow rate (mL/min) 
     0.9 2.41 
     1.0 2.38 
     1.1 2.29 
pH of buffer 
     3.7 2.31 
     3.8 2.38 
     3.9 2.40 
Concentration of buffer (mM) 
     8 2.34 
     10 2.38 
     12 2.35 
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Column temperature  
     19 2.41 
     20 2.38 
     21 2.35 
 
5.2.7 Result of Solution Stability 
 There was no significant change in the content of (R)-enantiomer  observed 
during solution stability experiments. The data are presented in Table 12. It can be 
seen from the data that % bias of the area of  (R)-enantiomer was within   2.0 %. 
Hence, Duloxetine sample solution is stable for at least 2 days.   
 
 Table 12: Result of Solution Stability 
Time 
interval 
(R)-enantiomer  
RT Area % Bias of Area 
Initial 5.196 64.18 - 
6 h 5.194 63.85 -0.51 
12 h 5.192 64.49 0.48 
24 h 5.193 63.95 -0.36 
48 h 5.192 63.31 -1.36 
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6.  Conclusion 
A simple, rapid and accurate reverse phase chiral LC method has been 
developed and validated for the enantiomeric separation of Duloxetine on the Chiral-
AGP column.  
In the strategy of method development, the effect of organic modifier, the 
effect of pH of buffer, the effect of concentration of buffer and the effect of column 
temperature on the resolution and retention of enantiomers have been evaluated. The 
thermodynamic parameters  ( H),  ( S) and  ( G) have been determined.   
The optimized chromatographic parameters gives baseline separation with 
resolution greater than 2.2 between the two enantiomers within 8 min. The method 
was completely validated showing satisfactory data for all the method validation 
parameters tested.  
The developed method can be used for the quantitative determination of chiral 
impurity [(R)-enantiomer] in the bulk drug substance. 
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1. Introduction  
 
 Approximately, 25 % of commercially available chiral drugs are either 
racemates or diastereomers & biological activity of chiral molecule substantially 
differs from its racemates or its stereoisomers is well documented [1, 2]. Thus, the 
separation of each isomer in such mixtures is usually critical to both the 
pharmaceutical industry as well as to the regulatory agencies to assure the safety and 
efficacy of the drug [3, 4]. Consequently, the industry regulators require the drug 
sponsors to provide assay methods capable of resolving and quantitating the 
stereoisomers to assess the stereo chemical integrity of the drug substance and drug 
product [5]. 
In line of our focus of research in part-A, chromatographic separation of 
different isomers, we have attempted separation of diastereomers in this section. 
Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers (non-
superimposable mirror images of each other). Diastereomers can have different 
physical properties and different reactivity. In another definition diastereomers are 
pairs of isomers that have opposite configurations at one or more (but not all) of the 
chiral centers so they are not mirror images of each other [6]. In simpler terms two 
stereoisomers are said to be diastereoisomers if they are not mirror images of each 
other and one or more stereogenic centers differ between the two stereoisomers.  
The new set of diastereomers was selected for the present study, the selected 
compound is 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-oxocyclopentyl)propanoic acid 
(Fig. 1). It has novel skeleton and an interesting molecule for generation of 
pharmacologically active compounds. Its molecular formula is C15H18O5S having 
molecular weight 310.37 g/mole. 
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(S, R)     (R, R) 
Fig. 1: Chemical Structure of 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-
oxocyclopentyl)propanoic acid  
C-alkylation of ethyl 2-[4-(methylthio)phenyl]acetate with 2(S)-iodomethyl-
8,8-dimethyl-6,10-dioxaspiro[4.5]decane and consecutive hydrolysis and oxidation 
yielded two diastereomers of 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-
oxocyclopentyl)propanoic acid [7].  As shown in Fig. 1, the title compound contains 
two chiral centers, one with fixed configuration (R) and an another chiral center is 
racemic therefore, two diastereomers (R,R) and (S,R) are possible. The one 
diastereomer of title compound can be converted to another diastereomer by 
crystallization induced dynamic resolution. To monitor this conversion process, 
suitable and precise chromatographic method was extensively needed.         
The coversion of undesired isomer to desired isomer is also very important to 
reduce waste from green chemistry angle. The green chemistry consists of chemicals 
and chemical processes designed to reduce or eliminate negative environmental 
impacts. The use and production of these chemicals may involve reduced waste 
products, non-toxic components, and improved efficiency.  
Green chemistry is a highly effective approach to pollution prevention because 
it applies innovative scientific solutions to real-world environmental situations. The 
12 Principles of Green Chemistry, originally published by Paul Anastas and John 
Warner [8] provide a road map for chemists to implement green chemistry.  
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This study describes development of HPLC method for separation of the two 
diastereomers of 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-oxocyclopentyl)propanoic 
acid on a non-chiral column. The method development involved the selection and 
optimization of the stationary phase, mobile phase, column temperature etc. The 
optimized method was subjected to partial validation. The method was validated for 
the parameters, such as, system suitability, peak homogeneity, precision, limit of 
detection, limit of quantification, linearity, robustness and finally solution stability. 
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2. Literature Review 
 
The literature review regarding chromatographic separation of diastereomers 
was revealed that various analytical methods were reported for different set of 
diastereomers in bulk drug and pharmaceutical formulation using chiral and non-
chiral column.  
The high performance liquid chromatography is a powerful and widely used 
technique for the separation and quantitation of diastereomers [9-17]. The use of 
chiral columns to separate the stereoisomers using HPLC is very common, following 
are the examples, where author used chiral column for the separation of 
stereoisomers. 
 
? Kumar N, Windisch V, Trivedi P and Golebiowski C. have reported use of 
 -cyclodextrin chiral column for the separation of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitor drug substance diastereomers, 
and their analogues [12]. 
? Kunath A, Theil F. and Wagner J. have reproted Diastereomeric and 
enantiomeric separation of monoesters prepared from meso-cyclopentanediols 
and racemic carboxylic acids on a silica phase and on amylose and cellulose 
chiral stationary phases [13]. 
? Wu C, Akiyama A and Straub IA. have reported high-performance liquid 
chromatographic reversed-phase and normal-phase separation of 
diastereomeric  -ketoamide calpain inhibitors on Nucleosil Chiral-2 column 
[11]. 
? Gopal D, Grinberg N, Dowling T, Prepall H, Bicker G, and Tway P. have 
used quinine as an additive to the mobile phase to enhance separation of 
diastereomers of pharmaceutical compound on a diol column in normal phase 
mode [14]. 
? Akapo S, McCrea C, Gupta J, Roach M and Skinner W. have used Chiral-
AGP column as protein based chiral stationary phase in reversed phase mode 
to analyze formoterol stereoisomers [16].  
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In light of frequent use of chiral column, separation of diastereomers using 
non-chiral column is certainly noteworthy. However, there are few reports describing 
use of non-chiral column in reversed phase mode to separate diastereomers. 
 
? Rauwald HW and  Beli A have reported high-performance liquid 
chromatographic separation and determination of diastereomeric 
anthrone-C-glucosyls in Caps aloes [9]. 
? Kirby DA, Miller CL and Rivier JE have reproted separation of 
neuropeptie Y diastereomers by high-performance liquid 
chromatography and capillary zone electrophoresis [10]. 
? Wang T. hasreported High-performance liquid chromatographic 
separation of  -methyl ADC-13 enolphosphate diphenyl ester and its 
 -methyl diastereomers [15]. 
? Wu C, Akiyama A and Straub IA. have reported high-performance 
liquid chromatographic reversed-phase and normal-phase separation of 
diastereomeric  -ketoamide calpain inhibitors [11]. 
 
There is no direct report available for the HPLC separation of diastereomers of 
the compound of interest, 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-
oxocyclopentyl)propanoic acid  on non-chiral column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part-A Section-II 
73 
3. Aim of Present Work 
 
As per preceding discussion, separation method for the stereoisomers is very 
much needed by pharmaceutical industries and regulatory agencies.  The aim of 
present study was to develop HPLC method for the separation of new set of 
diastereomers on non-chiral column. The selected compound is new moiety, which 
may further modify to generate pharmacologically active compound for the drug 
discovery program. The title compound, 2-[4-(methylsulfonyl)phenyl]-3-(3(R)-
oxocyclopentyl)propanoic was synthesized by chemist as per scheme 1. The mixture 
of two diastereomers (Fig.1) needed for the present study was obtained by de-
protection of the compound 6 with 2N HCl, Acetone at 26°C. 
Scheme 1 
 
 
C-alkylation of ethyl 2-[4-(methylthio)phenyl]acetate (2) with 2(S)-
iodomethyl-8,8-dimethyl-6,10-dioxaspiro[4.5]decane (3) followed by consecutive 
hydrolysis and oxidation yielded two diastereomers of 2-[4-(methylsulfonyl)phenyl]-
3-(3(R)-oxocyclopentyl)propanoic acid [7].  The iodo compound (3) was in turn 
synthesized from chiral acid (8) ([ ]D = +16.6o, c = 1.5, CH3OH) (Scheme 2), which 
was synthesized and resolved by chemist according to the literature procedure [18, 
19].  Additionally, chiral purity for iodo compound (3) was checked using chiral GC 
(Column: BetDEXtm [225+120], 60m, 0.25mm, thickness 0.25µm), which was found 
100 % chirally pure. The GC chromatograms of the racemic iodo compound and 
chirally pure enantiomer are shown in Fig. 2 and 3 respectively. 
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  Scheme 2 
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 Fig. 2: Chiral GC chromatogram of racemic iodo compound 
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   Fig. 3: Chiral GC chromatogram of chirally pure iodo compound 
 
Although, title compound (Fig. 1) contains two chiral centers, which may have 
theoretically four isomers. However, since one of the chiral center of cyclopentanone 
ring, attached to 3-position of propanoic acid is fixed. The another chiral center at 2-
position of propanoic acid was generated during synthesis is racemic. Therefore, one 
chiral center has fixed configuration (R) and  another chiral center is racemic, which 
results two diastereomers (S,R) and (R,R). The chemical method being employed in 
epimerization process from (6) to (1) was crystallization induced dynamic resolution. 
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 To understand extend of crystallization induced dynamic resolution method 
and to monitor epimerization process, the chemist needed suitable chromatographic 
method. The present study describes development and validation of the HPLC 
separation method for new set of two diastereomers, which can be utilized to monitor 
epimerization process. 
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4. Experimental 
 
4.1 Chemicals  
HPLC grade Triflouroacetic acid was purchased from Merck (Germany), 
while Acetonitrile was purchased from S.D. Fine Chemicals (India). Water used 
throughout the course of this study was purified by Barnstead (USA) water 
purification system. Chemistry Department of Zydus Research Centre, Ahmedabad, 
India, kindly supplied diastereomeric mixture of the title compound. 
 
4.2 Instrumentation 
HPLC system used was an Agilent Technology (1100 series, Germany), 
equipped with degasser, quaternary pump, auto sampler, auto injector, thermostatic 
compartment and photo diode array detector. The out put signal was monitored and 
processed using Agilent Chemstation software. Peak homogeneity was checked by 
Shimadzu LCMS 2010A (Japan) using positive electron spray ionization mode. 
 
4.3 Mobile Phase Preparation 
The mobile phase was 0.05 % triflouroacetic acid in water-acetonitrile (85:15, 
v/v). The 0.05 % triflouroacetic acid solution was prepared by dissolving 500  L 
triflouroacetic acid with water and prepared 1000 mL solution and filtered through a 
0.45µm nylon membrane (Millipore Pvt. Ltd. Banglore, India). The final mobile 
phase was prepared by mixing 850 mL of buffer solution and 150 mL of acetonitrile 
in 1000 mL mobile phase bottle and degassed in an ultrasonic bath (Spincotech Pvt. 
Ltd., Mumbai). 
 
4.4 Diluent Preparation  
Mobile phase used as a diluent. 
 
4.5 Sample Preparation  
Stock solution of diastereomeric mixture of the title compound (1000  g/mL) 
was prepared by dissolving the appropriate amount of the substance in mobile phase. 
The analyte concentration of each diastereomer was fixed as 100  g/mL. Working 
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solutions for method validation was prepared by subsequence dilution of the stock 
solution in mobile phase. 
 
4.6 Chromatographic Conditions  
The chromatographic conditions were optimized using a J’sphere-ODS-H80 
(150 mm   4.6 mm, 4  m, YMC make, Japan) HPLC column. The mobile phase was 
0.05 % triflouroacetic acid in water-acetonitrile (85:15, v/v). The flow rate was set at 
1.0 mL/min. The column was maintained at 30° C, and the detection was carried out 
at 228 nm. The injection volume was 5  L. The reverse phase columns ODS-AQ (250 
mm   4.6 mm, 5  m, YMC make, Japan) and Kromasil-C18 (150 mm   4.6 mm, 5 
 m) were also employed during method development. 
 
4.7 Method validation 
 
4.7.1 System suitability and Peak Homogeneity 
System suitability test is an integral part of chromatographic methods and is 
used to verify that the resolution and reproducibility of the system are adequate for the 
analysis to be performed. System suitability parameters such as, resolution (Rs), 
symmetry (S), retention factor (k), separation factor ( ) and efficiencies (N) were 
determined. Peak homogeneity of both diastereomers were confirmed using PDA and 
MS detector.   
 
4.7.2 Precision 
Precision of the method is the degree of agreement among the individual test 
results when the procedure is applied repeatedly to multiple sampling of a 
homogenous sample. The precision of the method was checked by analyzing six 
replicate samples of both diastereomers at the analyte concentration (100  g/mL) and 
calculating the percentage relative standard deviation of retention time and peak area. 
 
4.7.3 Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and Limit of quantification(LOQ) were determined 
at a signal-to-noise ratio of 3 and 10. LOD and LOQ were achieved by injecting a 
series of dilute solutions of both the diastereomers. 
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The precision of the developed diastereoselective method for both the 
diastereomers at LOQ was checked by analyzing six test solutions prepared at the 
LOQ level and calculating the percentage relative standard deviation of retention time 
and peak area. 
 
4.7.4 Linearity  
Detector response linearity was evaluated for both the diastereomers by 
determining seven working solutions from 0.5 (LOQ) to 200  g/mL, (0.5, 1, 2, 5, 10, 
50, 100 and 200  g/mL), prepared in mobile phase. Peak area and concentration of 
diastereomers were subjected to regression analysis to calculate calibration equation 
and correlation coefficient.  
 
4.7.5 Robustness 
The robustness of a method is the ability of the method to remain unaffected 
by small changes in parameters such as flow rate, mobile phase composition and 
column temperature. To determine robustness of the method, experimental conditions 
were purposely altered and chromatographic resolution between two diastereomers 
was evaluated. 
The flow rate of the mobile phase was 1.0 mL/min. To study the effect of flow 
rate on the resolution of diastereomers, it was changed by 0.1 units from 0.9 to 1.1 
mL/min. The effect of change in percent acetonitrile on resolution was studied by 
varying from – 1 to + 1 % while the other mobile phase components were held 
constant as stated in Chromatographic conditions. The effect of concentration of the 
trifloroacetic acid (in water) on resolution was studied at  0.04 % and 0.06 % instead 
of 0.05 %, while the other mobile phase components were held constant as stated in 
Chromatographic conditions. To study the effect of column temperature on the 
resolution of diastereomers, it was maintained at 25° C and 35° C instead of 30° C. 
 
4.7.6 Solution Stability  
Stability of sample solution at analyte concentration was studied by keeping 
the solution in tightly capped volumetric flask at room temperature on a laboratory 
bench for 2 days. Sample solution was analyzed for 6, 12, 24 and 48 h.  
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5. Result and Discussion 
 
 Development and Optimization of the HPLC Method 
The objective of this study was to separate the two diastereomers of the title 
compound, using a non-chiral column, since diastereomers possess different physical 
properties. The sample solution of mixture of two diastereomers was used for the 
method development. The wavelength of the detection was set 228 nm based on the 
UV spectra of both the diastereomers (Fig. 4 and Fig. 5) 
 
 
nm200 225 250 275 300 325 350 375  
Fig. 4: UV spectra of the Diastereomer-1  
 
 
nm200 225 250 275 300 325 350 375  
Fig. 5: UV spectra of the Diastereomer-2 
 
To develop the suitable HPLC method for the separation of diastereomers, 
different mobile phases and stationary phases were employed. For this, different 
columns were used, namely: YMC ODS-AQ, Kromasil-C18 and YMC J’sphere-ODS-
H80. 
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The compound of interest has free carboxylic acid group. Therefore, ionization 
of compound may play an important role in retention and as a result in the separation 
of both the diastereomers. To investigate effect of pH of the mobile phase, couples of 
experiments were performed using YMC ODS-AQ column. This column had 
hydrophilic endcappings, which could allow polar eluent to penetrate between the C18 
chains to enhance solute-stationary phase interactions. Stronger retention and often 
different selectivity are encountered on ODS-AQ compared with conventionally 
endcapped ODS [20]. Few of trials are discussed here. 
The initial attempt was made using phosphate buffer (pH 7.0; 20 mM), but 
separation was not achieved by using either methanol or acetonitrile as a organic 
modifier in different composition. Mixture of diastereomers was eluted before 2 
minutes as a single peak (Fig. 6). 
 
Trial Condition 1 
 Column: YMC ODS-AQ, 150 x 4.6 mm, 5  m 
 Mobile phase: Phosphate buffer (pH 7.0; 20 mM)-methanol (70:30, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Wavelength of detection: 228 nm 
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Fig. 6: Chromatogram of trial condition 1   
 
 It can be seen from the chromatogram that column could not discriminate two 
diastereomers of the compound of interest at pH 7.0 of the buffer. Theoretically, 
compound may be in ionized form at this pH and the ionized form of the compound 
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nature is polar and more loving to the mobile phase. Since, compound was not 
retaining in the column because of the mobile phase pH, stationary phase could not 
find sufficient time to discriminate both the diastereomers.  Therefore, mobile phase 
should use towards acidic pH. 
 In further attempt, acetate beffer (pH 4.5; 20 mM) and phosphate buffer (pH 
3.0; 20 mM) were tried. The separation of diastereomers was observed but it was not 
up to baseline (Fig. 7 and Fig. 8). 
 
Trial Condition 2  
 Column: YMC ODS-AQ, 150 x 4.6 mm, 5  m 
 Mobile phase: Acetate buffer (pH 4.5; 20 mM)-methanol-acetonitrile  
(80:15:5, v/v/v)  
Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Wavelength of detection: 228 nm 
 
m in5  1 0  1 5 2 0 2 5  
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Fig. 7: Chromatogram of trial condition 2 
 
Trial Condition 3  
 Column: YMC ODS-AQ, 150 x 4.6 mm, 5  m 
Mobile phase: phosphate buffer (pH 3.0; 20 mM)-methanol (70:30, v/v); 
Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Wavelength of detection: 228 nm 
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Fig. 8: Chromatogram of trial condition 3 
 
It can be said from the chromatograms of trial condition 2 and 3 that 
separation of the diastereomers observed towards acidic pH. However, resolution is 
not base-to-base, therefore, buffer pH and mobile phase composition should be 
optimized to get desire resolution between two diastereomers.  
  To improve the separation, 0.05 % trifloroacetic acid in water-acetonitrile 
(85:15, v/v) was tried. The baseline separation was achieved with slight fronting in 
the peaks of both the diastereomers using YMC ODS-AQ and Kromasil-C18 column. 
After these optimizations, non-chiral column YMC J’sphere-ODS-H80 (150 mm   4.6 
mm, 4  m) and mobile phase consisting of 0.05 % trifloroacetic acid in water-
acetonitrile (85:15, v/v) were found to be appropriate allowing good baseline 
resolution of both the diastereomers (Fig. 9). 
 
Optimized Condition  
 Column: YMC J’sphere-ODS-H80 (150 mm   4.6 mm, 4  m) 
Mobile phase: 0.05 % trifloroacetic acid in water-acetonitrile (85:15, v/v) 
Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
Wavelength of detection: 228 nm 
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Fig. 9: Chromatogram of optimized condition  
 
The optimized condition gave good peak shape, adequate separation and 
baseline resolution. System suitability parameters were also found within acceptable 
limit. Additionally, effect of the column temperature was also investigated on the 
separation of diastereomers. Experiment was carried out at 25, 30, 35, and 40° C 
column temperature while the other mobile phase components were held constant as 
stated in Optimized condition. The influence of temperature on the different 
parameters (retention and separation factors, peak symmetry, efficiencies, resolution) 
was summarized in Table 1. It was observed that an increase in temperature leads to a 
general decrease in the retention factors and resolution. Therefore, 30° C temperature 
seems suitable to achieve desirable diastereomeric separation.    
 
  Table 1: Effect of Column Temperature on System Suitability Parameters 
System suitability parameters  25°C 30°C 35°C 40°C 
Retention factor   
k1= 13.72 
k2= 14.91 
k1= 11.92 
k2= 12.94 
k1= 10.50 
k2= 11.40 
k1= 9.25 
k2= 10.03 
Resolution Rs=2.23 Rs=2.19 Rs=2.11 Rs=2.01 
Numbers of theoretical plates  
N1=13111 
N2=13248 
N1=12677
N2=13138
N1=12649 
N2=12734 
N1=12260
N2=12118
Symmetry  
S1=0.79 
S2=0.80 
S1=0.82 
S2=0.83 
S1=0.78 
S2=0.79 
S1=0.74 
S2=0.75 
Selectivity   =1.09  =1.08  =1.08  =1.08 
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To gain an insight in the retention mechanism, the thermodynamic Van’t Hoff 
relationship was studied by plotting ln k-values versus 1/T. Indeed, in HPLC, the 
partition coefficient (K) of a solute decreases when increasing the temperature [21]. 
 
ln K = -   G°/RT = -  H°/RT +  S°/R       (1) 
 
where  G° is the Gibbs free energy for the solute-stationary phase interaction, R is 
the gas constant (8.314 J/mol K),   H° and  S°, the enthalpy and entropy of transfer 
of the solute from the mobile to the stationary phase. 
The distribution constant K is directly linked to the retention factor k, following: 
 
k =     K          (2) 
with  , the stationary to mobile phase volume ratio. Therefore, expression (1) 
becomes: 
ln k = -  H°/RT +  S°/R + ln         (3) 
 
Experimentally, Van’t Hoff plots were made for both diastereomers, varying 
temperature from 298 to 313° K. It is presented in Fig. 10.  
 
 Fig. 10: Van’t Hoff Plot of both the Diastereomers 
 Linearity equation for the Diastereomers-1: y = 2481.3x – 5.7073 
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Linearity equation for the Diastereomers-2: y = 2426x – 5.4426 
A good linear correlation was observed over the studied range (r 0.999), 
indicating that the retention mechanism is independent of a change in temperature in 
the studied range (Table 2). From these linear plots, the standard enthalpy  H° and 
entropy  S° were calculated, using the slope (-  H°/R) and the intercept ( S°/R + ln 
 ), and results are summarized in Table 2. The enthalpy term represents the energy 
involved when the solute molecules break their interactions with the mobile phase and 
interact with, and enter, the stationary phase. These interactions result from 
intermolecular forces and are accompanied by the absorption or evolution of heat. It is 
seen that the Van't Hoff curve indicates a very large enthalpy value  but conversely a 
very low entropy contribution means that the distribution in favor of the stationary 
phase is dominated by molecular forces.  To clearify further, the  solute is retained in 
the stationary phase as a result of molecular interactions and that the forces between 
the solute molecules with those of the stationary phase are much greater than the 
forces between the solute molecules and those of the mobile phase. Thus, the change 
in standard enthalpy is the major contribution to the change in standard energy (Table 
2). It can be said, according to  G° negative values (Table 2), the solute transfer is 
enthalpically driven ( H°   T S°) in this temperature range. 
 
 Table 2: Thermodynamic results and correlation coefficients of Van’t Hoff plots 
for both diastereomers  
Thermodynamic  parameters Diastereomer-1 Diastereomer-2 
Standard enthalpy change, H° (J/mol) - 20629.53 - 20169.76 
Standard entropy change,  S° (J/mol) - 44.22 - 42.02 
Standard free energy change, G° (J/mol)a - 7451.97 - 7647.80 
Correlation coefficient (r) 0.999 0.999 
a T = 298 K 
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5.2        Results of Method Validation 
 
5.2.1 Results of System suitability and Peak Homogeneity 
The system suitability results, such as, retention factor, resolution, numbers of 
theoretical plates, symmetry and selectivity for both diastereomers are summarized in 
Table 3, which showed that resolution between both the diastereomers was not less 
than 2.1. 
  Table 3: System suitability data 
System suitability parameters Diastereomer-1 
(n =3) 
Diastereomer-2 
(n=3) 
Retention factor (k) 11.92 12.94 
Resolution (Rs) 2.19  
Numbers of theoretical plates (N) 12647 13138 
Symmetry (S) 0.83 0.82 
Selectivity ( )  1.09 
 
PDA and MS detector confirmed peak homogeneity of both peaks. Peak purity 
of both the diastereomers was not less than 0.999/990 using PDA detector. Report of 
peak purity is presented as Fig. 11 and 12 for diastereomers-1 and 2, respectively. 
  Fig. 11: Peak purity report of Diastereomer-1 
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  Fig. 12: Peak purity report of Diastereomer-2 
 
 The scanning (50-2000 mass unit) of both the peaks using MS detector was 
done to check the homogeneity. The LCMS total ion chromatogram of both 
diastereomers is presented in Fig. 13. The line spectra of diastereomer-1 and 
diastereomer-2 are shown in Fig. 14 and Fig. 15 respectively. The mass peaks of the 
title compound can be seen from the line spectra, corresponding to the M+1(311), 
M+NH4 (328), M+Na (333) and M+K (349), which indicate homogeneity of the 
peaks.  
 
 
 
 
 
 
 
 
 
   Fig. 13: LCMS total ion chromatogram of both the diastereomers. 
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Fig. 14: Line spectra of Diastereomer-1 
 
 
 
 
 
 
 
 
 
 
 
  Fig. 15: Line spectra of Diastereomer-2 
 
5.2.2 Results of Precision 
In the precision study, the percentage relative standard deviation (RSD) of 
both the diastereomers was found to be 0.1 % for the retention time and 0.3 % for the 
peak area, indicating good precision of the method. Data of precision study are 
summarized in Table 4.  
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     Table 4: Result of Precision Study 
 
 
 
 
 
  
 
 
 
 
 
 
5.2.3 Result of Limit of detection and Limit of quantification 
The LOD and LOQ concentration were estimated to be 0.15 and 0.50  g/ml 
for both the diastereomers, when the signal-to-noise ratio of 3 and 10 were used as the 
criteria. The method precision for diastereomer-1 and diastereomer-2 at LOQ was 1.8 
and 1.5 % RSD, respectively. The data of the precision study at LOQ level for both 
diastereomers are summarized in Table 5. 
     Table 5: Results of Precision study at LOQ level 
 
 
 
 
 
 
 
 
 
 
 
 
 
Precision at Test Concentration (100 ppm) 
Sr. No 
Diastereomer-1 Distereomer-2 
RT Area RT Area 
1 20.043 939.981 21.661 1081.985 
2 20.053 945.922 21.672 1088.509 
3 20.072 947.115 21.693 1091.014 
4 20.083 945.693 21.704 1088.827 
5 20.092 946.427 21.714 1090.215 
6 20.085 944.720 21.699 1089.456 
Average 20.071 944.98 21.691 1088.33 
SD 0.019 2.573 0.020 3.242 
% RSD 0.097 0.27 0.093 0.298 
Precision at LOQ level (0.5 ppm) 
Sr. No 
Diastereomer-1 Distereomer-2 
RT Area RT Area 
1 20.135 4.714 21.721 5.350 
2 20.139 4.751 21.777 5.305 
3 20.152 4.932 21.765 5.409 
4 20.130 4.720 21.782 5.337 
5 20.167 4.726 21.769 5.196 
6 20.151 4.713 21.754 5.253 
Average 20.146 4.759 21.761 5.308 
SD 0.014 0.086 0.022 0.075 
% RSD 0.068 1.801 0.101 1.419 
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5.2.4 Result of Linearity  
The described method was linear in the range of 0.5-200  g/ml for both the 
diastereomers. The calibration curve was drawn by plotting the peak area versus its 
corresponding concentration with a correlation coefficient of 0.999. The equation of 
the calibration curve for diastereomer-1 was y = 9.3363x – 2.0705 and for 
diastereomer-2 was   y = 10.732x – 2.4793. The results showed good correlation 
between the peak area and concentration of both the diastereomers.  The linearity plot 
of diastereomer-1 and diastereomer-2 are presented in Fig. 16 and Fig. 17 
respectively.   
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      Fig. 16: Linearity of Diastereomer-1 
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       Fig. 17: Linearity of Diastereomer-2 
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 The overlaid chromatograms of the linearity of the diastereomeric separation 
from 0.5 to 200  g/ml are presented in Fig. 18, while three-dimensional look is shown 
in Fig. 19. 
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        Fig. 18: Overlaid chromatograms of Linearity   
 
         
         Fig. 19: Three-dimensional presentation of the chromatograms of Linearity   
  
 
 
 
 
 
m in0 10 20 30 40 
m A U     
0 
5 
10 
15 
20 
25 
30 
0 .5  ppm
1 ppm  
2  ppm  
5  ppm  
10  ppm  
50  ppm
Part-A Section-II 
92 
5.2.5 Result of Robustness Study 
The chromatographic resolution between both diastereomers was used to 
evaluate the method robustness under modified conditions. Sufficient resolution 
between both the diastereomers was obtained under all separation conditions tested, 
which was demonstrated sufficient robustness. Results are summarized in Table 6. It 
can be seen from the data that method is robust for its intended use. 
 
Table 6: Results of Robustness Study 
Parameter Resolution between two 
diastereomers 
Flow rate (mL/min) 
     0.9 2.20 
     1.0 2.19 
     1.1 2.09 
Acetonitrile percentage in mobile phase 
     14 2.28 
     15 2.19 
     16 1.98 
Concentration of triflouroacetic acid ( %) in water 
     0.04 2.16 
     0.05 2.19 
     0.06 2.17 
Column temperature  
     25  2.23 
     30 2.19 
     35 2.11 
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5.2.6 Result of Solution Stability 
 There was no significant change in the peak area of both diastereomers was 
observed during solution stability experiments. The data are presented in Table 7. It 
can be seen from the data that % bias of the area was within   2.0 %. Hence, sample 
solution is stable for at least 2 days.   
 
           Table 7: Result of Solution Stability 
Time interval 
Diasteromer-1 Diasteromer-2 
Peak Area % Bias Peak Area % Bias 
Initial 945.92 - 1085.94 - 
6 h 944.85 - 0.11 1089.23 0.30 
12 h 947.15 0.13 1082.26 - 0.34 
24 h 941.32 - 0.49 1080.54 - 0.50 
48 h 935.21 - 1.13 1075.32 - 0.98 
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6.  Conclusion 
 
 A simple, suitable, linear, precise and economical HPLC method was 
described for the diastereomeric separation of the 2-[4-(methylsulfonyl)phenyl]-3-
(3(R)-oxocyclopentyl)propanoic acid.  
In the method development attempt, selection of the mobile phase and 
stationary phase was performed.  The effect of column temperature on the resolution 
and retention of two diastereomers have been evaluated. The thermodynamic 
parameters  ( H),  ( S) and  ( G) have been determined.   
The baseline separation was achieved on a non-chiral column (YMC J’shpere-
ODS-H80 with resolution greater than 2.0 between the two diastereomers. The 
method was validated with respect to system suitability, precision, LOD, LOQ, 
linearity, robustness and solution stability. Satisfactory results were observed for all 
the parameters. 
The proposed method can be used for monitoring conversion of one 
diastereomer to an another. The developed method can also be scaled up for the 
isolation of diastereomers using preparative HPLC. 
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1. Introduction 
 
Acrivastine is a potent competitive histamine H1-receptor antagonist. It is a 
second-generation, non-sedating antihistamine derived from the first-generation 
compound triprolidine. The drug lacks significant anticholinergic effects, and has a 
low potential to penetrate the central nervous system [1]. Due to its rapid onset of 
action, acrivastine will be particularly useful for ‘on demand’ therapy in patients with 
intermittent symptoms. It possesses specific antihistaminic activity for the treatment 
of allergic rhinitis with reduced potential for the sedative side effects that characterize 
triprolidine and other first-generation H1-antihistamines [2].  
The incidence of allergic disorders has been increasing dramatically 
throughout the world for the past several decades. Natural environmental allergens, 
air pollutants, stress, and xenobiotics have all been implicated in the genesis of these 
disorders [3, 4]. Although many allergic disorders are not considered life-threatening, 
they significantly reduce the quality of life for the patients and consume a great 
amount of healthcare resources. H1-antihistamines have been extensively used for the 
treatment of allergic disorders, especially allergic rhinitis and urticaria [5]. 
 The acrivastine is very example of geometric isomers. The terms cis and trans 
are from Latin, in which cis means "on the same side" and trans means "on the other 
side" or "across". The term "geometric isomerism" is considered an obsolete synonym 
of "cis-trans isomerism" by IUPAC. It is sometimes used as a synonym for general 
stereoisomerism (e.g., optical isomerism being called geometric isomerism); the 
correct term for non-optical stereoisomerism is diastereomerism. 
The cis/trans system for naming isomers is not effective when there are more 
than two different substituents on a double bond. The E/Z notation should then be 
used. Z (from the German zusammen) means together and corresponds to the term cis; 
E (from the German entgegen) means opposite and corresponds to the term trans. 
Whether a molecular configuration is designated E or Z is determined by the 
Cahn-Ingold-Prelog priority rules (higher atomic numbers are given higher priority). 
For each of the two atoms in the double bond, it is necessary to determine which of 
the two substituents is of a higher priority. If both of the substituents of higher priority 
are on the same side, the arrangement is Z; if they are on opposite sides, the 
arrangement is E. 
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1.1 Drug Profile 
 
1.1.1 Description  
 
Acrivatine is chemically, (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid (Fig. 1). Its molecular formula is 
C22H24N2O2   and molecular weight is 348.44 g/mole. 
 
N
NHO
O
 
 
 
Fig. 1:  Chemical Structure of Acrivastine 
 
 
1.1.2 Mechanism of action: 
Acrivastine is an analogue of triprolidine and it is considered to be relatively 
less sedating than traditional antihistamines; believed to involve competitive blockade 
of H1-receptor sites resulting in the inability of histamine to combine with its receptor 
sites and exert its usual effects on target cells [6]. 
 
1.1.3 Clinical Use 
Temporary relief of nasal congestion, decongest sinus openings, running nose, 
itching of nose or throat, and itchy, watery eyes due to hay fever or other upper 
respiratory allergies . 
 
1.1.4 Pharmacodynamics/Kinetics 
 
Metabolism: Minimally hepatic  
Time to peak: ~1.1 hours  
Excretion: Urine (84%); feces (13%) 
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1.1.5 Dosage 
 
Oral: Adults: 1 capsule 3-4 times/day 
 
1.1.6 Adverse Reactions 
 
>10%: Central nervous system: Drowsiness, headache  
1% to 10%:  
  Cardiovascular: Tachycardia, palpitation  
  Central nervous system: Nervousness, dizziness, insomnia, vertigo, 
lightheadedness, fatigue  
  Gastrointestinal: Nausea, vomiting, xerostomia, diarrhea  
  Genitourinary: Dysuria  
  Neuromuscular & skeletal: Weakness  
  Respiratory: Pharyngitis, cough increase  
  Miscellaneous: Diaphoresis  
<1%: Dysmenorrhea, dyspepsia 
  
1.1.7 Drug Interactions 
Decreased effect of guanethidine, reserpine, methyldopa, and beta-blockers. 
Increased toxicity with MAO inhibitors (hypertensive crisis), sympathomimetics, 
CNS depressants, ethanol (sedation) 
 
1.1.8 U.S. Brand Names 
 
Semprex®-D  
 
1.2 Heck Reaction 
The Heck reaction (also called the Mizoroki-Heck reaction) is the chemical 
reaction of an unsaturated halide (or triflate) with an alkene and a strong base and 
palladium catalyst to form a substituted alkene [7, 8]. Together with the other 
palladium-catalyzed cross-coupling reactions, this reaction is of great importance, as 
it allows to do substitution reactions on planar centers. It is named after the American 
chemist Richard F. Heck. 
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The reaction is performed in the presence of an organopalladium catalyst. The 
halide or triflate is an aryl, benzyl, or vinyl compound and the alkene contains at least 
one proton and is often electron-deficient such as acrylate ester or an acrylonitrile.The 
catalyst can be tetrakis(triphenylphosphine)palladium(0), palladium chloride or 
palladium(II) acetate. The ligand is triphenylphosphine or BINAP. The base is 
triethylamine, potassium carbonate or sodium acetate. Several reviews have been 
published [9, 10].  
1.2.1 Stereoselective Reaction 
This coupling reaction is stereoselective with a propensity for trans coupling 
as the palladium halide group and the bulky organic residue move away from each 
other in the reaction sequence in a rotation step. The Heck reaction is applied 
industrially in the production of naproxen and the sunscreen component octyl 
methoxycinnamate. The naproxen synthesis includes a coupling between a 
brominated naphthalene compound with ethylene [11]. In the recent literature, 
numbers of articles are publilshed regarding heack reaction which are revealed for 
formation of selective trans geometry of the product [12-27].    
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2. Literature Review 
 
A through literature review, it has been observed that acrivastine has been 
determined and studied by several procedures; gas chromatography mass-
spectrometric analysis [28], a sensitive radioimunoassay to measure plasma levels 
[29], two non-direct spectrofluori-metric methods [30,31] and several 
spectrophotometric procedures to measure acrivastine in urine and pharmaceuticals 
[30,32,33,34]. The high performance liquid chromatography method for the 
determination of acrivastine in capsules using ultraviolant detection [34, 35]. There 
are reports for the determination of the acrivastine in human urine and pharmaceutical 
by spectroflourimetric method [36] and by electrochemical method [37]. 
 The literature survey revealed that there are very few articles regarding HPLC 
determination of the acrivastine. There is no report available regarding separation of E 
and Z isomers of the acrivastine. To get literature insight, reports based on high 
performance liquid chromatography are discussed below in detail.    
 
T. G. Altuntas, S. S. Zanooz, D. Nebioglu, Quantitative determination of 
acrivastine and pseudoephedrine hydrochloride in pharmaceutical formulation 
by high performance liquid chromatography and derivative spectrophotometry. 
Journal of Pharmaceutical and Biomedical Analysis 17 (1998) 103-109. 
In this study, author described quantitative determination of acrivastine and 
pseudoephedrine hydrochloride in their pharmaceutical capcules form by high 
performance liquid chromatography method. The separation was performed on a 
reversed phase LiChrosorb RP-C18 analytical column (200 x 4.6 mm i.d., 5 mm 
particle size) (Hichrome Ltd., Berkshire, UK). The mobile phase consisted of a 
mixture of water/acetonitrile/methanol/perchloric acid/n-octylamine 
(500:130:25:13:0.3 v/v). The mobile phase was prepared daily, filtered, sonicated 
before use, and delivered at a flow rate of 3 ml/min. The detector wavelength was set 
at 260 nm [34]. 
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Xiaochen Gu, Hongtao Li, Kyle R. MacNair, F. Estelle R. Simons, Keith J. 
Simons. Simultaneous analysis of the H1-antihistamine acrivastine and the 
decongestant pseudoephedrine hydrochloride by high-performance liquid 
chromatography. Journal of Pharmaceutical and Biomedical Analysis 37 (2005) 
663-667. 
The author was used high-performance liquid chromatography (HPLC) for the 
simultaneous quantification of the H1-antihistamine acrivastine and the decongestant 
pseudoephedrine hydrochloride. Both compounds were detected at the wavelength of 
214 nm. A Waters ® C18 Nova-Pak ® column (4  m, 3.9 mm ×150 mm) was used 
for the analysis. The mobile phase was composed of acetate buffer (0.12 M sodium 
acetate trihydrate, pH adjusted to 4.0 using concentrated acetic 
acid)/acetonitrile/methanol at a volumetric ratio of 45:47:8. The mobile phase was 
delivered at a flow rate of 0.8 mL/min [35].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part-A Section-III 
102 
3. Aim of Present Work 
 
As, we can see in the preceding literature review, there are few HPLC 
methods reported for the determination Acrivastine. Additionally, there are no HPLC 
method reported for the separation of isomeric impurity, i.e. Z-isomer of Acrivastine 
from the Acrivastine. The aim of present work was to devise a suitable separation 
method and subsequently validate it.  
As described in the introduction section, Acrivastine drug (Fig. 1) has two 
unsaturated bonds, one at the 2-psition of propenoic acid and second at 1-position of 
the propene attached to 6-position of pyridine ring. All the four substituents at both 
double bonds are different, therefore four geometric isomers are possible, i. e. (E, E), 
(E, Z), (Z, E) and (Z, Z). Since, during the synthesis of Acrivastine the unsaturated 
bond at 2-position of propanoic acid is constructed by ‘Heck reaction’ and the Heck 
reaction is known for the generation of trans geometry predominantly. Therefore, 
configuration of the unsaturated bond at 2-position of propenoic acid is ‘E’, while the 
configuration of the unsaturated bond at 1-position of propene attached to 6-position 
of pyridine ring may ‘E’ or ‘Z’. The geometry of the one of the double bond is fixed, 
because of extensive precedences and mechanism of the Heck reaction. Therefore, 
two geometric isomers (E, E) and (E, Z) are possible during synthesis.   
The isomer (E, E) is desired isomer (Acrivastine) as a drug, while (E, Z) 
isomer is undesired. Therefore, it is necessary to monitor amount of undesired isomer 
present in Acrivastine, for which suitable, precise and accurate chromatographic 
method is needed. We have attempted to develop method for the determination of 
undesired geometric isomer (E, Z) in Acrivastine, which can be used for the support 
of process research and quality control of Acrivastine. Now onward, we refer 
undesired (E, Z) isomer, as a ‘Z-isomer’ of Acrivastine The structure of the ‘Z-
isomer’ is shown in Fig. 2.  
    The present work deals with the systematic method development for the 
separation of Acrivastine and its Z-isomer. The isolation and characterization of the 
Z-isomer and Acrivastine from the crude reaction mixture was attempted. The relative 
response factor of Z-isomer was determined. The method was validated for the 
parameters; eg. system suitability, specificity, linearity, accuracy, precision, limit of 
quantification and detection, robustness, intermediate precision and solution stability. 
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The developed method was recommended for routine monitoring of process 
development and quality control analysis. 
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Fig. 2:  Chemical Structure of Z-isomer of Acrivastine 
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4. Experimental 
 Materials and Instruments 
Drug Sample 
 Process research department of Zydus Research Centre, Cadila Healthcare 
Ltd., Ahmedabad, kindly provided the crude reaction mixture containing acrivastine 
and its Z-isomer in the ratio of 30:70 and also provided pure sample of acrivastine 
drug substance. 
Chemicals and Solvent Used 
  Acetonitrile - s d fine-CHEM Limited, Mumbai 
  Methanol - Merck, India 
  Trifluoro acetic acid – SIGMA-ALDRICH CHEMIE GmbH, Germany 
  Di-sodium hydrogen phosphate – Merck, India 
  Phosphoric acid – s.d. fine –CHEM  
  Potassium bromide - s d fine-CHEM Limited, Mumbai 
  Deuteriated  methanol – 99.8+ atom %D 
  Water – HPLC grade water 
Instruments used 
  HPLC – A Agilent 1100 series (Germany) HPLC system equipped 
with degasser auto sampler, auto injector, thermostatic compartment 
and photo diode array detector was utilized for method development 
and validation. The out put signal was monitored and processed using 
Agilent Chemstation software. 
  Preparative HPLC – SHIMADZU LC-8A, with class-VP software 
  FT-IR - SHIMADZU 8400S FT-IR, Shimadzu Make, Japan 
  Mass Spectrometry - Waters Quatromicro MSMS, Waters Make. 
  NMR – Bruker 300MHz 
  Freeze dryer - Sharp freeze -110, aapptec make 
  Rotavapour – BUCHI MAKE, Buchi rotavapor-R205, 
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    Buchi vaccume controller V-805 
  Analytical balance – Mettler Toledo, AX 105 Delta Range 
  pH Meter - Metrohm, 780 pH-Meter  
  Sonicator – Bandelin electronic Heinrichstra Be 3-4 D-12207 Berlin, 
Germany 
  Vortexer – Spinix 
 
 Preparation of 0.05 % TFA in Water 
  Transferred accurately 500 µL of Trifluoro acetic acid into a 
1000 mL volumetric flask containing approximately 700 mL water. Dissolved and 
make volume up to the mark with HPLC grade water, filter through 0.45 µm filter. 
 
4.3  Preparation of Diluent [Water:Acetonitrile (70:30, v/v)] 
Mixed accurately 350 mL of water and 150 mL of acetonitrile in 500 mL 
volumetric flask. After proper mixing, filter through 0.45 µm filter. 
 
4.4 Sample Preparation (0.5 mg/mL) 
Weighed accurately about 25 mg of Acrivastine sample into 50 mL of 
volumetric flask. Add 20 to 25 mL of diluent and sonicated to dissolve the solid. 
Diluted to volume upto the mark with diluent and mixed well. 
 
4.5 Chromatographic Parameters  
Elution              : Isocratic 
Column   : Cosmosil packed column, 5C18-PAQ (250 x 4.6 mm, 5 µm) 
Wave length  : 229 nm 
Column oven temp. : 30  C 
Flow rate  : 1.0 mL / min.  
Injection volume : 5 µL 
Run time  : 20 min 
Mobile phase  : 0.05 % TFA in water: Acetonitrile (72:28, v/v) 
Diluent  : Water:Acetonitrile (70:30) 
Sample conc.  : 0.5 mg/mL 
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4.6 Preparative HPLC method parameters 
Elution              : Isocratic 
Column   : DAC, (250X50mm) Self packed column, YMC Make 
Media used  : ODS-AQ, 10 m, 120A, YMC Make 
Wave length  : 229 nm 
Column  temp. : Ambient Temperature 
Flow rate  : 80.0 mL / min.  
Injection volume : 5 mL 
Mobile phase  : 0.05 % TFA in water: Acetonitrile (80:20, v/v) 
Diluent  : DMF:Methanol (1:9) 
Sample conc.  : 40 mg/mL 
RT of main peak : Approximately 38 min 
 
Procedure: 
About 200 to 250 mg crude reaction mixture was dissolved in minimum 
amount of DMF, sonicated to dissolve and then diluted with methanol to make 
volume of 5 mL, sample solution was filtered through 0.45  m filter. Sample solution 
was injected manually in equilibrated preparative HPLC system. The run was 
monitored using Class-VP software and main peak was collected in different 
fractions. After elution of the peaks of interest (~ 38 minutes), column switched over 
to 90 % Acetonitrile for 20 min to wash out other impurities and re-equilibrated for 
next injection.   
The HPLC analysis of the collected fraction in the developed method was used 
to segregate fractions as per its purity. The fractions of less than 99 % purity was 
mixed and re-injected through pump in preparative HPLC system to get desire purity 
level. Again collected fractions were monitored in analytical HPLC system. Finally, 
all the fractions with more than 99.0 % purity were mixed and concentrated using 
rotavapor. Concentrated fractions were subjected to freeze drying to get solid 
material. 
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4.7 Characterization methods  
The isolated materials using preparative HPLC were characterized by 
spectroscopic techniques such as, Mass, IR, NMR (H1, C13, DEPT).  
 
4.7.1 Mass Spectrometry 
The isolated compound was dissolved (about 100 ppm) in methanol and 
injected (2  L) through liquid chromatography flowed flow with methanol-water 
(90:10, v/v) at a flow rate 0.3 mL/min. The mass was operated in positive spary 
ionization (ESI+) mode with capillary voltage 3.5 KV, cone voltage 20V, source 
temperature 120°C, desolvation  temperature 400°C and   desolvation gas flow 
800L/hr. 
 
4.7.2 Infra-red Spectrocopy 
The IR spectra were recorded in solid state using KBr pallet in the region 4000 
cm–1 to 400 cm-1. The operated parameters are; Numbers of scan:20, Resolution:4, 
Beam: internal, Mirror speed: 2.8 and Gain: auto. 
 
4.7.3 Nuclear Magnetic Resonance 
1H (300 MHz) and 13C (300 MHz) NMR spectra of isolated acrivastine and its 
Z-isomer was recorded on an Avance DPX- 300MHz spectrometer Bruker 
(Germany). The probe was a 5 mm BBO z-gradient probe, optimized for inverse 
detection. Spectra were recorded in deuteriated  methanol (5-mm tubes) at 300 K. 
Sample concentration was 10 mg in 0.5 ml. The residual protonated resonance of the 
solvent (deuteriated  methanol) was used as an internal chemical shift standard, which 
was related to tetramethylsilane with chemical shifts of 3.3 and 49.0 ppm, 
respectively, for 1H and 13C. Processing of the raw data were performed using Bruker 
XWin 3.5 Nmr software. The pulse conditions were 9.8µs (attenuation 0db) for 1H and 
7.10µs (attenuation -1.0db) for 13C.  
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4.8 Relative Response Factor 
 
Sample preparation: 
Transferred an accurately weigh quantity of about 10 mg of acrivastine and its 
Z-isomer to 10 mL volumetric flasks, separately. Added about 7-8 mL of diluent to 
volumetric flask and sonicated to dissolve. Make volume up to the mark with diluent 
and mixed well to prepare 1000-ppm stock solution.  
100 µL of above stock solution of acrivastine and its Z-isomer was taken in a 
single 20 mL volumetric flask. Make volume up to the mark with diluent and mixed 
well to prepare 5-ppm working solution.  
 
Procedure: 
Five replicate of above solution was injected in the equilibrated 
chromatographic system at 229 nm. Average area of acrivastine and its Z-isomer was 
used to calculate relative response factor.  
 
4.9 Method validation  
4.9.1 System Suitability and Specificity 
The acrivastine and its Z-isomer were injected separately and together for the 
identification of the peak and specificity. The system suitability parameters such as, 
resolution (Rs), symmetry (S), retention factor (k), separation factor ( ) and 
efficiencies (N) were also evaluated.   
Analysis sequence: 
Analysis sequence for specificity test 
Sr. No. Sample No. of Injections 
1 Diluent 1 
2 Mobile phase 1 
3 Acrivastine 1 
4 Z-isomer 1 
5 Acrivastine + Z-isomer 3 
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 The system suitability parameters were evaluated from chromatogram of 
acrivastine  + Z-isomer for n=3.   
 
4.9.2 Precision 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribe conditions. The precision of an analytical 
procedure is usually expressed as the variance, standard deviation or coefficient of 
variance of a series of measurement. Here precision is determined by spiking the Z-
isomer with acrivastine at 100 % specification level. 
Preparation of Stock Solution of Z-isomer (50 ppm): 
Transferred an accurately weighed quantity of about 10 mg of Z-isomer to10 
mL volumetric flasks. Added about 5 mL of diluent to volumetric flask and sonicated 
to dissolve. Make volume up to the mark with diluent and mixed well to prepare 1000 
ppm solution. Took 1 mL of this solution to 20 mL volumetric flask and diluted with 
diluent to prepare 50 ppm  stock solution of Z-isomer. 
Preparation of Acrivastine Solution for Area Correction: 
Transferred an accurately weigh quantity of about 25 mg of acrivastine into 50 
mL volumetric flask. Added 20.0 mL of diluent and sonicated to dissolve. Make up 
the volume up to mark with diluent and mixed well. 
Preparation of Precision Solution (acrivastine with 100 % spiked Z-isomer): 
Transferred an accurately weigh quantity of about 25 mg of API into 50 mL 
volumetric flask. Added 1.0 mL of 50 ppm stock solution of Z-isomer and 20.0 mL 
diluent, sonicated to dissolve. Make up the volume up to mark with diluent and mixed 
well. 
Procedure: 
Acrivastine sample solution was injected for the area correction of Z-isomer. 
The five sample sets of precision solution were prepared and 5 µL was injected from 
each set on an equilibrated chromatographic system. The % RSD was calculated for 
area and retention time of acrivastine and its Z-isomer. 
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4.9.3 Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and Limit of quantification (LOQ) were determined 
at a signal-to-noise ratio of 3 and 10. LOD and LOQ were achieved by injecting a 
series of dilute solutions of Z-isomer. 
The precision of the developed method for Z-isomer at LOQ was checked by 
analyzing six test solutions of Z-isomer prepared at the LOQ level and calculating the 
percentage relative standard deviation of retention time and peak area. The accuracy 
of the method was checked for Z-isomer at LOQ level by calculating recovery of the 
Z-isomer from the sample of acrivastine spiked with Z-isomer at LOQ level. 
 
Preparation of Stock Solution of Z-isomer (10 ppm): 
Transferred an accurately weighed quantity of about 10 mg of Z-isomer to10 
mL volumetric flasks. Added about 5 mL of diluent to volumetric flask and sonicated 
to dissolve. Make volume up to the mark with diluent and mixed well to prepare 1000 
ppm solution. Took 1 mL of this solution to 100 mL volumetric flask and diluted with 
diluent to prepare 10 ppm  stock solution of Z-isomer. 
Preparation of solutions for LOD and LOQ 
 
The above solutions were injected on an equilibrated chromatographic system 
and measure signal to noise ratio for Z-isomer. 
Preparation of Acrivastine Solution for Area Correction  
As per section 4.9.2 Precision. 
Sr. No. Concentration Preparation of solution 
1 3.0 ppm 3.0 mL of stock solution (10 ppm) diluted to 10 mL 
2 2.0 ppm 2.0 mL of stock solution (10 ppm) diluted to 10 mL 
3 1.5 ppm 1.5 mL of stock solution (10 ppm) diluted to 10 mL 
4 1.0 ppm 5.0 mL of stock solution (10 ppm) diluted to 50 mL 
5 0.5 ppm 5.0 mL of 1.0 ppm solution diluted to 10 mL 
6 0.2 ppm 5.0 mL of 1.0 ppm solution diluted to 25 mL 
7 0.1 ppm 5.0 mL of 0.2 ppm solution diluted to 10 mL 
8 0.05 ppm 5.0 mL of 0.1 ppm solution diluted to 10 mL 
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Preparation of Precision and Accuracy Solution at LOQ Level 
Transferred an accurately weigh quantity of about 25 mg of API into 50 mL 
volumetric flask. Added 1.0 mL of 10 ppm stock solution of Z-isomer and 20.0 mL 
diluent, sonicated to dissolve. Make up the volume up to mark with diluent and mixed 
well. 
 The six replicates of for precision study was injected, while single run for 
accuracy determination at LOQ level was injected. The recovery was calculated using 
slope and Y-intercept value obtained from the linearity study.   
 
4.9.4 Linearity  
The linearity of an analytical procedure is its ability (within a given range) to 
obtain test results that are directly proportional to the concentration of analyte in the 
sample. The linearity of Z-isomer was evaluated from LOQ to 300 % concentration at 
specification level, i. e. 0.2 – 3.0 ppm for three consecutive days. 
 
Preparation of Z-isomer Solution for Linearity Study:  
The linearity solutions were prepared at concentration of 3, 2, 1.5, 1, 0.5, 0.2 
ppm as per the procedure described in the section 4.9.3 Limit of detection and Limit of 
quantification. 
Procedure: 
5 µL of each solution 0.2, 0.5, 1.0, 1.5, 2.0 and 3.0 was injected on an 
equilibrated chromatographic system. Area for each concentration was calculated and 
linearity was plotted for area against the concentration (ppm) for Z-isomer. The 
correlation coefficient was calculated for area against concentration. The equation for 
the linearity curve was also determined. Same procedure repeated at second and third 
day with fresh solution. The percentage relative standard deviation for the slope and 
Y-intercept was calculated.   
 
4.9.5 Accuracy/Recovery 
The accuracy of an analytical method is the closeness of test results obtained 
by the method to the true value. The standard addition and recovery experiments were 
conducted to demonstrate accuracy of the method. The study was carried out in 
triplicate for the determination of recovery of Z-isomer at 50 %, 100 % and 150 % 
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level with respect to the specification limit for Z-isomer. The recovery of Z-isomer 
was calculated from the slope and Y-intercept value range of 0.2-3.0 ppm (slope and 
Y-intercept values obtained in the linearity study).   
Preparation of Stock Solution of Z-isomer (10 ppm): 
As per section 4.9.3 Limit of Detection and Limit of Quantification 
Preparation of Acrivastine Stock Solution (1000 ppm): 
Transferred an accurately weigh quantity of about 25 mg of acrivastine into 25 
mL volumetric flask. Added 15.0 mL of diluent and sonicated to dissolve. Make up 
the volume up to mark with diluent and mixed well. 
Preparation of Acrivastine Solution for Area Correction: 
Transferred an accurately 5.0 mL of acrivastine stock solution in 10 mL 
volumetric flask. Added diluent to make up the volume up to mark and mixed well. 
Preparation of Recovery Solution (acrivastine with 50 % spiked Z-isomer): 
Transferred an accurately 5.0 mL of acrivastine stock solution(1000 ppm) and 
0.5 mL of Z-isomer stock solution(10 ppm) in 10 mL volumetric flask. Added diluent 
to make up the volume up to mark and mixed well. 
Preparation of Recovery Solution (acrivastine with 100 % spiked Z-isomer): 
Transferred an accurately 5.0 mL of acrivastine stock solution(1000 ppm) and 
1.0 mL of Z-isomer stock solution(10 ppm) in 10 mL volumetric flask. Added diluent 
to make up the volume up to mark and mixed well. 
Preparation of Recovery Solution (acrivastine with 150 % spiked Z-isomer): 
Transferred an accurately 5.0 mL of acrivastine stock solution(1000 ppm) and 
1.5 mL of Z-isomer stock solution(10 ppm) in 10 mL volumetric flask. Added diluent 
to make up the volume up to mark and mixed well. 
Procedure: 
5 µL of acrivastine and each recovery solution of Z-isomer were injected on 
equilibrated chromatographic system. The peak area of Z-isomer was determined. The 
corrected area of Z-isomer was used for the calculation of recovery at each level. 
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4.9.6 Robustness 
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small but deliberate variation in method parameters and provides an 
indication of its reliability during normal usage. The following parameters were 
changed to establish the robustness of the method.  The resolution between acrivastine 
and Z-isomer was determined to evaluate robustness. 
 
(a) Flow Rate Variation: 
The flow rate of the mobile phase was changed to 0.9 mL/min and 1.1 mL/min 
from 1.0 mL/min.  
 
(b) Mobile Phase Composition Variation: 
The mobile phase composition of 0.05% triflouro acetic acid:acetonitrile was 
changed to (71:29, v/v) and (73:27, v/v) from (72:28, v/v). 
 
(c) Column Oven Temperature Variation: 
The temperature of the column oven was changed to 28° C and 32° C from 
30° C.  
 
4.9.7 Intermediate Precision: 
Intermediate precision expresses variations; different days, different analysts, 
different equipments, different laboratories, etc. The objective of intermediate 
precision validation is to verify that the influence on the test results of operational and 
environmental variables of the analytical method. 
The precision test was carried out using different laboratory, different 
instrument, and different column on different day to establish intermediate precision 
of the method. 
Sample preparation and procedure: 
Sample preparation and procedure were same as shown in the section 4.9.2 
Precision The % Bias was determined between original condition and changed 
condition. 
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4.9.8 Solution Stability 
Stability of solution of acrivastine spiked with Z-isomer at specification level 
was studied by keeping the solution in tightly capped volumetric flask at room 
temperature on a laboratory bench for 2 days. Area of Z-isomer was checked for 12, 
24 and 48 h.    
Preparation of Stock Solution of Z-isomer (50 ppm): 
As per section 4.9.2 Precision. 
Preparation of Test Solution (acrivastine with 100 % spiked Z-isomer) 
 As per section 4.9.2 Precision. 
Procedure: 
5 µL of test solution was injected on equilibrated chromatographic system at 
every time point and area of the Z-isomer and acrivastine was determined. The % bias 
of area was calculated against initial value. 
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5. Result and Discussion 
 
5.1 Method Development 
 
The aim of this study is to develop chromatographic method for the separation 
of E/Z isomers of acrivastine. Structure of acrivastine and its Z-isomer are shown in 
Fig. 1 and Fig. 2 respectively in introduction section. The crude reaction mixture 
containing 30/70 ratios of E/Z isomers was used for the method development purpose. 
The wavelength for the detection was selected base of the UV spectra of both the 
isomers. The UV profile was obtained by scanning peaks from 200 to 400 nm using 
diode array detector. The UV spectra of acrivastine and its Z-isomer are presented in 
Fig. 3 and 4 respectively. It can be seen from the spectra that both isomers have first 
 max at about 200 nm but it is not an ideal wavelength for the good chromatography. 
The second  max of acrivastine is at 229nm, where Z-isomer has also reasonable 
absorbance. However, it is difficult to detect two different compounds at single 
wavelength with equal response. Therefore, 229nm wavelength was selected for the 
detection and relative response factor of Z-isomer was evaluated for accurate 
determination.      
 
 
nm200 225 250 275 300 325 350 375 
Spectra of acrivastine 
 
            Fig. 3: UV spectra of Acrivastine 
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nm200 225 250 275 300 325 350 375 
Spectra of Z-isomer 
 
Fig. 4: UV spectra of Z-Isomer 
 
HPLC is a widely used technique for the separation of geometric isomers. 
Now a day’s, variety of columns having different chemistry are available for the 
HPLC separation. The method development was initiated in J’sphere, ODS (150 x 4.6 
mm, 4 µm) column as a stationary phase. Column was kept under control temperature 
30° C. Quaternary pump was used to flow 1.0 mL/min. UV detector was operated at 
229 nm. As per the common development practice, method development was initiated 
with Water: Acetonitrile as a mobile phase in isocratic mode. Based on the 
observation of trials, different mobile phase components and stationary phases were 
tried to get desire separation goal. The detail of trials and its observation are described 
below.  
 
Trial Condition 1: 
 Column: J’sphere, ODS (150 x 4.6 mm, 4 µm) 
 Mobile phase: Water:Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 5 
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min0 2.5 5 7.5 10 12.5 15 17.5 20
mAU    
0 
50 
100 
150 
200 
250 
 7.022
 8.343
 
  
    Fig. 5: HPLC chromatogram of trial Condition 1 
 
Observation:  
It can be seen from the Fig. 5 that there was indication of separation. The peak 
shape was not good and there was no baseline resolution. Therefore, some buffer or 
ion-pairing reagent should be tried. 
 
Trial Condition 2: 
 Column: J’sphere, ODS (150 x 4.6 mm, 4 µm) 
 Mobile phase: Phosphate buffer (pH:6.8, 20mM):Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 6 
 
 
min0 5 10 15 20 25 
mAU    
0 
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200 
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300 
 7.229 
 8.563
 
 
   Fig. 6: HPLC chromatogram of trial Condition 2 
 
 
Observation:  
It was observed from chromatogram of trial condition 2 there was 
improvement in the separation but till the resolution and peak shapes were not up to 
the mark.  
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Trial Condition 3: 
 Column: J’sphere, ODS (150 x 4.6 mm, 4 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 7 
 
 
min0 5 10 15 20 25 30 
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   Fig. 7: HPLC chromatogram of trial Condition 3 
 
Observation:  
From the Fig. 7, it can be said that baseline separation achieved using 0.05 % 
triflouro acetic acid but retention was much. Peak broadening was observed for both 
the isomers. 
Based on the above three trials, it can be concluded that 0.05 % triflouro acetic 
acid and acetonitrile are preferable as a mobile phase components. To improve peak 
shapes and to reduce retention, different stationary phases should be tried.    
 
Trial Condition 4: 
 Column: YMC C8 (250 x 4.6 mm, 5 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 8 
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min0 10 20 30 40 
mAU    
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    Fig. 8: HPLC chromatogram of trial condition 4 
 
Observation:  
The peak shapes were not good and long retention.  
 
Trial Condition 5: 
 Column: Kromasil, C18 (250 x 4.6 mm, 5 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 9 
 
 
min0 10 20 30 40 50 60 
mAU    
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20 
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 66.796 
 
 
    Fig. 9: HPLC chromatogram of trial condition 5 
 
Observation:  
The peak shapes were broad and retention was too long. 
 
Trial Condition 6: 
 Column: YMC ODS-AQ (150 x 4.6 mm, 5 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 10 
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mAU    
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   Fig. 10: HPLC chromatogram of trial condition 6 
 
Observation:  
It can be seen from the Fig. 10 that there was adequate baseline resolution and 
peak shape was also improved in this column. Still, retention can be optimized using 
different brand of AQ column. 
 
Trial Condition 7: 
 Column: Cosmosil packed column, 5C18-PAQ (250 x 4.6 mm, 5 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (75:25, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 11 
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  Fig. 11: HPLC chromatogram of trial condition 7 
 
Observation:  
It can be observed from the chromatogram of trial condition 7 that both 
isomers were well separated with resolution 3.56, peak shapes were also good. 
Therefore, Cosmosil packed 5C18-PAQ column was found to be suitable for desire 
separation. Now, mobile phase composition should be optimized to reduce retention 
with maintaining adequate resolution.     
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Trial Condition 8: 
 Column: Cosmosil packed column, 5C18-PAQ (250 x 4.6 mm, 5 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (70:30, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 12 
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  Fig. 12: HPLC chromatogram of trial condition 8 
 
 
Observation:  
It can be seen from Fig. 12 that both isomers were well separated; with 
resolution 2.56. The both the isomers were eluted within 10 minutes and peak shapes 
were also good. However, to be in safer side for baseline resolution, 28 % 
composition of acetonitrile should be tried instead of 30 %.  
 
Trial Condition 9: 
 Column: Cosmosil packed column, 5C18-PAQ (250 x 4.6 mm, 5 µm) 
 Mobile phase: 0.05 % Triflouro acetic acid:Acetonitrile (72:28, v/v) 
 Flow Rate: 1.0 ml/min 
 Column Temperature: 30°C 
 Chromatogram: Fig. 13 
 
.      
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   Fig. 13: HPLC chromatogram of trial condition 9 
 
Observation:  
It can be observed from Fig. 13 that acrivastine and its Z-isomer were well 
separated; with resolution 2.98. The both the isomers were eluted within 12 minutes 
and peak shapes were symmetric. The retention was also ideal and selectivity was 
higher than the trial condition 8.  
It can be concluded from the entire method development discussion that trial 
condition 9 was optimal among all tested trial conditions. It was finalized for further 
validation study. Chromatographic parameters are as below. 
 
Elution              : Isocratic 
Column   : Cosmosil packed column, 5C18-PAQ (250 x 4.6 mm, 5 µm) 
Wave length  : 229 nm 
Column oven temp. : 30  C 
Flow rate  : 1.0 mL / min.  
Injection volume : 5 µL 
Run time  : 20 min 
Mobile phase  : 0.05 % TFA in water: Acetonitrile (72:28, v/v) 
Diluent  : Water:Acetonitrile (70:30) 
Sample conc.  : 0.5 mg/mL 
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5.2 Preparative HPLC Isolation 
 
About 1.0 to 1.5 g reaction mixture was purified by preparative HPLC. The 
fractions collected manually at five different points of the peak and purity was 
checked by analytical HPLC. It has been observed that fraction collected at the apex 
of peak was pure more than 99.0 %, rest all fractions were below 99.0 % purity in all 
injection run.  
Therefore, all the fractions below 99.0 % purity were mixed and re-injected 
for the further purification. The peak was collected in three parts and its purity was 
checked by analytical HPLC. The purity of all the three factions was found more than 
99.0 %. To get the solid material, fractions were concentrated and then dried using 
freeze-dryer. After two days drying cycle, white solid material was observed. The 100 
mg Z-isomer and 65 mg acrivastine was obtained having purity greater than 99.0 %.     
These materials were subjected to complete characterization by spectroscopic 
techniques. 
 
5.3 Characterization of Isomers 
 
The isolated samples of Acrivastine and its Z-isomer were subjected to 
complete identification and characterization. The samples were prepared at analyte 
concentration and injected in equilibrated chromatographic system. The retention time 
and UV spectrum obtained in the PDA detection was matched with that of crude 
reaction mixture for identification. The purity of the Acrivastine and its Z-isomer was 
found 99.26 and 99.02 % respectively.  
The mass spectra obtained for Acrivastine and its Z-isomer are shown in Fig. 
14 and 15 respectively. The mass spectrum showed peak at 349.56 m/z corresponds to 
the M+1 in positive ESI mode, which confirmed molecular weight of both isomers. 
The presence of the different functional group was confirmed by IR 
spectroscopy. Thus, α,β-unsaturated carboxylic acid appeared at 3416 cm-1 in 
Acrivastine as broad band, whereas in its Z-isomer, it appeared at 3379 cm-1. 
Similarly, the carbonyls in both cases appeared at 1618 and 1686 cm-1 respectively. 
The IR bands observed at different wave number are presented in Table 1. The IR 
spectra are shown is Fig. 16 and 17. 
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Fig. 14: Mass spectrum of Acrivastine 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: Mass spectrum of Z-isomer of Acrivastine 
 
 
Acrivastine
220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760
% 
0 
  
 349.56 
278.50 
217.43 267.52
279.47 
297.62 327.58 
350.53 
698.08 351.51 
377.59 395.61
469.45413.63 434.65 485.67515.81 611.43562.47551.74 593.74 675.16 619.16
699.05 
720.09 726.15 753.11
 
 Z-isomer
180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580
% 
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 349.21
278.29 
244.17 179.45 230.42 191.32 258.83 
279.20 
310.20300.12 331.27
350.18
381.28371.19
353.18
382.25
530.44 502.45 413.35 436.25 448.36 477.18 566.93542.90 580.09
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Table 1: IR bands of at different wave number 
Wave number (cm-1) 
Acrivastine Z-isomer 
3416, 1618, 1564, 1445, 1375 1298, 
1157 
3379, 3038, 1686, 1630, 1566, 1452, 1410, 
1302, 1202, 1136 
  
 
Fig. 16: IR spectrum of Acrivastine 
 
Part-A Section-III 
126 
Fig. 17: IR spectrum of Z-isomer of Acrivastine 
The widely used and acceptable technique for the structure elucidation and 
confirmation is NMR. The NMR spectra was obtained using 300 MHz instrument for 
1H, 13C and DEPT in deuteriated methanol. The peak observed in 1H and 13C NMR 
are complied in Table 2 and 3 for acrivastine and Table 4 and 5 for its Z-isomer 
respectively. The NMR spectra of acrivastine for 1H, 13C and DEPT are shown in Fig. 
18, 19 and 20, while for Z-isomer are shown in Fig. 21, 22 and 23. 
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       Table 2: 1H-NMR of Acrivastine 
Chemical Shift  (  ppm) Proton No. 
7.61 (t, 1H, ArH) 4 
7.43 (d, J=15.6 Hz, 1H, CH)  7 
7.36 (d, J=7.5 Hz, 1H, ArH)  5 
7.32 (d, J=8.1 Hz, 2H, ArH) 13, 18 
7.20 (t, 1H, ArH) 3 
7.13 (d, J=7.8 Hz, 2H, ArH) 14, 17 
7.09 (d, J=15.6 Hz, 1H, CH) 8 
6.78 (d, J=7.7 Hz, 1H, CH) 19 
3.83 (d, J=7.2 Hz, 2H, CH2) 20 
3.31 – 3.26 (m, 4H, CH2 x 2) 22, 25 
2.40 (s, 3H, CH3) 16 
2.01 (bs, 4H, CH2 x 2) 23, 24 
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        Table 3: 13C-NMR of Acrivastine 
Chemical Shift (  ppm) Nature of Carbon Assignment 
175.07 
Quaternary 
9 
157.37, 155.5 2, 6 
148.04 11 
139.63 15 
134.88 12 
138.58, 139.80 
Methine 
4, 7 
131.07 5 
130.76, 130.61 13, 14, 17,  18 
122.45, 123.50, 123.68 3, 8, 19 
54.55 
Methylene 
20, 22, 25 
24.02 23, 24 
21.30 Methyl 16 
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Fig. 18: 1H-NMR of Acrivastine 
 
Fig. 19: 13C-NMR of Acrivastine 
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Fig. 20: 13C-DEPT of Acrivastine 
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  Table 4: 1H-NMR of Z-isomer 
Chemical Shift (  ppm) Proton No. 
7.88 (t, 1H, ArH) 4 
7.76 (d, J=15.8 Hz, 1H, CH) 7 
7.69 (d, J=7.8 Hz, 1H, ArH) 5 
7.19(s, 4H, ArH) 13, 14, 17, 18 
7.18 (d, J=6.9 Hz, 1H, ArH) 3 
6.88 (d, J=15.8 Hz, 1H, CH) 8 
6.25 (t, J=7.5 Hz, 1H, CH) 19 
4.00 (d, J=6.9 Hz, 2H, CH2) 20 
3.67 (bs, 2H, CH2) 22, 25 
3.20 (bs, 2H, CH2) 
2.33 (s, 3H, CH3) 16 
2.09 (bs, 4H, CH2 x 2) 23, 24 
 
 
 
 
 
Part-A Section-III 
130 
 
        Table 5: 13C-NMR of Z-isomer 
Chemical Shift (  ppm) Nature of Carbon Assignment 
175.04 
Quaternary 
9 
157.35, 155.36 2, 6 
148.61 11 
139.62 15 
134.89 12 
139.85, 138.54 
Methine 
7, 4 
131.04, 130.77, 130.62 5, 13, 18, 14, 17 
123.66, 123.52, 122.43 8, 3, 19 
54.57 
Methylene 
20, 22, 25 
24.02 23, 24 
21.30 Methyl 16 
 
 
Fig. 21: 1H Spectrum of Z-isomer 
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Fig. 22: 13C Spectrum of Z-isomer 
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Fig. 23: 13C-DEPT of Z-isomer 
Being regioisomers, Acrivastine and its Z-isomers, by and large show similar 
1H and 13C-NMR patterns. Both provide complete accountability for every proton and 
carbon via their δ values, types of protons, carbons, multiplicity patterns, integration 
and nature of carbons (methyl, methylene, methane and quaternary) via DEPT 
experiments. The differences are due to their geometric isomer nature, which is 
described below.    
The characterization of geometric isomers of Acrivastine in 1H-NMR, 
deshielding of H19 at 6.78 δ ppm is obvious in E-isomer, i. e. Acrivastine due to intra 
molecular H-bonding, whereas it is shielded at 6.25   δ ppm in Z-isomer. Similar 
effects of shielding (3.83 δ ppm for CH2, H20) in E-isomer and deshielding (4.00 δ 
ppm) of Z-isomer are noteworthy. 
Form above spectroscopic data of Mass, IR and NMR (1H. 13C and DEPT) 
confirmed the structure of both the isomers and the values for 1H-NMR, 13C-NMR 
and Mass are in total agreement with assigned chemical structure. 
 
5.4 Determination of the Relative Response Factor (RRF) of Z-isomer 
 
Since, two different compounds may have different UV profile, therefore, 
detection of them at single wavelength will not give equal response. In order to 
calculate exact amount of impurity, relative response factor is required. Here, 
response factor of Z-isomer relative to acrivastine has been determined. The results of 
experiment are presented in Table 6. 
 
          Table 6: Results of Relative Response Factor  
 
Parameters Acrivastine Z-isomer 
Area - 1 102 57.7 
Area - 2 101.4 58 
Area - 3 103.6 58.3 
Area - 4 103.5 58.3 
Area - 5 103.1 58.6 
Average Area 102.72 58.18 
SD 0.87 0.31 
RSD 0.85 0.53 
RRF 1 0.57 
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Correction Factor 1 1.76 
 It can be seen from the Table 1 that response of the Z-isomer is less at 229nm 
as compare to acrivastine, which is also supported by UV spectra. The multiplication 
of correction factor and percentage of Z-isomer from the area normalize method will 
give exact amount present in the tested sample.  
 
5.5 Results of Method Validation  
5.5.1 Results of System Suitability and Specificity 
The system suitability results are summarized in Table 7, which showed that 
resolution between acrivastine and its Z-isomer was not less than 2.8. Peak purity of 
acrivastine and its Z-isomer was not less than 0.999/990 using PDA detector. Report 
of peak purity is presented in Fig. 24. 
 
    Table 7: System suitability data 
 
System suitability parameters Z-isomer 
(n =3) 
Acrivastine 
(n=3) 
Retention factor (k) 2.54 2.87 
Selectivity ( )  1.13 
Resolution (Rs) 2.98  
Symmetry (S) 0.78 0.80 
Theoretical Plates (N) 10766 12297 
 
 
  (a)     (b) 
Fig. 24: Peak purity report of (a) Acrivastine and (b) Z-isomer 
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The retention time of the peak of acrivastine and its Z-isomer was 10.8 and 9.9 
minutes respectively. No interference was observed in the chromatogram of the 
diluent and mobile phase at the retention time of acrivastine and its Z-isomer. The 
retention time identification of acrivastine and its Z-isomer and chromatogram of the 
specificity study are presented as Fig. 25, 26 and 27. 
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Fig. 25: Chromatogram of Acrivastine 
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Fig. 26: Chromatogram of Z-isomer 
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Fig. 27: Chromatogram of Acrivastine + Z-isomer 
 
5.3.2 Result of Precision 
  The precision was determined for acrivastine spiked with Z-isomer at 100 % 
specification level. The relative standard deviation of retention time and area was 
calculated for six replicates injection. The area of Z-isomer was corrected with ‘3.5’ 
area already present in the selected batch of acrivastine sample. The result of precision 
study is presented in Table 8.  
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Table 8: Result of Precision Study 
Precision Data 
Sr. No 
Acrivastine Z-isomer 
RT Area RT Area Corrected Area 
1 10.85 11000.10 9.928 16.50 13.00 
2 10.848 11040.30 9.925 16.70 13.20 
3 10.838 11043.20 9.919 16.60 13.10 
4 10.829 11057.70 9.912 16.60 13.10 
5 10.833 11073.30 9.915 16.30 12.80 
6 10.83 11104.10 9.911 16.30 12.80 
Average 10.84 11053.12 9.92 16.50 13.00 
SD 0.01 34.93 0.01 0.17 0.17 
% RSD 0.08 0.32 0.07 1.01 1.29 
 
It can be seen from the data that relative standard deviation of retention time 
and peak area is less than 0.1 % and 2.0 %, respectively for acrivastine and its Z-
isomer. The result of precision are within general acceptance limit, therefore 
developed method is precise for its intended use.   
 
5.3.3 Result of Limit of Detection and Limit of Quantitation 
The LOD and LOQ concentration were estimated to be 0.05 and 0.2 ppm for 
Z-isomer, when the signal-to-noise ratio of 3 and 10 were used as the criteria. The 
method precision for Z-isomer at LOQ was 2.7 % RSD; data are presented in Table 9. 
The area of Z-isomer was corrected with ‘3.5’ area already present in the selected 
batch of acrivastine sample. The recovery of Z-isomer at LOQ was 106.5 % in the 
spiked acrivastine sample. It can be said that LOQ value of the Z-isomer is quite law 
than the specification limit. The method is precise and accurate at LOQ level. 
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Table 9: Results of Precision study at LOQ level 
Sr. No 
Z-isomer at LOQ level 
RT Area Corrected Area 
1 9.844 7.30 3.80 
2 9.847 7.40 3.90 
3 9.847 7.20 3.70 
4 9.859 7.40 3.90 
5 9.863 7.30 3.80 
6 9.893 7.50 4.00 
Average 9.86 7.35 3.85 
SD 0.02 0.10 0.11 
% RSD 0.19 1.43 2.72 
 
 
5.3.4 Result of Linearity of Z-isomer 
The described method was linear in the range of 0.2-3.0 ppm for Z-isomer. 
Plotting the peak area versus its corresponding concentration with a correlation 
coefficient of 0.999 drew the calibration curve. The equation of the calibration curve 
for Z-isomer was y = 12.1937x + 1.1019. Linearity was checked for Z-isomer over the 
same concentration range for three consecutive days. The peak area at different 
concentration of Z-isomer for Day-1, Day-2 and Day-3 are presented in Table 10, 11 
and 12 respectively. The linearity graph of Day-1, Day-2 and Day-3 are shown in Fig. 
28, 29 and 30 respectively. The percentage relative standard deviation of the slope 
and Y-intercept of the calibration curve were 1.08 and 7.79, respectively. The data are 
summarized in Table 13. It can be concluded that method is linear within the studied 
range. 
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                 Table 10: Data of linearity of Z-isomer at Day-1 
Concentration (ppm) Area 
0.2 3 
0.5 7.6 
1 13.6 
1.5 19.1 
2 25.9 
3 37.1 
 
Linearity at Day-1
y = 12.089x + 1.1954
r = 0.999
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        Fig. 28: Linearity plot of Z-isomer at Day-1  
 
                 Table 11: Data of linearity of Z-isomer at Day-2 
Concentration (ppm) Area 
0.2 3 
0.5 7.6 
1 13 
1.5 19.2 
2 25.8 
3 37.2 
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Linearity at Day-2 y = 12.151x + 1.0266
r = 0.999
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      Fig. 29: Linearity plot of Z-isomer at Day-2  
 
                Table 12: Data of linearity of Z-isomer at Day-3 
Concentration (ppm) Area 
0.2 3.3 
0.5 7.4 
1 13.2 
1.5 19.9 
2 26.1 
3 37.8 
 
Linearity at Day-3 y = 12.341x + 1.0836
r = 0.999
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    Fig. 30: Linearity plot of Z-isomer at Day-3  
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 The general acceptance criteria for correlation coefficient are, it should not be 
less than 0.995. The correlation coefficient of Z-isomer was 0.999. The result showed 
the excellent correlation between the peak area and concentration for Z-isomer in 
developed method. 
 
Table 13: Results of Linearity Study 
Linearity 
Equation of Calibration curve 
Slope Intercept 
Day 1 12.089 1.1954 
Day 2 12.151 1.0266 
Day 3 12.341 1.0836 
Average 12.1937 1.1019 
SD 0.13 0.086 
% RSD 1.08 7.79 
 
 
5.3.5 Result of Accuracy/Recovery 
In order to determine the accuracy of the method standard addition and 
recovery experiments were conducted in triplicate at 50, 100 and 150 % level of Z-
isomer with respect to specification limit, i.e. 0.5, 1 and 1.5 ppm of Z-isomer. The 
recovery was calculated from slope and Y-intercept of the calibration curve obtained 
in linearity study. The acrivastine batch used for the study contains small amount of 
Z-isomer, therefore for the area correction, API sample was injected at same 
concentration. The area obtained was ‘3.5’.  
 The area obtained for Z-isomer in the spiked recovery solution was corrected 
by area present in the acrivastine sample solution. The recovery Z-isomer at all the 
tested level was calculated and mean of recovery of three different sets was also 
determined. The data are presented in Table 14. 
 
 
 
 
 
Part-A Section-III 
140 
Table 14: Results of accuracy/recovery of Z-isomer 
Test 
Accuracy at 50 % level Accuracy at 100 % level Accuracy at 150 % level 
Set1 Set 2 Set3 Set1 Set 2 Set3 Set1 Set 2 Set3 
Area 10.4 10.7 10.5 16.6 16.5 16.4 22.8 23.0 22.6 
Corrected 
area 
6.9 7.2 7.0 13.1 13.0 12.9 19.3 19.5 19.1 
% 
Recovery 
95.10 100.02 96.74 98.40 97.58 96.76 99.50 100.59 98.40 
Mean 
Recovery 
97.29 % 97.58 % 99.50 % 
% RSD 2.58 0.84 1.10 
 
It can be seen from the data that recovery of Z-isomer is between 95 to 101 % 
at all the tested level. The recovery experiment demonstrated excellent accuracy of 
the developed method for the determination of Z-isomer in acrivastine bulk drug. 
 
5.3.6 Result of Robustness 
The chromatographic resolution between acrivastine and its Z-isomer was 
used to evaluate the method robustness under modified conditions. The results 
robustness testing are summarized in Table 15. 
 
Table 15: Results of Robustness Study 
Parameter Resolution between 
Acrivastine and its Z-isomer 
Flow rate (mL/min) 
     0.9 3.09 
     1.0 2.98 
     1.1 2.83 
Mobile Phase Composition (0.05 % TFA:Acetonitrile, v/v) 
     71:29 2.79 
     72:28 2.98 
     73:29 3.21 
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Column Temperature (° C) 
     28 3.05 
     30 2.98 
     32 2.84 
 
The resolution between acrivastine and its Z-isomer was found 2.98 in original 
condition. There was no major effect observed on resolution, under all the deliberately 
changed conditions. Therefore, it can be concluded that the developed method is 
robust for its intended use. 
 
5.3.7 Result of Intermediate Precision 
In order to evaluate reproducibility and ruggedness of the method, precision test 
was repeated using different instrument and column in second laboratory at different 
day. The experiment was carried out for acrivastine spiked with Z-isomer at 100 % 
specification level. The relative standard deviation of retention time and area was 
calculated for six replicates injection. The area of Z-isomer was corrected with ‘3.6’ 
area of Z-isomer obtained in the selected batch of acrivastine sample on same day. The 
result of precision study is presented in Table 16.  
The intermediate precision of the method was established by calculating 
percentage bias of retention time and area at two different conditions. The result of 
ruggedness is shown in Table. 17.    
 
Table 16: Result of Precision Study at Different Day 
Precision Data 
Sr. No 
Acrivastine Z-isomer 
RT Area RT Area Corrected Area 
1 10.825 11050.10 9.931 16.80 13.20 
2 10.846 11088.30 9.926 16.70 13.10 
3 10.826 11095.20 9.918 16.80 13.20 
4 10.844 11064.70 9.92 16.60 13.00 
5 10.824 11073.30 9.915 16.50 12.90 
6 10.839 11040.10 9.935 16.90 13.30 
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Average 10.83 11068.62 9.92 16.72 13.12 
SD 0.010 21.39 0.01 0.15 0.15 
% RSD 0.09 0.19 0.08 0.88 1.12 
 
 
Table 17: Results of Intermediate Precision Study 
Compd 
Average Retention Time Average Peak Area 
Original 
Conditio
Different 
Condition % Bias 
Original 
Condition
Different 
Condition % Bias 
Z-isomer 9.92 9.92 0.0 13.00 13.12 0.92 
Acrivastine 10.84 10.83 -0.10 11053.12 11068.62 0.14 
 
The bias between original and different conditions was found below 2.00 % 
for retention time peak area of acrivastine and its Z-isomer. Therefore, it can be 
concluded that developed method is rugged enough for its intended use. 
 
5.3.8 Result of Solution Stability 
Solution stability of acrivastine was carried out in diluent for 48 hours. The % 
bias of the area of Z-isomer was calculated with the initial area of fresh injection. The 
result of the solution stability is presented in Table 18. 
 
           Table 18: Result of Solution Stability 
Sr. No. Time (h) Area of Z-isomer % Bias 
1 0 16.4 - 
2 12 16.5 0.61 
3 24 16.3 -0.61 
4 48 16.2 -1.21 
 
The bias of area of Z-isomer after 12, 24 and 48 hours was found less than   
2.0 %. From data, it can be said that the sample solution is stable at room temperature 
for atleast 48 hours. Therefore, it can be concluded that sample solution can be use 
within 48 hours from the time of preparation. 
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6. Conclusion 
 
A simple, rapid, robust, suitable, precise and accurate HPLC method has been 
developed and validated for the determination of Z-isomer in acrivastine bulk drug. 
The systematic method development was approached in the selection of wavelength, 
selection of stationary phase, selection of mobile phase components and composition. 
The relative response factor was also determined for Z-isomer. 
The method was extended to preparative HPLC isolation of the Z-isomer from 
the crude reaction mixture. Successfully, Z-isomer was isolated with HPLC purity 
99.02 %. The isolated pure Z-isomer was completely characterized by 1H, 13C-NMR 
and DEPT, IR, UV, Mass and HPLC. The spectroscopic difference between 
acrivastine and its Z-isomer was discussed. 
The developed method was completely validated for the determination of the 
Z-isomer in acrivastine with respect to specificity, system suitability, linearity, limit 
of detection and quantitation, accuracy, precision, robustness, intermediate precision 
and solution stability. The result of validation showed satisfactory data for all the 
method validation parameters tested.  
The developed method can be used for the determination of Z-isomer in 
acrivastine with limit of detection 0.05-ppm level. 
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1. Introduction 
 
Impurities in pharmaceuticals are the unwanted chemicals thoset remain with the 
Active Pharmaceutical Ingredients (APIs), or develop during formulation, or upon aging 
of both API and formulated APIs to medicines. The presence of these unwanted 
chemicals even in small amounts may influence the efficacy and safety of the 
pharmaceutical products. Impurity profiling (i.e., the identity as well as the quantity of 
impurity in the pharmaceuticals), is now getting receiving important critical attention 
from regulatory authorities. The different pharmacopoeias, such as the British 
Pharmacopoeia (BP) and the United States Pharmacopoeia (USP), are slowly incorpora 
ting limits to allowable levels of impurities present in the APIs or formulations. Also, the 
International Conference on Harmonization (ICH) has published guidelines on impurities 
in new drug substances [1], products [2], and residual solvents [3]. In addition, Ahuja [4] 
and Gorog [5] have published books covering different aspects of impurities, including 
the governmental regulations and guidelines and the identification and monitoring of 
impurities found in drug products. There is a significant demand for the impurity-
reference standards along with and the API reference standards for both regulatory 
authorities and pharmaceutical companies.  
Organic impurities may arise during the manufacturing process and/or on storage 
of the drug substance. The major source of organic impurities is process related 
impurities. 
Starting materials, intermediates, precursors etc. are the most common impurities found 
in every API unless a proper care is taken in every step involved throughout the multi-
step synthesis. Sometimes, impurities of intermediate and precursor generate structurally 
related by-product during synthesis.   
The study describes development and validation of the chromatographic method 
for the determination of the process related impurities. Azathioprine has been selected for 
the study. It is an immunosuppressive drug co-administered with cyclosporine and 
corticoids to prevent rejection after transplantation. Ultra Performance Liquid 
Chromatography (UPLC) method for the determination of four impurities (Impurity-A, 
Impurity-B, Impurity-C and Impurity-D) along with azathioprine has been developed. 
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Structural information of the impurities are presented in Table 1. Specification limit of 
each impurity has been decided that it should not be more than 0.2 %. The synthesis of 
azathioprine as described in Scheme 1[6], Impurity-A and Impurity-B may be present as 
an un-reacted precursor, while Impurity-C [5-Chloro-1-methyl-2,4-dinitro-1H-imidazole] 
is the impurity arising by over reaction during synthesis of Impurity-B and Impurity-D is 
the byproduct of the coupling of Impurity-A and Impurity-C as per this route of 
synthesis. 
HNO 3H2SO4
N
N
Cl
NO2
N
N
N
N
N
H
SN
NO2
N
N
N
N
H
SH
N
N
N
N
H
OH
P2S5
N
N
Cl
5-Chloro-1-methyl-imidazole
5-Chloro-1-methyl-4-nitro- imidazole
(Impurity-B)
Azathioprine
6-Mercaptopurine
(Impurity-A)
Pyridine
6-Hydroxypurine
Base
water
 
    Scheme 1: Synthetic scheme of Azathioprine 
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Table 1: Structural Information About Impurities 
Code of 
Impurity Structure Description 
Impurity-A N
NNH
N
SH
 
IUPAC Name: 9H-Purine-6-thiol 
 
Molecular Formula: C5H4N4S 
 
Molecular Weight: 152.18 g/mol 
 
HPLC Purity: 99.97 % 
Impurity-B 
N
N
O2N
Cl
CH3  
IUPAC Name: 5-Chloro-1-methyl-
4-nitro-1H-imidazole 
 
Molecular Formula: C4H4ClN3O2 
 
Molecular Weight: 161.55 g/mol 
 
HPLC Purity: 99.98 % 
Impurity-C 
N
N
CH3
O2N
Cl
NO2
 
IUPAC Name: 5-Chloro-1-methyl-
2,4-dinitro-1H-imidazole 
 
Molecular Formula: C4H3ClN4O4 
 
Molecular Weight: 206.54 g/mol 
 
HPLC Purity: 95.40 % 
Impurity-D 
N
NNH
N
S
N
N
CH3
O2N
NO2
 
IUPAC Name: 6-(3-Methyl-2,5-
dinitro-3H-imidazol-4-ylsulfanyl)-
9H-purine 
 
Molecular Formula: C9H6N8O4S 
 
Molecular Weight: 322.26 g/mol 
 
HPLC Purity: 99.50 % 
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1.1 Drug Profile 
 
1.1.1 Description  
Azathioprine (Fig. 1) is the nitro imidazole derivative of 6-mercaptopurine. It is 
chemically, 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-9H-purine. Its molecular 
formula is C9H7N7O2S having molecular weight 277.26 g/mole. 
 
N
NNH
N
S
N
N
CH3
O2N
 
 
 
Fig. 1:  Chemical Structure of Azathioprine 
 
 
1.1.2 Mechanism of Action 
 The exact mechanism of immunosuppressive activity of azathioprine has not been 
determined. Azathioprine, which is an antagonist to purine metabolism, may inhibit RNA 
and DNA synthesis. The drug may also be incorporate into nucleic acid resulting in 
chromosomes break, malfunctioning of the nucleic acid, or synthesis of fraudulent 
proteins. The drug may also inhibit coenzyme formation and functioning, there by 
interfering with cellular metabolism. Mitosis may be  inhibited by drug [7]. 
 Azathioprine is also a potent inhibitor of mixed lymphocyte culture responses and 
can readily suppress the in vitro generation of cytotoxic T cells. These observations 
suggest that drugs exert preferential toxicities for murine T cells. Blymphocytes for mice 
appear to vary in there susceptibility for thiopurines. By contrast, the activity of human B 
cells can be readily suppressed with this drug whereas T helper function is completely 
unaltered. In addition to immunosuppressive properties, thiopurins are capable of 
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exerting anti-inflammatory activities, primary by inhibiting the replication of 
hematopoietic precursors.  
 
1.1.3 Clinical Use 
Adjunct with other agents in prevention of rejection of kidney transplants; also 
used in severe active rheumatoid arthritis unresponsive to other agents, other autoimmune 
diseases (ITP, SLE, MS, Crohn's disease). 
A study has suggested that long-term treatment with Azathioprine may prevent 
extravation and cause reduction in neutrophile trafficking which may be beneficial for 
maintaining remission in IBD. 
In addition immunosuppressive properties, thiopurines are capable of exerting 
anti-inflammatory activities by inhibiting cyclooxygenase production [7, 8]. 
 
1.1.4 Pharmacokinetics 
Azathioprine is fast and extensively metabolized when administer orally in mice. 
Azathioprine undergoes first pass metabolism in mice indicated by the presence of 
thiouric acid, the end product of azathioprine metabolism in intestinal mucosa and liver. 
The initial concentration of 6-MP extracted from the organs was about 10 fold those 
found in plasma indicating rapid cellular uptake of 6-MP. The conversion of azathioprine 
to 6-mercaptopurine in vivo may be catalyzed largely enzymatically by glutathione S-
transferase in the liver [9]. 
 6-MP administration in rhesus monkeys, 6-MP levels were described by a two-
compartment body model; mean terminal half life; plasma clearance (CLp) and volume 
of distribution (Vdss) were 41.6 ± 12.1 min, 48 ± 15.4 ml/min/kg and 1.76 ± 0.64 
liters/kg respectively. 
 
Distribution: Crosses placenta  
Protein binding: ~30%  
Metabolism: Extensively hepatic via xanthine oxidase to mercaptopurine (active); 
mercaptopurine requires detoxification by thiopurine methyltransferase (TPMT)  
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Half-life elimination: Parent drug: 12 minutes; mercaptopurine: 0.7-3 hours; End-stage 
Renal disease: Slightly prolonged  
Excretion: Urine (primarily as metabolites) 
 
1.1.5 Dosage 
I.V. dose is equivalent to oral dose (dosing should be based on ideal body weight):  
Children and Adults: Renal transplantation: Oral, I.V.: 2-5 mg/kg/day to start, then 1-3 
mg/kg/day maintenance  
Adults: Rheumatoid arthritis: Oral: 1 mg/kg/day for 6-8 weeks; increase by 0.5 mg/kg 
every 4 weeks until response or up to 2.5 mg/kg/day  
 
Dosing adjustment in renal impairment: 
Clcr 10-50 mL/minute: Administer 75% of normal dose daily  
Clcr<10 mL/minute: Administer 50% of normal dose daily  
Hemodialysis: Slightly dialyzable (5% to 20%)  
Administer dose posthemodialysis: CAPD effects: Unknown; CAVH effects: Unknown 
 
1.1.6 Adverse Reactions 
Central nervous system: Fever, chills  
Dermatologic: Alopecia, erythematous or maculopapular rash  
Gastrointestinal: Nausea, vomiting, anorexia, diarrhea, aphthous stomatitis, pancreatitis  
Hematologic: Leukopenia, thrombocytopenia, anemia, pancytopenia (bone marrow 
suppression may be determined, in part, by genetic factors, ie, patients with TPMT 
deficiency are at higher risk)  
Hepatic: Hepatotoxicity, jaundice, hepatic veno-occlusive disease  
Neuromuscular & skeletal: Arthralgias  
Ocular: Retinopathy  
Miscellaneous: Rare hypersensitivity reactions which include myalgia, rigors, dyspnea, 
hypotension, serum sickness, rash; secondary infection may occur secondary to 
immunosuppression 
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1.1.7 Overdosage/Toxicology 
 Symptoms of overdose include nausea, vomiting, diarrhea, and hematologic 
toxicity. Following initiation of essential overdose management, symptomatic and 
supportive treatment should be instituted. Dialysis has been reported to remove 
significant amounts of the drug and its metabolites, and should be considered as a 
treatment option in those patients who deteriorate despite established forms of 
therapy[10]. 
 
1.1.8 Drug Interactions 
ACE inhibitors: Concomitant therapy may induce leukopenia.  
Allopurinol: May increase serum levels of azathioprine's active metabolite 
(mercaptopurine). Decrease azathioprine dose to 1/3 to 1/4 of normal dose.  
Aminosalicylates (olsalazine, mesalamine, sulfasalazine): May inhibit TPMT, increasing 
toxicity/myelosuppression of azathioprine. Use caution.  
Warfarin: Effect may be decreased by azathioprine[11]. 
 
1.1.9 International Brand Names 
Alti-Azathioprine (CA); Apo-Azathioprine® (CA); Azafalk® (DE); Azahexal® (AU); 
Azamedac® (DE); Azamun® (AU, CZ, FI, NZ, RO); Azamune® (GB); Azanin® (JP); 
Azapress® (ZA); Aza-Q® (DE); Azarek® (CH, DE); azathiodura® (DE); Azathioprin 
1A Pharma® (DE); Azathioprin AL® (DE); Azathioprin beta® (DE); Azathioprine® 
(GB, PL, RO, TR); Azathioprine PCH® (SG, TR); Azathioprine Pharmachemie® (TH); 
Azathioprin Hexal® (DE); Azathioprin-Puren® (DE); Azathioprin-ratiopharm® (DE); 
Azathioprin Stada® (DE); Azatioprina Asofarma® (AR); Azatioprina® (CL); 
Azatioprina Filaxis® (AR); Azatioprina Wellcome® (IT); Azatioprin NM Pharma® 
(SE); Azatrilem® (MX); Azopi® (IL); Azopine® (IE); Azoran® (IN); Colinsan® (DE); 
Gen-Azathioprine (CA); Immunoprin® (GB); Imuger® (IE); Imunen® (BR); Imuprin® 
(CY, FI, RO); Imuran® (AR, AU, BD, BE, BG, BR, CA, CL, CZ, EC, GB, HR, HU, ID, 
IE, IL, IN, KW, LU, MX, NL, NZ, PL, RO, RU, SG, SI, TH, TR, YU); Imuran® [inj.] 
(RO, TR); Imuran Paranova® (DK); Imurek® (AT, CH, DE); Imurek® [inj.] (AT, CH, 
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DE); Imurel® (DK, ES, FI, FR, NO, SE); Oprisine® (GB); Thioprine® (AU, NZ); 
Transimune® (IN); Zaprine 50® (ZA); Zytrim® (DE) 
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2. Literature Review 
 
The literature survey revealed that Azathioprine was mainly determined by HPLC 
method, since information was not obtained on UPLC. 
A through literature review, it has been observed that numerous HPLC methods 
have been developed for the determination of 6-MP and its metabolites in biological 
fluids [12-15]. In addition, a HPLC-mass spectrometry method for the detection of 6-
TGNs and 6-mMPNs has been developed, recently [16]. Few of the literature input 
described below in detail. 
 
US Pharmacopoeia, USP 30, 2007, 1471-72 
Test for Mercaptopurine: Prepare three solutions in 6 N ammonium hydroxide 
containing respectively, 20 mg of Azathiopurine per mL, 2 mg of USP Azathiopurine RS 
per mL, and 200 µg of USP Mercaptopurine RS, on the anhydrous basis, per mL. Apply 
5 µL volumes of the solution at points about 2 cm from the bottom edge of a thin-layer 
chromatographic plate coated with a 0.25 mm layer of microcrystalline cellulose. Allow 
the spot to dry, and develop the chromatogram in a suitable chamber, using butyl alcohol, 
previously saturated with 6 N ammonium hydroxide, as a solvent, until the solvent front 
has moved about 15 cm from the point of application. Remove the plate, air-dry and 
locate the spot by viewing under short- and long wavelength UV light: any spot in the 
chromatogram from Azothioprine, other than the principal spot, is not more intense than 
the spot in the chromatogram obtained with USP Mercaptopurine RS (1.0%) [17]. 
 
Ahmed F. Hawwa, Jeff S. Millership, Paul S. Collier, James C. McElnay 
Development, validation of an HPLC method for the rapid and simultaneous 
determination of 6-mercaptopurine and four of its metabolites in plasma and red 
blood cells. Journal of Pharmaceutical and Biomedical Analysis (2008), 
doi:10.1016/j.jpba.2008.10.045 
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Chromatographic separation was achieved using reversed phase chromatography 
with isocratic elution. An Atlantis™ dC18 column [150 mm × 3.9 mm (i.d.); particle 
size, 3 µm; Waters] protected with a guard cartridge [20 mm × 3.9 mm; particle size, 3 
µm; Waters] was used as the stationary phase. 
The mobile phase, consisting of acetonitrile, methanol and KH2PO4 (0.02 M; pH 
2.25) (3:1:96, v/v/v), was filtered and degassed through a 0.45 µm filter and pumped at a 
flow rate of 1 ml/min. The column temperature was maintained at 25°C. 
UV detection was employed at 322 nm (for the detection of 6-MP and the 6-mMP 
derivative) and 342 nm (for the detection of 6-TU, 6-TG and 6-TX) [18]. 
 
Thierry Dervieux, Roselyne Boulieu, Simultaneous determination of 6-thioguanine 
and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by 
HPLC, Drug monitoring and toxicology, Clinical chemistry 44:3, 551-555 (1998) 
6-TG and Me6-MP derivative liberated from the nucleotide moiety were analyzed 
by a reversed-phase HPLC method. The separation was performed on a Purospher RP 18-
e column, 5-mm particle size, protected by a Purospher RP 18-e guard column (from 
Merck) with a linear gradient elution mode with 0.02 mol/L potassium phosphate (pH 
3.5) and 0.02 mol/L potassium phosphate (pH 3.5):methanol (40:60 by vol). The 
concentration of methanol varied from 0 to 200 mL/L over a period of 12 min. The flow 
rate was 1.2 mL/min. Detection of 6-TG and Me6-MP derivative was performed at 341 
nm and 304 nm respectively. Peak identity was confirmed through library matching by 
comparison of unknown peak to reference spectra of calibrator. All analyses were 
performed at ambient temperature [15]. 
 
Tatiana Tatit Fazio, Anil Kumar Singh, Erika Rosa Maria Kedor-Hackmann, 
Maria Ines Rocha Miritello Santoro. Quantitative determination and sampling of 
azathioprine residues for cleaning validation in production area. Journal of 
Pharmaceutical and Biomedical Analysis 43 (2007) 1495--1498 
The aim of the author for this study was to validate simple analytical method for 
verification of residual azathioprine in equipments used in the production area and to 
confirm efficiency cleaning procedure. Analytical conditions were developed through the 
LC system using Nova-Pak C18 (3.9mm×150 mm, 4µm) WATERS®. The mobile phase 
Part-B Section-I 
156 
was constituted of methanol--water--acetic acid (20:80:1, v/v/v), at a flow rate of 1.0 
mL/min. UV detection was made at 280 nm. The volume of injection was fixed at 20µL. 
All analyses were done at room temperature 25±2 °C, approximately. The mobile phase 
was prepared fresh each day, vacuum-filtered through a 0.45 µm Millex® (HV) 
hydrophilic membrane and degassed by ultrasonication for 20 min [19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Aim of Present Work 
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As per discussion in the literature review, a few chromatographic methods are 
reported for the determination of the impurities and metabolites of azathioprine. So far to 
our present knowledge, there is no validated UPLC method for the determination of 
process related impurities in azathioprine. In official compendia and in-house standard 
testing procedure of laboratory for old drugs, most of the methods are in HPLC. Though 
HPLC is a well-established reliable technique used in controlling the quality and 
consistency of active pharmaceutical ingredients and dosage forms, it is often a slow 
technique because of complexity of some of the samples, it could still be improved. In the 
recent trend, most of the laboratories are being equipped with fast LC. Ultra Performance 
Liquid Chromatography (UPLC) is a new category of separation technique based upon 
well-established principles of liquid chromatograph, which utilize sub-2  m particles for 
stationary phase. To accelerate process development and fast quality control of old drugs, 
chromatographic methods using advance technology are most welcomed. Therefore, our 
aim is to develop simple, rapid and accurate UPLC method for the determination of the 
process related impurities of azathioprine bulk drug, which can be used comfortably in 
day-to–day activities.  
    The present work deals with the systematic method development studies, 
determination of the relative response factor for each impurity and validation of the 
method. In the method validation, specificity, linearity, accuracy, precision and limit of 
quantification and detection have been evaluated for each impurity. The robustness and 
solution stability of the method were also established. The developed method is 
recommended for routine monitoring of process development and quality control 
analysis. 
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4. Experimental 
 
 Materials and Instruments 
Drug and Impurities Samples 
 Azathioprine, Impurity-A, Impurity-B, Impurity-C and Impurity-D were in-
house samples, synthesized by Process Research Department of Zydus Research 
Center, Cadila Healthcare Ltd., Ahmedabad. 
 
Chemicals and Solvent Used 
  Methanol – s d fine-CHEM Limited, Mumbai 
  Acetonitrile - s d fine-CHEM Limited, Mumbai 
  Trifluoro acetic acid – SIGMA-ALDRICH CHEMIE GmbH, Germany 
  Hydrochloric acid – s d fine-CHEM Limited, Mumbai 
  Sodium hydroxide - s d fine-CHEM Limited, Mumbai 
  Hydrogen peroxide - s d fine-CHEM Limited, Mumbai 
  Potassium bromide - s d fine-CHEM Limited, Mumbai 
  Water – HPLC grade water 
 
Instruments Used 
  UPLC – WATERS ACQUITY Ultra performance LC 
  Analytical balance – Mettler Toledo 
  Sonicator – Bandelin electronic Heinrichstra Be 3-4 D-12207 Berlin, Germany 
  Vortexer – Spinix 
 
 Preparation of 0.05 % TFA in water 
Transferred accurately 500 µL of Trifluoro acetic acid into a 1000 mL 
volumetric flask containing approximately 700 mL of water. Dissolved  and make 
volume up to the mark with HPLC grade water, filter through 0.45 µm filter. 
 
4.3  Preparation of Diluent (0.1 % ammonia in methanol) 
  Transferred accurately 250 µL of ammonia solution into a 250 mL volumetric 
flask. Dissolved and make up to the volume with HPLC grade methnaol, filter 
through 0.45 µm filter. 
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4.4 Test Sample Preparation 
Weighed accurately about 25 mg of Azathioprine sample into 25 mL of 
volumetric flask. Add 10 to 15 mL of diluent and sonicated to dissolve the solid. 
Diluted to make up volume up to the mark with diluent and mixed well. 
 
4.5 Chromatographic Parameters of Finalized Method 
Elution              : Gradient 
Column   : AQUITY UPLC BEH C18, 100 x 2.1 mm, 1.7 µm  
Wave length  : 220 nm 
Column oven temp. : 30  C 
Flow rate  : 0.35 mL / min.  
Injection volume : 1 µL 
Retention time  : About 2.8 min.  
Run time  : 5 min 
Mobile phase  : 0.05 % TFA in water: Acetonitrile (Gradient) 
Diluent  : 0.1 % Ammonia in methanol 
Sample conc.  : 1.0 mg/mL 
Gradient program : 
 
Time (minutes) 0.05 % TFA in Water (%) Acetonitrile (%) 
0.0 97 03 
1.0 97 03 
3.5 40 60 
4.0 40 60 
4.1 97 03 
5.0 97 03 
 
Sequence run to determine impurities: 
Sr. No. 
Solution to be 
injected 
No. of injections 
Cumulative 
injections 
1 Diluent 1 1 
2 Mobile phase 1 2 
3 Sample preparation 2 4 
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Calculation: 
 Calculate the amount of impurities and % purity by area normalization, 
calculate exact amount of impurities by multiplying the obtained value with 
correction factor of known individual impurities. 
 
4.6 Relative Response Factor 
 
Sample preparation: 
Transferred an accurately weigh quantity of about 10 mg of azathioprine and 
each impurities into 10 mL volumetric flasks, separately. Added about 7-8 mL of 
diluent into volumetric flask and sonicated to dissolve. Make volume up to the mark 
with diluent and mixed well to prepare 1000-ppm stock solution.  
100 µL of above stock solution of azathioprine and each impurities was taken 
in a single 20 mL volumetric flask. Make volume up to the mark with diluent and 
mixed well to prepare blend 5-ppm working solution.  
 
Procedure: 
Five replicate of above solution was injected in the equilibrated 
chromatographic system at 220 nm. Average area of azathioprine and each impurities 
was used to calculate relative response factor.  
 
4.7 Method Validation for Impurities 
 
4.7.1 Specificity and System Suitability 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components that may be expected to be present. Typically this might include 
impurities, degradants, matrix etc. 
To evaluate the interference from degradants, forced degradation study was 
carried out by stress testing of API under the following stress conditions. 
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Stress Type Condition 
Acid Hydrolysis Treated with 1 mL of 5 N HCl and heat at 60° C on a 
water bath for 1 hour. 
Base Hydrolysis Treated with 1 mL of 0.1 N NaOH and heat at 60° C 
on a water bath for 1 hour. 
Peroxide Oxidation Treated with 0.5 mL of 30 % H2O2 and heat at 60° C 
on water bath for 1 hour. 
 
Procedure: 
About 10 mg of API was accurately weighed and transferred into a 10 mL 
volumetric flask. 5 mL of stress solution was added to it and the solution was heated 
at 60° C on water bath for 1 hour. The sample solution was then allowed to cool at 
room temperature and approximately neutralized it. About 2 mL of diluent was added 
to it and the solution was sonicated for 10 minutes and then was diluted up to the 
mark with diluent. The solution was mixed well and then filtered through 0.22  m 
filters. The sample solution was then injected into equilibrated chromatographic 
system. Peak purity of the principle peak was checked in impurities spiked solution 
and stressed solution using photo diode array detector. 
Analysis sequence: 
Analysis sequence for specificity test 
Sr. No. Sample No. of Injections 
1 Diluent 1 
2 Mobile phase 1 
3 Standard API solution 1 
4 Impurity A 1 
5 Impurity B 1 
6 Impurity C 1 
7 Impurity D 1 
8 API + Impurities 1 
9 Diluent – Acid Hydrolysis 1 
10 API – Acid Hydrolysis 1 
11 Diluent – Base Hydrolysis 1 
12 API – Base Hydrolysis 1 
13 Diluent – Peroxide Oxidation 1 
14 API – Peroxide Oxidation 1 
 
 The system suitability parameters were evaluated from chromatogram of blend 
sample solution of impurities and API.   
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4.7.2 Linearity  
The linearity of an analytical procedure is its ability (within a given range) to 
obtain test results that are directly proportional to the concentration of analyte in the 
sample. 
Preparation of Stock Solution of Each Impurity (10 ppm): 
Transferred an accurately weighed quantity of about 10 mg of each impurities 
to 100 mL volumetric flasks, separately. Added about 50 mL of diluent to volumetric 
flask and sonicated to dissolve. Make volume up to the mark with diluent and mixed 
well to prepare 100 ppm solution. Diluted 5 mL of this solution to 50 mL with diluent 
to prepare 10 ppm stock solutions of each impurities. 
 
Preparation of 150 % (at specification level) Solution: 
3 mL of stock solution was taken to 10 mL volumetric flask and make up the 
volume up to mark with diluent and mixed well. 
 
Preparation of 100 % (at specification level) Solution: 
2 mL of stock solution was taken to 10 mL volumetric flask and make up the 
volume up to mark with diluent and mixed well. 
 
Preparation of 50 % (at specification level) Solution: 
5 mL of stock solution was taken to 50 mL volumetric flask and make up the 
volume up to mark with diluent and mixed well. 
Preparation of 25 % (at specification level) Solution: 
5 mL of 50 % solution was taken to 10 mL volumetric flask and make up the 
volume up to mark with diluent and mixed well. 
Preparation of 10 % (at specification level) Solution: 
5 mL of 50 % solution was taken to 25 mL volumetric flask and make up the 
volume up to mark with diluent and mixed well. 
Preparation of 5 % (at specification level) Solution: 
5 mL of 10 % solution was taken to 10 mL volumetric flask and make up the 
volume up to mark with diluent and mixed well. 
Procedure: 
1 µL solutions of 5 %, 10 %, 25 %, 50 %, 100 %, and 150 % of each impurity 
were injected on an equilibrated chromatographic system. Area for each concentration 
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was calculated and linearity was plotted for area against the concentration for each 
impurity. The regression coefficient was calculated for the linearity curve.  
 
4.7.3 Limit of Detection and Quantitation  
The detection limit of an individual analytical procedure is the lowest amount 
of analyte in a sample that can be detected but not necessary quantitated as an exact 
value. The quantitation limit of an individual analytical procedure is the lowest 
amount of an analyte in a sample which can be quantitatively determined with 
suitable precision and accuracy. Demonstrate the limit of detection and quantification 
based on the residual standard deviation ( ) and slope (S) of linearity data obtained by 
preparing the diluted standard solutions in the range of 150 % (3 ppm) to 5 % (0.1 
ppm) of target concentration. 
The linearity curve obtained in linearity study for each impurities were used to 
determined standard deviation ( ) and slope (S). The following formulas were used to 
calculate LOD and LOQ. 
 
 
                                                            3.3   
Limit of Detection (LOD)          =    ---------- 
                                                              S 
 
                                                            10   
Limit of Quantification (LOQ)   =    -------- 
                                                              S 
 
4.7.4 Accuracy and Recovery 
The accuracy of an analytical method is the closeness of test results obtained 
by the method to the true value. Here accuracy is demonstrated at 50 %, 100 % and 
150 % level with respect to the specification limit for each impurity. Recovery was 
determined in triplicates and reported. 
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Preparation of Blend Stock Solution of Impurities (10 ppm): 
Transferred an accurately weighed quantity of about 10 mg of each impurities 
to 100 mL volumetric flasks, separately. Added about 50 mL of diluent to volumetric 
flask and sonicated to dissolve. Make volume up to the mark with diluent and mixed 
well to prepare 100 ppm solution. Took 5 mL of solution of each impurity to 50 mL 
volumetric flask and diluted with diluent to prepare 10 ppm blend stock solution 
containing each impurity. 
 
Standard Solutions For Impurities: 
3, 2 and 1 mL of 10 ppm stock solution was taken in three different 10 mL 
volumetric flask and make up the volume up to mark with diluent and mixed well to 
got the concentration of 150, 100 and 50 % respectively. 
 
Solution A: Preparation of API Sample: 
Transferred an accurately weighed quantity of about 10 mg of API into 10 mL 
volumetric flask. Added 7-8 mL of diluent and sonicate to dissolve. Make up the 
volume up to mark with diluent and mixed well. 
 
Solution B: Preparation of API Sample with 50 % Spiked Impurities: 
Transferred an accurately weighed quantity of about 10 mg of API into 10 mL 
volumetric flask. Added 1.0 mL of 10 ppm stock solution and sonicate to dissolve. 
Make up the volume up to mark with diluent and mixed well. 
 
Solution C: Preparation of API Sample with 100 % Spiked Impurities: 
Transferred an accurately weighed quantity of about 10 mg of API into 10 mL 
volumetric flask. Added 2.0 mL of 10 ppm stock solution and sonicate to dissolve. 
Make up the volume up to mark with diluent and mixed well. 
 
Solution D: Preparation of API Sample with 150 % Spiked Impurities: 
Transferred an accurately weigh quantity of about 10 mg of API into 10 mL 
volumetric flask. Added 3.0 mL of 10 ppm stock solution and sonicate to dissolve. 
Make up the volume up to mark with diluent and mixed well. 
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Procedure: 
1 µL of each standard solution of impurities in duplicate and solution A, B, C 
and D were injected on equilibrated chromatographic system. Area for each impurity 
was determined and recovery was calculated with respect to area of standard impurity 
solution at the same concentration level. Same experiment was performed for three 
sets of recovery solutions. 
 
4.7.5 Precision 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribe conditions. The precision of an analytical 
procedure is usually expressed as the variance, standard deviation or co-efficient of 
variation of a series of measurement. Here precision is determined by spiking the 
impurities with API at 100 % specification level. 
 
Preparation of Blend Stock Solution of Each Impurity (10 ppm): 
Transferred an accurately weighed quantity of about 10 mg of each impurities 
to 100 mL volumetric flasks, separately. Added about 50 mL of diluent to volumetric 
flask and sonicated to dissolve. Make volume up to the mark with diluent and mixed 
well to prepare 100 ppm solution. Took 5 mL of solution of each impurity to 50 mL 
volumetric flask and diluted with diluent to prepare 10 ppm blend stock solution 
containing each impurity. 
 
Preparation of API Sample with 100 % Spiked Impurities: 
Transferred an accurately weigh quantity of about 10 mg of API into 10 mL 
volumetric flask. Added 2.0 mL of 10 ppm stock solution and sonicate to dissolve. 
Make up the volume up to mark with diluent and mixed well. 
 
Procedure: 
Five sample sets were prepared and 1 µL was injected from each set on an 
equilibrated chromatographic system. Area was determined for API and each 
impurity. % RSD was calculated for area and retention time. 
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4.7.6 Robustness 
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small but deliberate variation in method parameters and provides an 
indication of its reliability during normal usage. The following parameters were 
changed and analysed the test sample against standard.   
 
(a) Flow Rate Variation: 
The flow rate of the mobile phase was changed to 0.33 mL/min and 0.37 
mL/min from 0.35 mL/min. Resolution was determined between the main peak and 
closest impurity i.e. impurity-B. 
 
(b) Column Oven Temperature Variation: 
The temperature of the column oven was changed to 28° C and 32° C from 
30° C. Resolution was determined between the main peak and closest impurity i.e. 
impurity-B. 
 
(c) TFA Concentration Variation: 
The concentration of the triflouro acetic acid was changed to 0.04 % and 0.06 
% from 0.05 %. Resolution was determined between the main peak and closest 
impurity i.e. impurity-B. 
 
4.7.7 Ruggedness 
The ruggedness of an analytical method is the degree of reproducibility of test 
results obtained by the analysis of the same samples under a variety of normal test 
conditions such as different laboratories, different analysts, different instrument, and 
different column. Ruggedness is normally expressed as the lack of the influence on 
the test results of operational and environmental variables of the analytical method. 
Ruggedness was determined by using different laboratory, different 
instrument, and different column on an another day. 
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Sample Preparation and Procedure: 
Sample preparation and procedure were same as shown in the test of precision 
(4.7.5). % Bias was determined between original condition and changed condition. 
 
4.7.8 Solution Stability 
Stability of the sample in diluent is required for a reasonable time to generate 
reproducible and reliable results. Solution stability study carried out for 24 h. 
 
Sample Preparation: 
Transferred an accurately weigh quantity of about 25 mg of API into 25 mL 
volumetric flask. Added 10.0 mL of diluent and sonicate to dissolve. Make up the 
volume up to mark with diluent and mixed well. 
Procedure: 
Initial, after 12 h and after 24 h % purity was determined and % bias was 
calculated. 
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5. Result and Discussion 
 
 
5.1 Method Development 
 
The present study is aimed at developing a UPLC system capable of eluting 
and resolving azathioprine and its impurities originated from the synthesis. Structure 
of impurities and azathioprine are shown in Table 1 and Fig. 1 respectively in 
introduction section. The blend sample solution containing about 10 ppm 
concentration of  all the four impurities and 100 ppm azathioprine in diluent were 
used for the method development. To detect all the compounds in a single run, 
selection of wavelength become challenging task since, UV profile of all the 
compounds may differ. The UV spectra of all the compound was taken in diluent are 
presented in Fig. 3, 4, 5, 6 and 7. It can be seen that it is difficult to detect all the 
compounds at single wavelength with equal response. Therefore, based on UV profile 
of all the compounds 220 nm wavelength was selected as common wavelength for the 
detection. Relative response factor of all the impurities was evaluated for accurate 
determination.      
 
 
 
nm200 225 250 275 300 325 350 375 
Spectra of API 
 
                    Fig. 3: UV spectra of Azathioprine 
 
 
 
 
Part-B Section-I 
169 
 
 
nm200 225 250 275 300 325 350 375 
Spectra of Impurity-A 
 
         Fig. 4: UV spectra of Impurity-A 
 
 
nm 200 225 250 275 300 325 350 375 
Spectra of Impurity-B 
 
        Fig. 5: UV spectra of Impurity-B 
 
 
nm 200 225 250 275 300 325 350 375 
Spectra of Impurity-C 
 
         Fig. 6: UV spectra of Impurity-C 
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nm 200 225 250 275 300 325 350 375 
Spectra of Impurity-D 
 
         Fig. 7: UV spectra of Impurity-D 
 
UPLC is a new technique, where sub two-micron particles are used. Because 
of the small particle size used in the column, chemistry of the stationary phase plays 
fewer roles in method development. Method development was initiated in Acquity 
UPLC BEH C18 (100 x 2.1 mm, 1.7 µm) column as a stationary phase. Column was 
kept under control temperature 30° C. Binary pump was used to flow 0.4 mL/min. 
TUV detector was operated at 220 nm.  
 
As per the common development practice method development was initiated 
with Water: Acetonitrile as a mobile phase in isocratic mode. In due course, cross 
combination of the 0.05 % TFA in water and methanol was also tried as a mobile 
phase. 1 µL of blend sample preparation was injected in equilibrated chromatographic 
system using above mentioned parameters.  
 
Trial 1: Mobile phase: Water: Acetonitrile (90:10), rest of the conditions as discussed 
above. 
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  Fig. 8: UPLC chromatogram of trial 1 
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Trial 2: Mobile phase: Water:  Methanol (90:10), rest of the conditions as discussed 
above. 
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Fig. 9: UPLC chromatogram of trial 2 
 
 
Observation: From the above trials 1 and 2, it was observed that impurities were not 
properly eluted. Last eluting peak in trial 1 (Fig. 8) was 8.4 minutes and in trial 2 (Fig. 
9) was 11.6 minutes, which are too long for UPLC technique. Peak shapes were also 
not proper therefore, some buffer of ion pairing reagent should be tried. 
 
 
Trial 3: Mobile phase: 0.05 % TFA in Water: Acetonitrile (90:10), rest of the 
conditions as discussed above. 
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Fig. 10: UPLC chromatogram of trial 3 
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Trial 4: Mobile phase: 0.05 % TFA in Water: Methanol (90:10), rest of the 
conditions as discussed above. 
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Fig. 11: UPLC chromatogram of trial 4 
 
 
Observation:  
From the above trials 3 (Fig. 10) and 4 (Fig. 11), it was observed that peak 
shapes were found to be ok. In the condition of trial 3 (Fig. 10), first eluting peak was 
eluted with dead volume and last eluting peak was eluted at 8.4 minutes. In the similar 
line, in trial 4 (Fig. 11), last eluting peak was eluted at 11.9 minutes. As, stated earlier, 
it is too long time for the good UPLC method. Since, all the compounds of interest 
have different polarity depending on its chemical structure therefore to separate and 
elute all the compounds within define time frame, gradient elution should be tried. 
 To get gradient elution pattern, small linear gradient were employed for the 
method development. It has been scanned for all the cross combination of water and 
0.05 % TFA in water with acetonitrile and methanol to finalize mobile phase 
components, while column (Acquity UPLC BEH C18 (100 x 2.1 mm, 1.7 µm), flow 
rate (0.4ml/min), column temperature (30° C) and wavelength (220nm) were kept 
constant.  
Gradient Program 
Time (min) 0.05% TFA in water (%) Acetonitrile (%) 
1.0 95 05 
2.0 10 90 
3.0 10 90 
3.1 95 05 
4.0 95 05 
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Trial 5: Mobile phase: Water:Acetonitrile (Gradient) 
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Fig. 12: UPLC chromatogram of trial 5 
 
 
Trial 6: Mobile phase: Water:Methanol (Gradient) 
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Fig. 13: UPLC chromatogram of trial 6 
 
 
Trail 7: Mobile phase: 0.05 % TFA in water:Acetonitrile (Gradient) 
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Fig. 14: UPLC chromatogram of trial 7 
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Trial 8: Mobile phase: 0.05 % TFA in water:Methanol (Gradient) 
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Fig. 15: UPLC chromatogram of trial 8 
 
 
Observation: 
 From the above trials, it can be seen that gradient elution has advantage over 
isocratic elution. The chromatograms of screening of different mobile phase 
components in same gradient program are presented in Fig. 12, 13, 14 and 15. It can 
be observed that combination of 0.05 % TFA in water and acetonitrile (Fig. 14) gave 
better result than any other tested combination, which can be further improved. 
Therefore, now finalizing 0.05 % TFA in water and acetonitrile as a mobile phase 
components, gradient program should be optimized to get desire retention and 
resolution. 
 After above experimental input, further attempt was made to optimize the 
gradient program. Couple of slow gradient programs were tried to increase resolution 
between impurities maintaining peak shape and retention and also played with flow 
rate to achieve separation goal. Finally, flow rate 0.35 mL/min and following gradient 
program were found to be optimal for determination of process related impurities in 
azathioprine. Chromatogram of the finalize condition is presented in Fig. 16. 
Gradient Program 
Time (minutes) 0.05 % TFA in Water (%) Acetonitrile (%) 
1.0 97 03 
3.5 40 60 
4.0 40 60 
4.1 97 03 
5.0 97 03 
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Fig. 16: Chromatogram of finalize condition  
 
It can be seen from the Fig. 16 that all the impurities and azathioprine are well 
separated within 5 minutes run time. The method was found to be simple and rapid for 
its routine use. The developed method was subjected for validation. Just to check 
effect of different column chemistry, Acquity UPLC HSS T3 1.8 µm (100 x 2.1mm) 
column was tried in optimized chromatographic parameters. The chromatogram is 
presented in Fig. 17. 
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Fig. 17: Chromatogram on Acquity UPLC HSS T3 1.8 µm (100 x 2.1mm) 
  Column 
 
 It can be seen from Fig. 17 that two impurities were merged in column 
Acquity UPLC HSS T3 1.8 µm (100 x 2.1mm). Therefore, earlier column, AQUITY 
UPLC BEH C18 (100 x 2.1 mm, 1.7 µm) was found to be right choice.  
 
 From the entire method development discussion the final optimized 
parameters of the UPLC method for the determination of the process related 
impurities in azathioprine are as below. 
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Elution              : Gradient 
Column   : Acquity UPLC BEH C18, 100 x 2.1 mm, 1.7 µm  
Wave length  : 220 nm 
Column oven temp. : 30  C 
Flow rate  : 0.35 mL / min.  
Injection volume : 1 µL 
Run time  : 5 min 
Mobile phase  : 0.05 % TFA in water: Acetonitrile (Gradient) 
Diluent  : 0.1 % Ammonia in methanol 
Sample conc.  : 1.0 mg/mL 
Gradient program : 
 
Time (minutes) 0.05 % TFA in Water (%) Acetonitrile (%) 
1.0 97 03 
3.5 40 60 
4.0 40 60 
4.1 97 03 
5.0 97 03 
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5.2 Determination of the Relative Response Factor (RRF) 
 
Since, all the impurities have different UV profile, therefore, detection of them 
at single wavelength will not give equal response. In order to calculate exact amount 
of impurity, relative response factor is required. Here, response factor of all the four 
impurities relative to azathioprine have been determined. Results of experiment are 
presented in Table 2. 
   
   Table 2: Result of Relative Response Factor Determination Study 
 
Parameters API Imp-A Imp-B Imp-C Imp-D 
Area - 1 27432 25666 12360 20886 25578 
Area - 2 25792 24852 12479 19763 24554 
Area - 3 26571 25983 12584 20224 25055 
Area - 4 27083 25681 12875 20292 25235 
Area - 5 26942 25536 12851 19911 25015 
Average 
Area 
26764.00 25543.60 12629.80 20215 25087.40 
SD 624.84 419.91 227.31 434 371.91 
RSD 2.33 1.64 1.80 2.15 1.48 
RRF 1 0.94 0.47 0.80 0.94 
Correction 
Factor 
1 1.06 2.12 1.25 1.06 
 
 
 It can be seen from the Table 2 that response of the Impurity-B is very less at 
220nm as compare to other impurities, which is also supported by UV spectra of 
Impurity-B (Fig. 5). The response of Impurity-A and Impurity-D is almost equivalent 
to azathioprine. The multiplication of correction factor and percentage of impurity 
from the area normalize method will give exact amount of that impurity.  
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5.3 Result of Method Validation 
 
5.3.1 Result of Specificity and System Suitability 
 
The retention time of the peak of interest in the sample solution was 2.8 
minutes. Impurities were well resolved from each other as well as from the main peak. 
No interference was observed in the chromatogram of the diluent and mobile phase at 
the retention time of the sample as well as impurities. Retention time and compound 
are described in Table 3. The retention time identification of the impurities and 
chromatogram of the specificity study after subtraction with diluent are presented as 
Fig. 18, 19, 20, 21, 22 and 23. 
 
            Table 3: Retention time for API and its Impurities 
Name of the Sample 
Retention time of the main peak 
(minutes) 
Diluent No peak 
Mobile phase No peak 
Impurity-A 1.4 min 
Impurity-B 3.0 min 
Impurity-C 3.5 min 
Impurity-D 3.4 min 
Azathioprine (API) 2.8 min 
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  Fig. 18: Chromatogram of Impurity-A 
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 Fig. 19: Chromatogram of Impurity-B 
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 Fig. 20: Chromatogram of Impurity-C 
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Fig. 21: Chromatogram of Impurity-D 
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Fig. 22: Chromatogram of Azathioprine (API) 
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 Fig. 23: Chromatogram of blend sample containing API and all the impurities 
 
After specificity establishment, system suitability parameters were evaluated 
for the all compounds. The system suitability results are shown in Table 4. The 
system suitability chromatogram after subtraction with diluent is presented in Fig. 24 
and without diluent subtraction is presented in Fig. 25. 
 
Table 4: Results of System Suitability 
 
Name Retention Time Selectivity Resolution
USP 
Resolution
USP 
Tailing 
USP Plate 
Count 
Impurity-A 1.374    1.29 2901.07 
API 2.800 2.63 19.6 20.1 1.42 84984.33 
Impurity-B 2.994 1.08 4.88 4.78 1.29 83346.89 
Impurity-D 3.368 1.15 8.93 8.75 1.27 100817.7 
Impurity-C 3.526 1.06 3.45 3.36 1.38 80375.01 
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Fig. 24: Chromatogram of System suitability after subtraction with diluent  
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Fig. 25: Chromatogram of System suitability without subtraction of diluent
  
 The forced degradation of the azathioprine under all the stress condition was 
carried out as a part of specificity study. The result and observation of the forced 
degradation study are discussed below. 
 
Acid Hydrolysis: 
Minor degradation was observed after acid treatment. A degradation product 
of 0.67 % was observed in the sample chromatogram, which was 0.03 % present 
initially. The relative retention time of degradant is 1.11 with respect to main peak. 
All degradant products were well resolved from the peak of azathioprine. The % 
purity of sample was found 99.33 %, which was initially 99.86 %. The Chromatogram 
of acid hydrolysis is presented in Fig. 26. 
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Fig. 26: Chromatogram of Acid hydrolysis 
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Base Hydrolysis: 
Degradation was observed after base treatment. A degradation product of 2.07 
% was observed in the sample chromatogram, which was 0.02 % present initially. The 
relative retention time of degradant is 0.50 with respect to main peak. All degradant 
products were well resolved from the peak of azathioprine. The % purity of sample 
was found 97.93 %, which was initially 99.86 %. The Chromatogram of base 
hydrolysis is presented in Fig. 27. It can be seen form the chromatogram that 
degradation product observed at 1.4 minutes. The retention time was same as 
Impurity-A. Therefore, Impurity-A may be base degradation product also. It is also 
supported by literature that 6-mercaptopurine is active metabolite of the azathioprine. 
 
1.
40
5
2.
79
3
AU
0.00
0.10
0.20
0.30
0.40
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
API
Base Hydrolysis
 
Fig. 27: Chromatogram of Acid hydrolysis 
 
Peroxide Oxidation: 
Degradation was not observed after peroxide treatment. The % purity of 
sample was found 99.85 %, which was initially 99.86 %. The Chromatogram of 
peroxide oxidation is presented in Fig. 28. 
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Fig. 28: Chromatogram of Acid hydrolysis 
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Peak Purity: 
 Peak purity of the principle peak was checked in impurities spiked solution 
and stressed solution using photo diode array detector. Peak purity was passed for all 
the solution at the threshold level 990. Representative peak purity report is shown in 
Fig. 29. 
 
 
 
 
 
 
 
 
 
Fig. 29: Peak purity chromatogram of principle peak 
 
Conclusion: Method is capable to resolve degradants and that conformed stability 
indicating power of the UPLC method. 
 
5.3.2 Result of Linearity of Impurities 
The linearity of all the impurities was evaluated from the 5 % to 150 % of the 
specification limit. The described method was linear in the range of 0.1 - 3 ppm for all 
the impurities. The calibration curve was drawn by plotting the concentration verses 
its corresponding peak area with a correlation coefficient greater than 0.995. The 
equation of the calibration curve was also calculated for all the impurities. The data of 
slope, Y-intercept and correlation coefficient for all the impurities are presented in 
Table  9. 
  
 
 
 
 
 
 
     
990   
The purity factor is within the threshold limit
| |
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Impurity-A:  
 The peak area at different concentration for Impurity-A is presented in Table 5 
and linearity plot is shown in Fig. 30. 
  
Table 5: Data of linearity of Impurity-A  
Concentration 
Area Percentage of 
specification limit 
ppm 
150 3 19992 
100 2 13970 
50 1 7335 
25 0.5 3557 
10 0.2 1354 
5 0.1 941 
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         Fig. 30: Linearity plot of Impurity-A  
 
Acceptance Criteria: Correlation coefficient should not be less than 0.995. 
 
Conclusion:  
The correlation coefficient of Impurity-A was 0.999. The result showed the 
excellent correlation between the peak area and concentration for Impurity-A in 
developed method. 
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Impurity B: 
The peak area at different concentration for Impurity-B is presented in Table 6 
and linearity plot is shown in Fig. 31. 
 
Table 6: Data of linearity of Impurity-B  
Concentration 
Area Percentage of 
specification limit 
ppm 
150 3 9784 
100 2 5963 
50 1 3020 
25 0.5 1032 
10 0.2 380 
5 0.1 139 
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       Fig. 31: Linearity plot of Impurity-B 
 
Acceptance Criteria: Correlation coefficient should not be less than 0.995. 
 
Conclusion:  
The correlation coefficient of Impurity-B was 0.998. The result showed the 
excellent correlation between the peak area and concentration for Impurity-B in 
developed method. 
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Impurity-C:  
 The peak area at different concentration for Impurity-C is presented in Table 7 
and linearity plot is shown in Fig. 32. 
 
Table 7: Data of linearity of Impurity-C  
Concentration 
Area Percentage of 
specification limit 
ppm 
150 3 14198 
100 2 9365 
50 1 5065 
25 0.5 2004 
10 0.2 706 
5 0.1 333 
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      Fig. 32: Linearity plot of Impurity-C 
 
Acceptance Criteria: Correlation coefficient should not be less than 0.995. 
 
Conclusion:  
The correlation coefficient of Impurity-C was 0.999. The result showed the 
excellent correlation between the peak area and concentration for Impurity-C in 
developed method. 
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Impurity-D:  
 The peak area at different concentration for Impurity-D is presented in Table 8 
and linearity plot is shown in Fig. 33. 
 
Table 8: Data of linearity of Impurity-D  
Concentration 
Area Percentage of 
specification limit 
ppm 
150 3 17324 
100 2 11435 
50 1 6192 
25 0.5 2479 
10 0.2 1020 
5 0.1 580 
 
 
Linearity of Impurity-D y = 5809.1x - 78.675
r = 0.999
0
5000
10000
15000
20000
0 1 2 3 4
Concentration in ppm
Pe
ak
 A
re
a Series1
Linear
(Series1)
 
       Fig. 33: Linearity plot of Impurity-D 
 
Acceptance Criteria: Correlation coefficient should not be less than 0.995. 
 
Conclusion:  
The correlation coefficient of Impurity-D was 0.999. The result showed the 
excellent correlation between the peak area and concentration for Impurity-D in 
developed method. 
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Table 9: Results of Linearity Study  
 
 
 
 
 
 
 
 
 
 
5.3.3 Result of Limit of Detection and Quantitation 
 The six point linearity plot with range from 0.1 to 3.0 ppm concentration , 
obtained in linearity study (Section 5.3.2) for all the impurities were used to determine 
limit of detection and limit of quantitation by calibration curve method.  The result 
obtained in limit of detection and quantitation are presented in Table 10. 
 
Table 10: Result for LOD and LOQ test 
Parameters Impurity A Impurity B Impurity C Impurity D 
Residual 
Standard 
Deviation 327.24 245.87 251.30 297.88 
Slope 6667.2 3318 4803.6 5809.1 
LOD 0.16 0.24 0.17 0.17 
LOQ 0.49 0.74 0.52 0.51 
 
 It can be seen from the Table 10 that limit of detection and quantitation of 
Impurity-A, Impurity-C and Impurity-D are almost same. The value of limit of 
detection and quantitation of Impurity-B is higher compare to other impurities, which 
is also supported by RRF data. It can concluded that limit of quatitation of all the 
impurities are far below than the specification limit. 
Parameter 
Result  
Impurity A Impurity B Impurity C Impurity D 
Correlation 
coefficient  0.999 0.998 0.999 0.999 
Slope 6667.2 3318 4803.6 5809.1 
Y-Intercept 302.04 - 374.09 - 165.57 - 78.68 
 
Part-B Section-I 
189
5.3.4 Result of Accuracy and Recovery 
In order to determine the accuracy of the method standard addition and 
recovery experiments were conducted in triplicate at 50, 100 and 150 % level of each 
impurity with respect to specification limit, i.e. 1, 2 and 3 ppm of each impurity. The 
recovery of the each impurity spiked with API was calculated from the area of 
impurity standard solution at that particular level of concentration of accuracy study. 
The PI batch used for the study contains small amount of Impurity-A and Impurity-D, 
therefore for the correction of these impurities, API sample was injected at same 
concentration. The area obtained in the API for these impurities are shown in Table 
11.  
 
         Table 11: Area of impurities in API sample solution 
Impurity Impurity A Impurity B Impurity C Impurity D 
Area 1914 ND ND 1604 
 
Impurity A: 
 The area obtained from the standard solution of the impurity-A at 50, 100 and 
150 % level, i.e. 1, 2 and 3 ppm are presented in Table 12.  
 
               Table 12: Area of standard sample solution of Impurity-A 
Injection No. 
Standard at 
50 % level 
Standard at 
100 % level 
Standard at 
150 % level 
1 4470 10440 16730 
2 4465 10528 16796 
3 4459 10495 16768 
Average area 4464.67 10487.67 16764.67 
 
 The area obtained for Impurity-A in the spiked recovery solution was 
corrected by area present in the API sample solution. The recovery of Impurity-A at 
all the tested level was calculated and mean of recovery of three different sets was 
also determined. The data are presented in Table 13. 
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Table 13: Results of accuracy and recovery of Impurity-A 
Test 
Accuracy at 50 % level Accuracy at 100 % level Accuracy at 150 % level 
Set1 Set 2 Set3 Set1 Set 2 Set3 Set1 Set 2 Set3 
Area 6352 6398 6379 12401 12360 12398 18689 18726 18769 
Corrected 
area 
4438 4484 4465 10487 10446 10484 16775 16812 16855 
% 
Recovery 
99.40 100.43 100.01 99.99 99.60 99.97 100.06 100.28 100.54 
Mean 99.95 % 99.85 % 100.29 % 
 
Conclusion:  
It can be seen from the data that recovery of impurity-A is between 99 to 101 
% at all the tested level. The recovery experiment demonstrated excellent accuracy of 
the developed method for the determination of Impurity-A in azathioprine bulk drug. 
 
Impurity B: 
 The area obtained from the standard solution of the impurity-B at 50, 100 and 
150 % level, i.e. 1, 2 and 3 ppm are presented in Table 14.  
 
   Table 14: Area of standard sample solution of Impurity-B 
Injection No. 
Standard at 
50 % level 
Standard at 
100 % level 
Standard at 
150 % level 
1 2042 4126 6205 
2 2050 4165 6183 
3 2058 4136 6195 
Average area 2050 4142.33 6194.33 
 
 The recovery of Impurity-B at all the tested level was calculated and mean of 
recovery of three different sets was also determined. The results and data are 
presented in Table 15. 
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Table 15: Results of accuracy and recovery of Impurity-B 
Test 
Accuracy at 50 % level Accuracy at 100 % level Accuracy at 150 % level 
Set1 Set 2 Set3 Set1 Set 2 Set3 Set1 Set 2 Set3 
Area 1998 2046 2010 4075 4085 4123 6215 6096 6108 
% 
Recovery 
97.46 98.80 98.05 98.37 98.62 99.53 100.33 98.41 98.61 
Mean 98.44 % 98.84 % 99.12 % 
 
Conclusion:  
It can be seen from the data that recovery of impurity-B is between 98 to 100 
% at all the tested level. The recovery experiment demonstrated excellent accuracy of 
the developed method for the determination of Impurity-B in azathioprine bulk drug. 
 
Impurity C: 
The area obtained from the standard solution of the impurity-C at 50, 100 and 
150 % level, i.e. 1, 2 and 3 ppm are presented in Table 16.  
 
  Table 16: Area of standard sample solution of Impurity-C 
Injection No. 
Standard at 
50 % level 
Standard at 
100 % level 
Standard at 
150 % level 
1 2382 4856 7035 
2 2372 4869 6991 
3 2361 4859 7015 
Average area 2371.67 4861.33 7013.67 
 
The recovery of Impurity-C at all the tested level was calculated and mean of 
recovery of three different sets was also determined. The results and data are 
presented in Table 17. 
 
 
Part-B Section-I 
192
 
Table 17: Results of accuracy and recovery of Impurity-C 
Test 
Accuracy at 50 % level Accuracy at 100 % level Accuracy at 150 % level 
Set1 Set 2 Set3 Set1 Set 2 Set3 Set1 Set 2 Set3 
Area 2403 2376 2397 4866 4823 4896 6985 6934 7023 
% 
Recovery 
101.32 100.18 101.07 100.10 99.21 100.71 99.59 98.86 100.13 
Mean 100.19 % 100.01 % 99.53 % 
 
Conclusion:  
It can be seen from the data that recovery of impurity-C is between 99 to 101 
% at all the tested level. The recovery experiment demonstrated excellent accuracy of 
the developed method for the determination of Impurity-C in azathioprine bulk drug. 
 
Impurity D: 
The area obtained from the standard solution of the impurity-D at 50, 100 and 
150 % level, i.e. 1, 2 and 3 ppm are presented in Table 18.  
 
    Table 18: Area of standard sample solution of Impurity-D 
Injection No. 
Standard at 
50 % level 
Standard at 
100 % level 
Standard at 
150 % level 
1 4706 11010 17593 
2 4715 10994 17629 
3 4728 10999 17609 
Average area 4716.33 11001 17610.33 
 
The area obtained for Impurity-D in the spiked recovery solution was 
corrected by area present in the API sample solution. The recovery of Impurity-D at 
all the tested level was calculated and mean of recovery of three different sets was 
also determined The data are presented in Table 19. 
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Table 19: Results of accuracy and recovery of Impurity-D 
Test 
Accuracy at 50 % level Accuracy at 100 % level Accuracy at 150 % level 
Set1 Set 2 Set3 Set1 Set 2 Set3 Set1 Set 2 Set3 
Area 6386 6350 6302 12563 12605 12598 19205 19298 19268 
Corrected 
area 4782 4746 4698 10959 11001 10994 17601 17694 17664 
% 
Recovery 
101.39 100.63 99.61 99.62 100.0 99.94 99.95 100.48 100.30 
Mean 100.21 % 99.85 % 100.24 % 
 
Conclusion:  
It can be seen from the data that recovery of impurity-D is between 99 to 101 
% at all the tested level. The recovery experiment demonstrated excellent accuracy of 
the developed method for the determination of Impurity-D in azathioprine bulk drug. 
 
5.3.5 Result of Precision 
  The precision was determined for all the impurities at 100 % specification 
level spiked in API sample. The relative standard deviation of retention time and area 
was calculated for five replicates injection. The result of precision of retention time and 
area is presented in Table 20 and Table 21, respectively.  
 
Table 20: Results of Precision of Retention Time 
Injection No. Impurity-A Impurity-B Impurity-C Impurity-D API 
1 1.362 3.012 3.528 3.376 2.813 
2 1.364 3.013 3.529 3.377 2.815 
3 1.361 3.012 3.528 3.376 2.813 
4 1.361 3.012 3.528 3.376 2.813 
5 1.359 3.011 3.527 3.375 2.812 
Average 1.36 3.01 3.53 3.38 2.81 
SD 0.001 0.001 0.001 0.001 0.001 
% RSD 0.13 0.02 0.02 0.02 0.04 
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Table 21: Results of Precision of Peak Area 
Injection No. Impurity-A Impurity-B Impurity-C Impurity-D API 
1 11908 3893 4963 11532 5695412 
2 12162 4015 5026 11922 5784108 
3 11955 3977 4958 11567 5685863 
4 11999 3987 4913 11969 5799792 
5 11899 3956 4911 11875 5756444 
Average 11984.6 3965.6 4954 11773.0 5744323.8
SD 106.95 45.80 47 207.09 51518.04 
% RSD 0.89 0.02 0.95 1.76 0.90 
 
Conclusion:  
It can be seen from the data that relative standard deviation of retention time 
and peak area is less than 0.2 % and 2.0 %, respectively for all the impurities and API. 
The result of precision are within general acceptance limit, therefore developed 
method is precise for its intended use.   
 
5.3.6 Result of Robustness 
The chromatographic resolution between API and closest eluting impurity, i. e. 
Impurity-B was used to evaluate the method robustness under modified conditions. 
The results robustness testing are summarized in Table 22. 
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Table 22: Results of Robustness Study  
 
Parameter Resolution between API and 
Impurity-B 
Flow rate (mL/min) 
     0.33 5.08 
     0.35 4.85 
     0.37 4.65 
Column Temperature (° C) 
     28 4.94 
     30 4.85 
     32 4.76 
Concentration of Triflouro acetic acid (%) 
     0.04 4.83 
     0.05 4.85 
     0.06 4.84 
 
Conclusion: 
The resolution between API and closest eluting impurity, i.e. Impurity-B was 
found 4.85 in original condition. There was no major effect observed on resolution, 
under all the deliberately changed conditions. Therefore, it can be concluded that the 
developed method is robust for its intended use. 
 
5.3.7 Result of Ruggedness 
In order to evaluate reproducibility and ruggedness of the method, precision test 
was repeated using different instrument and column in second laboratory at different 
day. The experiment was carried out for all the impurities at 100 % specification level 
spiked in API sample. The relative standard deviation of retention time and area was 
calculated for five replicates injection. The result of precision of retention time and 
area is presented in Table 23 and Table 24, respectively. The ruggedness of the method 
was established by calculating percentage bias of retention time and area at two 
different conditions. The result of ruggedness is shown in Table. 25.    
Part-B Section-I 
196
Table 23: Results of Precision of Retention Time at Different Set of Conditions 
Injection 
No. Impurity-A Impurity-B Impurity-C Impurity-D API 
1 1.361 3.011 3.529 3.386 2.814 
2 1.363 3.021 3.527 3.384 2.818 
3 1.362 3.018 3.529 3.389 2.813 
4 1.363 3.013 3.528 3.392 2.815 
5 1.36 3.024 3.527 3.387 2.82 
Average 1.36 3.02 3.53 3.39 2.82 
SD 0.001 0.01 0.001 0.001 0.001 
% RSD 0.10 0.18 0.03 0.09 0.10 
 
Table 24: Results of Precision of Peak Area at Different Set of Conditions 
Injection 
No. Impurity-A Impurity-B Impurity-C Impurity-D API 
1 11970 3991 4955 11666 5701234 
2 12110 3952 4965 11824 5699524 
3 11980 3967 4977 11867 5723546 
4 12110 4012 4945 11905 5699584 
5 11954 3911 4966 11766 5712683 
Average 12024.8 3966.6 4962 11805.6 5707314.2
SD 78.33 38.60 12 93.60 10603.15 
% RSD 0.65 0.97 0.24 0.79 0.19 
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Table 25: Results of Ruggedness study 
Compd 
Average Retention Time Average Peak Area 
Original 
Condition
Different 
Condition % Bias 
Original 
Condition
Different 
Condition % Bias 
Impurity
A  
1.36 1.36 0.0 11984.6 12024.8 0.34 
Impurity
B 
3.01 3.02 0.33 3965.6 3966.6 0.03 
Impurity
C 
3.53 3.53 0.0 4954 4962 0.16 
Impurity
D 
3.38 3.39 0.30 11773.0 11805.6 0.28 
API 2.81 2.82 0.36 5744323.8 5707314.2 -0.64 
 
Conclusion:  
The bias between original and different conditions was found below 2.00 % 
for retention time and peak area of all the impurities and API. Therefore, it can be 
concluded that developed method is rugged enough for its intended use. 
 
5.3.8 Result of Solution Stability 
Solution stability of azathioprine (API) was carried out in diluent for 24 hours. 
The % bias of purity was calculated with the purity of fresh injection. The result of 
the solution stability is presented in Table 26. 
           Table 26: Result of Solution Stability 
Sr. No. Time (hrs) % Purity % Bias 
1 0 99.86 - 
2 12 99.87 0.01 
3 24 99.85 -0.01 
 
Conclusion:  
The bias of % purity of Azathioprine after 12 and 24 hours was found 0.01 %. 
The data it can be said that the sample solution is stable at room temperature for 
atleast 24 hours. Therefore, it can be concluded that sample solution can be use within 
24 hours from the time of preparation. 
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6. Conclusion 
 
A simple, suitable, precise and accurate UPLC method has been developed 
and validated for the determination of process related impurities in azathioprine bulk 
drug. The systematic method development was approached in the selection of 
wavelength, mode of elution and mobile phase components. The forced degradation 
was also performed to demonstrate specificity of the method.   
The developed method was completely validated for all the four impurities 
with respect to specificity, system suitability, linearity, limit of detection and 
quantitation, accuracy, precision, robustness, ruggedness and solution stability. The 
result of validation showed satisfactory data for all the method validation parameters 
tested.  
The developed method can be used for the determination of process related 
impurities (Impurity-A, Impurity-B, Impurity-C and Impurity-D) and azathioprine in 
the bulk drug substance. 
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1. Introduction 
 
Pioglitazone hydrochloride (Actos) was previously under joint development 
by Takeda Chemical Industries (Osaka, Japan) and Upjohn (Kalamazoo, MI) as an 
oral treatment for non-insulin dependent diabetes mellitus (NIDDM), i.e. type-2 
diabetes and was undergoing clinical testing for safety and efficacy. It has been shown 
to affect abnormal glucose and lipid metabolism associated with insulin resistance by 
enhancing insulin action on peripheral tissues in animal models [1-3]. 
Type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus 
(NIDDM), or adult-onset diabetes) is a disorder that is characterized by high blood 
glucose in the context of insulin resistance and relative insulin deficiency [4]. While it 
is often initially managed by increasing exercise and dietary modification, 
medications are typically needed as the disease progresses. There are an estimated 
23.6 million people in the U.S. (7.8% of the population) with diabetes with 17.9 
million being diagnosed [5], 90% of whom are type 2 [6]. With prevalence rates 
doubling between 1990 and 2005, CDC has characterized the increase as an epidemic 
[7].  
Traditionally considered a disease of adults, type 2 diabetes is increasingly 
diagnosed in children in parallel to rising obesity rates [8] due to alterations in dietary 
patterns as well as in life styles during childhood [9].  
According to CDC, about 23.613 million people in the United States, or 8% of 
the population, have diabetes. The total prevalence of diabetes increased to 13.5% 
from 2005-2007. It is thought that only 24% of diabetes is now undiagnosed, down 
from an estimated 30% in 2005 and from the previously estimated 50% in ca 1995. 
About 90–95% of all North American cases of diabetes are type 2 [10], and 
about 20% of the population over the age of 65 has diabetes mellitus type 2. The 
fraction of type 2 diabetics in other parts of the world varies substantially, almost 
certainly for environmental and lifestyle reasons, though these are not known in 
detail. Diabetes affects over 150 million people worldwide and this number is 
expected to double by 2025 [10]. In india also about 20% population are suffering 
from diabetes and it is fast grawing. In coming future india may be known as Diabetes 
capital of the world, looking total popultation. There is also a strong inheritable 
genetic connection in type 2 diabetes: having relatives (especially first degree) with 
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type 2 increases risks of developing type 2 diabetes very substantially. In addition, 
there is also a mutation to the Islet Amyloid Polypeptide gene that results in an earlier 
onset, more severe, form of diabetes [11, 12]. About 55 percent of type 2 are obese 
[13]-chronic obesity leads to increased insulin resistance that can develop into 
diabetes, most likely because adipose tissue (especially that in the abdomen around 
internal organs) is a (recently identified) source of several chemical signals to other 
tissues (hormones and cytokines). Other research shows that type 2 diabetes causes 
obesity as an effect of the changes in metabolism and other deranged cell behavior 
attendant on insulin resistance [14] However, genetics play a relatively small role in 
the widespread occurrence of type 2 diabetes. This can be logically deduced from the 
huge increase in the occurrence of type 2 diabetes which has correlated with the 
significant change in western lifestyle [15].  
 
 Drug Profile 
 
1.1.1 Description  
Pioglitazone hydrochloride is chemically ( )-5-{[[4-2-(5-ethyl-2-
pyridinyl)ethoxy]phenyl]methyl}-2,4-thiaz-olidinedione monohydrochloride (Fig. 1), 
Its molecular formula is C9H6N7O2S .HCl  and molecular weight is 406.93 g/mole. 
 
N O
S
NH
O
OHCl  
Fig. 1:  Chemical Structure of Pioglitazone Hydrochloride 
 
1.1.2 Mechanism of Action 
Pioglitazone is a drug that reduces the amount of glucose (sugar) in the blood. 
It is in a class of anti-diabetic drugs called "thiazolidinediones" that are used in the 
treatment of type II diabetes. The other member in this class is rosiglitazone 
(Avandia). (Another member of this class, troglitazone or Rezulin, was removed from 
the market because of liver toxicity.) Patients with type II diabetes cannot make 
enough insulin, and the cells of their body do not respond normally to the reduced 
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amounts of insulin that are present. (Insulin is the hormone produced by the pancreas 
that stimulates cells to remove glucose from the blood.) Pioglitazone often is referred 
to as an "insulin sensitizer" because it attaches to the insulin receptors on cells 
throughout the body and causes the cells to become more sensitive (more responsive) 
to insulin. As a result, more glucose is removed from the blood. At least some insulin 
must be produced by the pancreas in order for pioglitazone to work [16]. 
Pioglitazone also lowers the level of glucose in the blood by reducing the 
production and secretion of glucose into the blood by the liver. In addition, 
pioglitazone may alter the blood concentrations of lipids (fats) in the blood. 
Specifically, it decreases triglycerides and increases the "good" (HDL) cholesterol. 
 
1.1.3 Clinical Use 
Pioglitazone is an anti-diabetic drug (thiazolidinedione-type, also called 
"glitazones") used along with a proper diet and exercise program to control high blood 
sugar in patients with type 2 diabetes (non-insulin-dependent diabetes). It works by 
helping  restore body's proper response to insulin, thereby lowering blood sugar. 
Effectively controlling high blood sugar helps prevent heart disease, strokes, kidney 
disease, blindness, and circulation problems, as well as sexual function problems 
(impotence). Since it requires naturally-secreted insulin to be effective, pioglitazone is 
not recommended in type I diabetes where the amount of insulin is very low or absent.  
Pioglitazone is used either alone or in combination with other anti-diabetic 
medications (e.g., metformin, sulfonylureas, insulin) [17]. 
 
1.1.4 Pharmacodynamics/Kinetics [18] 
Onset of action: Delayed  
Peak effect: Glucose control: Several weeks  
Distribution: Vss (apparent): 0.63 L/kg  
Protein binding: 99.8%  
Metabolism: Hepatic (99%) via CYP2C8/9 and 3A4 to both active and inactive 
metabolites  
Half-life elimination: Parent drug: 3-7 hours; Total: 16-24 hours  
Time to peak: ~2 hours  
Excretion: Urine (15% to 30%) and feces as metabolites 
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1.1.5 Dosage 
Oral dose for Adults:  
Monotherapy: Initial: 15-30 mg once daily; if response is inadequate, the dosage may 
be increased in increments up to 45 mg once daily; maximum recommended dose: 45 
mg once daily  
 
1.1.6 Side Effects 
Some common side effects associated with pioglitazone use are listed below:  
Cough or cold  
Headache  
Inflammation of the sinuses or throat  
Muscle pain  
Swelling or fluid retention  
Weight gain  
Decreased triglycerides and increased HDL (good cholesterol)  
 
1.1.7 Drug Interaction 
Pioglitazone may reduce the effectiveness of oral contraceptives. In some 
cases, other forms of birth control are needed.  
High blood sugar is more likely to occur if pioglitazone is taken with drugs 
that elevate blood sugar, such as the following:  
  Isoniazid  
  Diuretics  
  Steroids  
  Phenothiazines (Compazine and others)  
  Thyroid medicine  
  Oral contraceptives and other hormones  
  Seizure medicines  
  Diet pills or medicines to treat asthma, colds or allergies.  
Low blood sugar is more likely to occur if pioglitazone is given with drugs that lower 
blood sugar, such as the following:  
  Nonsteroidal anti-inflammatory drugs (NSAIDs)  
  Aspirin or other salicylates (including Pepto-Bismol)  
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  Sulfa drugs  
  Monoamine oxidase inhibitors (MAOI)  
  Beta-blockers  
  Probenecid  
The following drugs can interact with pioglitazone:  
  Midazolam (Versed)  
  Gemfibrozil (Lopid)  
  Rifampin (Rifadin)  
  Furosemide (Lasix)  
  Nifedipine (Adalat, Procardia)  
 
1.1.8 Research 
Recent research findings have shed light on some of pioglitazone's long-term 
effects. In particular, pioglitazone therapy is associated with a decrease in adverse 
cardiac outcomes, including recurrent heart attack, in high-risk subjects [19]. A 
separate review of several different clinical trials concluded that pioglitazone is 
associated with a significantly lower risk of death, heart attack, or stroke among a 
diverse population of patients with diabetes [20]. 
 
1.1.9 International Brand Names 
Actos® (AR, AT, BE, BR, CA, CH, CO, CR, CZ, DE, DK, ES, FI, FR, GB, GT, HN, 
IT, JP, NO, NZ, PA, RO, SE, SI, SV, TH); Cereluc® (AR); Glizone® (IN); G-Tase® 
(IN); Opam® (IN) 
 
1.2 Forced Degradation  
Forced degradation is the process of subjecting drug compounds to extreme 
chemical and environmental conditions to determine product breakdown levels and 
preliminary degradation kinetics, and to identify degradant species. It is particularly 
useful when little information is available about potential degradation products.  
These studies also provide information about the degradation pathways and 
degradation products that could be formed during storage. The results of degradation 
studies facilitate stability indicating method (SIM) development, the design of 
formulations, the choice of storage conditions and packaging, an understanding of the 
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chemistry of the drug molecule, and stability problem solving, in which knowledge of 
chemical behaviour can be used to improve a drug product. 
Forced degradation studies are designed to generate product-related variants 
and develop analytical methods to determine the degradation products formed during 
accelerated pharmaceutical studies and long-term stability studies. Any significant 
degradation product should be evaluated for potential hazard and therefore there is a 
need for characterization and quantitation. 
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2. Literature Review 
 
A thorough literature review, it has been observed that few articles were 
published on analytical method of pioglitazone hydrochloride and its metabolites for 
its biological studies [21-29]. Few papers are also published on the analytical methods 
for the bulk drug and formulation of pioglitazone hydrochloride and its combination 
with Metformine and Glimepiride [30-34]. A stability indicating RP-HPLC methods 
were also reported for pioglitazone hydrochloride bulk drug and tablets [35, 36]. T. 
Radhakrishna et al. reported HPLC and MECK methods for the determination of the 
pioglitazone hydrochloride in bulk and pharmaceutical formulation [37]. The 
structural characterization of the impurities in pioglitazone was also published by Y. 
R. Kumar et. al. [38].  
 
 The literature survey revealed that there are articles regarding HPLC 
determination of the pioglitazone in bulk drug and formulations. There is also report 
regarding impurities characterization of pioglitazone. However, there is no report 
available regarding isolation and characterization of degradation products of 
pioglitazone hydrochloride. To get literature insight, few of the articles are discussed 
below in detail.    
 
T. Radhakrishna, D. Sreenivas Rao, G. Om Reddy. Determination of 
pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC 
and MEKC methods. Journal of Pharmaceutical and Biomedical Analysis, 
29 (4) (2002)  593-607. 
In this study, author has developed High Performance Liquid 
Chromatographic (HPLC) and Micellar Electrokinetic Chromatographic (MEKC) 
methods for the determination of pioglitazone hydrochloride. Pioglitazone and its 
unsaturated impurity were separated by MEKC in less than 7 min using a 43 cm x 50 
 m i.d. uncoated fused-silica capillary with extended light path for better sensitivity 
(25 kV at 30 °C) and a background electrolyte (BGE) consisting of 20% acetonitrile 
(v/v) in 20 mM sodium borate buffer pH 9.3 containing 50 mM sodium dodecyl 
sulphate (SDS).  The MEKC method was compared with HPLC method using a 5  m 
symmetry C18 column (250 x 4.6 mm i.d.) eluted with a mobile phase consisting of a 
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mixture of 50% (v/v) acetonitrile and 10 mM potassium dihydrogen phosphate buffer, 
adjusting the pH to 6.0 with 0.1 M KOH. was used for the separation. The flow rate of 
mobile phase was 1.0 mL/min and the column was operated at ambient temperature ( 
~ 22 °C). The sample injection volume was 10  l. The photodiode array detector was 
set at a wavelength of 225 nm. [37]. 
 
Y. R. Kumar, A. R. Reddy, S. Eswaraiah, K. Mukkanti, M. S. Reddy, M. V. 
Suryanarayana. Structural characterization of impurities in pioglitazone. 
Pharmazie. 59 (11) (2004) 836-839. 
In this article, author described characterization of three prominent impurities 
of pioglitazone bulk drug, which were detected up to concentrations of 0.1% (ranging 
from 0.05-0.1%) by reversed phase HPLC. These impurities were isolated from 
enriched mother liquor samples and characterized as 5-(4-hydroxybenzyl)-1,3-
thiazolidine-2,4-dione (I) 5-(4-fluorobenzyl)-1,3-thiazolidine-2,4-dione (II), 2-[2-(4-
bromophenoxy) ethyl-5-ethyl pyridine (III) based on their 1H, and 13C NMR, DEPT, 
Mass and IR spectral data [38].  
 
T. Thilak kumar, B. M. Rao, A. Jamal Abdul Nasser, A. Nallasivam, K. 
Balakumaran. A validated specific stability-indicating RP-HPLC method for 
pioglitazone hydrochloride. Analytical Chemistry An Indian Journal. 7(4) (2008) 
255-262. 
The author have reported HPLC method employing linear gradient elution in 
Zorabax Bonus RP18 column with water :trifluoroacetic acid in the ratio of 
100:0.05(v/v) as a mobile phase-A and acetonitrile:trifluoroacetic acid in the ratio of 
100:0.05(v/v) as a mobile phase - B. The gradient program: time/% of MP-B is 0/10, 
12/65,16/65, 17/10 with post run 5 min. The flow rate of the mobile phase was 
1.0mL/min. The column was maintained at 30° C and the wavelength was monitored 
at a wavelength of 225nm. The injection volume was 10 L [36]. 
  Part-B Section-II 
209 
3. Aim of Present Work 
 
As discussed in the literature review, few HPLC methods have been developed 
and reported for the determination of pioglitazone hydrochloride in bulk drug, 
formulation and biological metrics. In 2002, T. Radhakrishna et. al. [37] performed 
stress testing of the pioglitazone as a part of specificity study, where they observed 
complete degradation in 0.1N NaOH. They have also referred about degradation in 
oxidative condition but degradation products were not characterized. Six years later, 
in 2008 T. Thilak kumar et. al. [36] have also performed forced degradation of 
pioglitazone to evaluate stability indicating power of the method, where they have 
observed degradation in 0.5N NaOH but degradants were not characterized.  
The International Conference on Harmonization (ICH) guideline entitled 
‘Stability Testing of New Drug Substances and Products’ (Q1A(R2)) requires that 
stress testing be carried out to elucidate the inherent stability characteristics of the 
active substance [39]. It suggests that the degradation products that are formed under 
a variety of conditions should be identified and degradation pathways established. The 
characterization of the degradation products formed during stress testing is also very 
important to understand the impurity profile of stability batches. Literature search 
reveal that Pioglitazone hydrochloride is very prompt to degrade in basic condition. 
To the best of our knowledge, there are no reports available regarding isolation and 
characterization of the major degradation products of pioglitazone hydrochloride. 
Therefore, it is necessary to isolate and characterize major degradation products of 
pioglitazone hydrochloride under basic condition to contribute some information in 
the world of pharmaceuticals.  
Since, research and development is a continuous process, in line of this we 
have extended the research done by T. Thilak kumar et. al. [36] further. They have 
reported significant degradation under base hydrolysis. The major degradant formed 
at RRT of 1.05 in the range of 10 % a/a. Apart from that 4 more degradants formed in 
the level of 1-3 % a/a. They have claimed their method as a stability indicating, it 
means that all the degradation products forms during stress testing are well-separated 
form the peak of pioglitazone. Therefore, we have adopted the same method for our 
study and repeated forced degradation of pioglitazone under variety of stress 
conditions. We have attempted scale of degradation process and isolated the 
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degradation products by preparative HPLC system. The isolated pure material was 
characterized by spectroscopic techniques, such as, LC-MS, FT-IR and NMR (1H, 
13C, DEPT) for structure elucidation. Mechanistic arguments have been advanced to 
support structure elucidation. Additionally, chemical transformations have been 
utilized to prove the structure of both degradation products. 
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4. Experimental 
 
 Materials and Instruments 
Drug Sample 
 Process research department of Zydus Research Centre, Cadila Healthcare 
Ltd., Ahmedabad, kindly provided the sample of pioglitazone hydrochloride drug 
substance with purity of 99.86 %. 
Chemicals and Solvent Used 
  Acetonitrile - s d fine-CHEM Limited, Mumbai 
  Methanol - Merck, India 
  Trifluoro acetic acid – SIGMA-ALDRICH CHEMIE GmbH, Germany 
  Hydrochloric acid – s d fine-CHEM Limited, Mumbai 
  Sodium hydroxide - s d fine-CHEM Limited, Mumbai 
  Hydrogen peroxide - s d fine-CHEM Limited, Mumbai 
  Chloroform - s d fine-CHEM Limited, Mumbai 
  Deuteriated  DMSO – 99.9 atom % D  
  Water – HPLC grade water 
Instruments Used 
  HPLC – A Agilent 1100 series (Germany) HPLC system equipped with degasser 
auto sampler, auto injector, thermostatic compartment and photo diode array 
detector was utilized for method development and validation. The out put signal 
was monitored and processed using Agilent Chemstation software. 
  Preparative HPLC – SHIMADZU LC-8A, with class-VP software 
  FT-IR - SHIMADZU 8400S FT-IR, Shimadzu Make, Japan 
  Mass Spectrometry - Waters Quatromicro MSMS, Waters Make. 
  NMR – Bruker 300MHz 
  Freeze dryer - Sharp freeze -110, aapptec make 
  Rotavapour – BUCHI MAKE, Buchi rotavapor-R205, 
    Buchi vaccume controller V-805 
  Analytical balance – Mettler Toledo, AX 105, Delta Range 
  Sonicator – Bandelin electronic Heinrichstra Be 3-4 D-12207 Berlin, Germany 
  Vortexer – Spinix 
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 Preparation of Mobile Phase-A (0.05 % TFA in water) 
  Transferred accurately 500 µL of Trifluoro acetic acid into a 1000 mL 
volumetric flask containing 900 mL of water. Dissolved and make up to the volume 
with HPLC grade water, filter through 0.45 µm filter. 
 
 Preparation of Mobile Phase-B (0.05 % TFA in acetonitrile)  
  Transferred accurately 500 µL of Trifluoro acetic acid into a 1000 mL 
volumetric flask containing 900 mL of acetonitrile. Dissolved and make up to the 
volume with acetonitrile, filter through 0.45 µm filter. 
 
4.4  Preparation of Diluent [Water:Acetonitrile (60:40, v/v)] 
  Mixed accurately 300 mL of water and 200 mL of acetonitrile in 500 mL 
volumetric flask. After proper mixing, filter through 0.45 µm filter. 
 
4.5 Sample preparation (0.25 mg/mL) 
Weighed accurately about 25 mg of pioglitazone hydrochloride sample into 
100 mL of volumetric flask. Add 50 to 60 mL of diluent and sonicated to dissolve the 
solid. Make up the volume with diluent and mixed well. 
 
4.6 Chromatographic parameters for analytical HPLC 
Elution              : Gradient 
Column   : Zorbax eclipsed C18 (150 x 4.6 mm, 5 µm) 
Wave length  : 225 nm 
Column temperature : 30  C 
Flow rate  : 1.0 mL / min.  
Injection volume : 10 µL 
Run time  : 22 min 
Mobile phase-A : 0.05 % TFA in water 
Mobile phase-B : 0.05 % TFA in acetonitrile 
Diluent  : Water:Acetonitrile (60:40) 
Sample conc.  : 0.25 mg/mL 
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Gradient program : 
 
Time (minutes) Mobile Phase-A (%) Mobile Phase-B (%) 
0.0 90 10 
12.0 35 65 
16.0 35 65 
17.0 90 10 
22.0 90 10 
 
Purity of the sample was calculated as per area normalization method. 
 
4.7 Forced Degradation of Pioglitazone Hydrochloride 
 
4.7.1 Preparation of 5N HCl 
44.14 mL of concentrate HCl (11.3N) added in 100 mL volumetric flask 
containing approximately 40 mL water and make up to the mark with water and 
mixed well. 
 
4.7.2 Acid Degradation 
About 25 mg of pioglitazone hydrochloride was accurately weighed and 
transferred into a 10 mL volumetric flask. 5 mL of 5N HCl was added to it and the 
solution was heated at 70° C on water bath for 1 hour. The sample solution was then 
allowed to cool at room temperature and approximately neutralized it using 5N 
NaOH. The solution was sonicated for 10 minutes and diluted up to the mark with 
diluent. The solution was mixed well and then filtered through 0.45  m filters. Took 1 
mL of this solution in 10 mL volumetric flask and diluted upto the mark with diluent 
and mixed well. The sample solution (10  L) was injected on an equilibrated 
chromatographic system.  
 
4.7.3 Preparation of 5N NaOH 
Accurately, weighed 20 g of NaOH in beaker and dissolved it in minimum 
amount of water, sonicated to dissolve. Then, transferred it into 100 mL volumetric 
flask, washed beaker twice with water and transferred into the same volumetric flask. 
Make up volume upto the mark with water and mixed well. 
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4.7.4 Base Degradation 
About 25 mg of pioglitazone hydrochloride was accurately weighed and 
transferred into a 10 mL volumetric flask. 5 mL of 5N NaOH was added to it and the 
solution was heated at 70° C on water bath for 1 hour. The sample solution was then 
allowed to cool at room temperature and approximately neutralized it using 5N HCl. 
The solution was sonicated for 10 minutes and diluted up to the mark with diluent. 
The solution was mixed well and then filtered through 0.45  m filters. Took 1 mL of 
this solution in 10 mL volumetric flask and diluted upto the mark with diluent and 
mixed well. The sample solution (10  L) was injected on an equilibrated 
chromatographic system.  
 
4.7.5 Preparation of 30 % H2O2 
16.6 mL of H2O2 (Assay 30.0 %) added in 100 mL volumetric flask containing 
approximately 40 mL water and make up to the mark with water and mixed well. 
 
4.7.6 Peroxide Degradation 
About 25 mg of pioglitazone hydrochloride was accurately weighed and 
transferred into a 10 mL volumetric flask. 5 mL of 5 % H2O2 was added to it and the 
solution was heated at 70° C on water bath for 1 hour. The sample solution was then 
allowed to cool at room temperature. The solution was hessy, small amount of 
methanol was added and sonicated for 10 minutes to dissolve and diluted up to the 
mark with diluent. The solution was mixed well and then filtered through 0.45  m 
filters. Took 1 mL of this solution in 10 mL volumetric flask and diluted upto the 
mark with diluent and mixed well. The sample solution (10  L) was injected on an 
equilibrated chromatographic system.  
 
4.7.7 Degradation Without Degrading Agent 
About 25 mg of pioglitazone hydrochloride was accurately weighed and 
transferred into a 10 mL volumetric flask. 5 mL of diluent was added to it and the 
solution was heated at 70° C on water bath for 1 hour. The sample solution was then 
allowed to cool at room temperature. The solution was sonicated to dissolve and 
diluted up to the mark with diluent. The solution was mixed well and then filtered 
through 0.45  m filters. Took 1 mL of this solution in 10 mL volumetric flask and 
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diluted upto the mark with diluent and mixed well. The sample solution (10  L) was 
injected on an equilibrated chromatographic system.  
 
4.7.8 Thermal Degradation 
About 100 mg of pioglitazone hydrochloride spreaded in the pettri dish and 
exposed it, in the oven at 105°C for 52 hrs. Took, accurately weighed 25 mg  sample 
after thermal exposure in 10 mL volumetric flask. 5 to 6 mL diluent added and 
sonicated to dissolve the solid. Make up the volume with diluent and mixed well. 
Took 1 mL of this solution in 10 mL volumetric flask and diluted upto the mark with 
diluent and mixed well. The sample solution (10  L) was injected on an equilibrated 
chromatographic system.  
 
4.7.9 UV-light Degradation 
About 100 mg of pioglitazone hydrochloride spreaded in the pettri dish and 
exposed it, under UV-light for 52 hrs. Took, accurately weighed 25 mg  sample after 
UV-light exposure in 10 mL volumetric flask. 5 to 6 mL diluent added and sonicated 
to dissolve the solid. Make up the volume with diluent and mixed well. Took 1 mL of 
this solution in 10 mL volumetric flask and diluted upto the mark with diluent and 
mixed well. The sample solution (10  L) was injected on an equilibrated 
chromatographic system.  
 
4.8 Scale-up of Degradation of Pioglitazone Hydrochloride 
4.8.1 Experiment - 1  
Accurately, weighed 10g of NaOH in beaker and dissolved it in 25 mL of 
water, sonicated to dissolve. Took 1.5 g, pioglitazone hydrochloride in 150 mL RBF 
and then, transferred solution of NaOH from beaker to RBF and mixed well. The RBF 
was heated at 100° C and 50 rpm for 2 hours. The reaction solution was allowed to 
cool at room temperature and approximately neutralized with HCl. To get clear 
solution, it was sonicated and mixed well using vortex. The reaction solution was 
subjected to HPLC analysis to check extend of degradation and HPLC profile.  
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4.8.2 Experiment - 2 
About 750 mg of pioglitazone hydrochloride was weighed and transferred into 
a 150 mL RBF. 25 mL of 5N NaOH was added to it and the solution was heated at 
75° C and 50 rpm on water bath for 2 hours. The reaction solution was allowed to 
cool at room temperature and approximately neutralized it using 5N HCl.  To get 
clear solution, it was sonicated and mixed well using vortex. The reaction solution 
was subjected to HPLC analysis to check extend of degradation and HPLC profile.  
 
4.9 Isolation of Degradation Products 
4.9.1 Preparative HPLC Method Parameters 
Elution              : Gradient 
Column   : Modcol, (250X50mm) Self packed column, Vydac Make 
Media used  : ODS-AQ, 10 m, 120A, YMC, Make 
Wave length  : 225 nm 
Column  temp. : Ambient Temperature 
Flow rate  : 70.0 mL / min.  
Injection volume : 5 mL 
Mobile phase  : A : 0.05 % TFA in water 
  B: Acetonitrile  
Gradient Program : 
Time (minutes) 0.05 % TFA in Water Acetonitrile 
0 78 22 
4 78 22 
30 50 50 
35 10 90 
40 10 90 
41 78 22 
45 78 22 
 
4.9.2 Procedure 
The reaction mixture obtained from scale-up experiments of base degradation 
was filtered through 0.45  m filter and 5 mL of this solution was injected manually in 
equilibrated preparation HPLC system. The run was monitored using Class-VP 
software and desired peak was collected manually in different fractions for both the 
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degradation product. The collected fractions were subjected to HPLC analysis. The 
procedure was repeated to purify remaining reaction mixture to isolate both 
degradation products.    
The HPLC analysis of the collected fractions was used to segregate fractions 
as per its purity. The fractions of less than 98 % purity was mixed and re-injected 
through pump in preparative HPLC system to get desire purity level. Again, collected 
fractions were monitored in analytical HPLC system. Finally, all the fractions with 
more than 98.0 % purity were mixed and concentrated using rotavapor. Concentrated 
fractions were subjected to freeze drying, to get purified material of both the 
degradation products. 
 
4.10 Characterization of Degradation Products 
The isolated materials using preparative HPLC were characterized by 
spectroscopic techniques such as, Mass, IR, UV and NMR (1H, 13C, DEPT).  
 
4.10.1 Mass Spectrometry 
The isolated compound was dissolved (about 100 ppm) in methanol and 
injected (2  L) through liquid chromatography flowed flow with methanol-water 
(90:10, v/v) at a flow rate 0.3 mL/min. The mass was operated in positive spary 
ionization (ESI+) mode with capillary voltage 3.5 KV, cone voltage 20V, source 
temperature 120°C, desolvation  temperature 400°C and   desolvation gas flow 
800L/hr. 
 
4.10.2 Infra-red Spectrocopy 
The IR spectra were recorded in chloroform in the region 4000 cm–1 to 400 
cm-1. The operated parameters are; Numbers of scan:20, Resolution:4, Beam: internal, 
Mirror speed: 2.8 and Gain: auto. 
 
4.10.3 Nuclear Magnetic Resonance 
1H (300 MHz) and 13C (300 MHz) NMR spectra of isolated degradation 
products were recorded on an Avance DPX- 300MHz spectrometer Bruker 
(Germany). The probe was a 5 mm BBO z-gradient probe, optimized for inverse 
detection. Spectra were recorded in deuteriated  DMSO (5-mm tubes) at 300 K. 
Sample concentration was 10 mg in 0.5 ml. The residual protonated resonance of the 
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solvent (DMSO-d6) was used as an internal chemical shift standard, which was 
related to tetramethylsilane with chemical shifts of 2.5 and 39.5 ppm, respectively, for 
1H and 13C. Processing of the raw data was performed using Bruker XWin 3.5 Nmr 
software. The pulse conditions were 9.8µs (attenuation 0db) for 1H and 7.10µs 
(attenuation -1.0db) for 13C.  
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5. Result and Discussion 
 
As, we have discussed in preceding sections that forced degradation of the 
pioglitazone hydrochloride was attempted as a part of specificity study or to evaluate 
stability indicating power of the analytical method in literature. Here, our goal of the 
study was to isolate and characterize the degradation products of the pioglitazone 
hydrochloride under basic conditions. Therefore, we have adopted recently published 
HPLC method [36] for the study and the forced degradation of the pioglitazone 
hydrochloride was carried out at analytical scale for five different stress conditions. 
The stress condition and level of stress was increased, than the reported in the 
literature for better understanding of the degradation in different conditions. 
The degradation procedure was scaled up for the isolation of degradants. The 
major degradation product was isolated using preparative HPLC and characterized by 
spectroscopic techniques. 
 
5.1 Result of Forced Degradation  
The sample of pioglitazone hydrochloride was prepared at analyte 
concentration in diluent and analyzed using HPLC method before exposure. The 
chromatogram of untreated sample is shown in Fig. 1. The purity of the sample was 
found 99.74 %.  
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  Fig. 1: Chromatogram of pioglitazone hydrochloride sample (untreated) 
 
The pioglitazone hydrochloride was forced to degrade by acid and base 
hydrolysis, peroxide oxidation, heat exposure and UV-light exposure. The analysis of 
the degradation samples was done by HPLC to compare chromatographic profile with 
untreated sample and to understand degradation. 
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5.1.1 Acid Degradation 
The pioglitazone hydrochloride was treated with 5N HCl, as described in 
‘experimental section’ and subjected to HPLC analysis. The chromatogram of the 
sample treated by acid is shown in Fig. 2. The purity of the sample after acid 
degradation was found 99.76 %, which was equal to the untreated sample and there 
was no new peak observed in the chromatogram. Therefore, it can be concluded that 
pioglitazone hydrochloride is not degraded under acidic stress condition. 
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   Fig. 2: Chromatogram of acid degradation 
 
5.1.2 Base Degradation 
The pioglitazone hydrochloride was treated with 5N NaOH, as described in 
‘experimental section’ and subjected to HPLC analysis. The chromatogram of the 
sample treated by base is shown in Fig. 3.  
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   Fig. 3: Chromatogram of base degradation 
 
 It can be seen from the Fig. 3 that many new impurities are formed by base 
degradation of pioglitazone hydrochloride. There was significant degradation under 
base treatment. The purity of the sample was found only 32.1 %. The two major 
degradation products were observed, at retention time 8.24 (RRT:1.04) and 8.93 
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(RRT:1.12) minutes with 55% and 11% a/a contribution respectively. It has also been 
observed that if sample was treated under exhaustive base degradation condition, i. e. 
100°C for 2 hours then only first degradation product (RRT: 1.04) was formed 
(Chromatogram: Fig. 4). 
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   Fig. 4: Chromatogram of base degradation with harder condition 
 
5.1.3 Peroxide Degradation 
The pioglitazone hydrochloride was treated with 5% H2O2 (Hydrogen 
Peroxide) in water, as described in ‘experimental section’ and subjected to HPLC 
analysis. The chromatogram of the sample treated by hydrogen peroxide is shown in 
Fig. 5.  
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   Fig. 5: Chromatogram of peroxide degradation  
 
It can be seen from Fig. 5 that very mild degradation is observed under 
perxode treatment. The new impurities formed are in the range of less than 0.5 % a/a 
by area-normalized method. The purity of the sample after peroxide degradation was 
found 98.58 %. The major peak observed at retention time 1.54 minutes was found in 
the diluent containing same concentration of hydrogen peroxide. Therefore, it has not 
been integrated in the chromatogram. 
  Part-B Section-II 
222 
5.1.4 Thermal Degradation 
The pioglitazone hydrochloride was exposed at 105° C for 52 hours, as 
described in ‘experimental section’ and subjected to HPLC analysis. The 
chromatogram of the sample treated by heat for thermal decomposition is shown in 
Fig. 6. The purity of the sample after thermal degradation was found 99.75 %, which 
was equal to the untreated sample and there was no new peak observed in the 
chromatogram. Therefore, it can be concluded that pioglitazone hydrochloride is not 
degraded under thermal stress condition. 
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   Fig. 6: Chromatogram of thermal degradation 
 
5.1.5 UV-light Degradation 
The pioglitazone hydrochloride was exposed under UV-light for 52 hours, as 
described in ‘experimental section’ and subjected to HPLC analysis. The 
chromatogram of the sample treated by UV-light is shown in Fig. 7. The purity of the 
sample after UV-light degradation was found 99.73 %, which was equal to the 
untreated sample and there was no new peak observed in the chromatogram. 
Therefore, it can be concluded that pioglitazone hydrochloride is not degraded under 
UV-light stress condition. 
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   Fig. 7: Chromatogram of UV-light degradation 
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 It can be seen from above degradation studies that the major degradation was 
observed only in base treatment while all other tested stress conditions were not 
shown major degradation of pioglitazone hydrochloride. The peroxide oxidation 
showed very mild degradation. 
  To study the effect of physical forces and to confirm the role of degrading 
agent, the experiment was conducted using same experimental procedure and 
conditions in absence of degrading agent, i.e. HCl, NaOH, H2O2.  The chromatogram 
is presented in Fig. 8. The purity of the sample was found 99.78 %, which was equal 
to the untreated sample and there was no new peak observed in the chromatogram. 
Therefore, it can be concluded that only physical forces do not degrade pioglitazone 
hydrochloride in absence of degrading agent. 
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   Fig. 8: Chromatogram of degradation without degrading agent 
 
The major degradation product, observed in base degradation study was at 
RRT 1.04, which is same as reported by T. Thilak kumar et al. [36]. The author has 
not referred anything about second degradation product at RRT 1.12. He has also not 
characterized degradation product. Since, the pioglitazone hydrochloride mainly 
degrades under base treatment and forms two major degradation products. Therefore, 
we have focused only in base degradation and targeted to isolate and characterize two 
major degradation products observed at RRT 1.04 and 1.12.     
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5.2 Scale-up of Base Degradation 
 In order to isolate degradation product by preparative HPLC, the base 
degradation was scaled up from milligram to gram level. The scale-up experiment-1, 
as described in ‘experimental section’ showed that pioglitazone hydrochloride was 
almost degraded and converted in the 95 % degradation product-1 (RRT:1.04). The 
producr-2 was not formed. The chromatogram of experiment-1 is shown in Fig. 9. 
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    Fig. 9: Chromatogram of scale-up experiment-1 for base degradation. 
  
 To get degradation product-2, scale-up experiment-2 was planned as described 
in ‘experimental section’ using mild condition than the experiment-1. The HPLC 
chromatogram of the experiment-2 of scale reaction is shown in Fig. 10.  
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  Fig. 10: Chromatogram of scale-up experiment-2 for base degradation 
 
 It can be seen from the Fig. 10 that both the desired degradation products were 
formed. The area contribution of the degradation product-1 and degradation product-2 
in the chromatogram was 81.7% and 13.5 % respectively while un-reacted 
pioglitazone remained 4.5 %. The both reaction mixture was subjected to preparative 
isolation. 
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 5.3 Preparative HPLC Isolation 
The degradation products present in reaction mixture obtained from scale-up 
experiments was isolated by preparative HPLC. The fractions collected manually at 
five different points of the peak and purity was checked by analytical HPLC. It has 
been observed that fraction collected at the apex of peak was pure more than 98 %, 
for degradation product-1 and 99 % for degradation product-2 rest all fractions were 
below 98 % purity. The typical chromatogram of preparative HPLC separation of 
degradation products is shown in Fig. 11. 
 
Fig. 11: Chromatogram of preparative HPLC separation  
 
All the fractions below 98 % purity were mixed and re-injected for the further 
purification. The peak was collected in three parts and its purity was checked by 
analytical HPLC. The purity of all the three factions was found more than 98 % for 
degradation product-1 and 99 % for degradation product-2. To get purified material, 
fractions were concentrated and then lyophilized using lyophilizer. After three days 
drying cycle, sticky semi solid material was observed for both the degradation 
products. The purity of the purified materials was check by analytical HPLC. The 
HPLC chromatograms of isolated degradation product-1 and 2 are shown in Fig. 12 
and 13, respectively. The purity of degradation product-1 was 98.1 % and  
degradation product-2 was 99.2 %. These materials were subjected to complete 
characterization by spectroscopic techniques. 
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   Fig. 12: HPLC Chromatogram of isolated degradation product-1 (98.1 %) 
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  Fig. 13: HPLC Chromatogram of isolated degradation product-2 (99.2 %) 
 
5.3 Characterization of Degradation Products 
 
The isolated degradation products and pioglitazone were subjected to 
complete identification and characterization. The retention time and UV spectrum 
obtained in the PDA detection during HPLC analysis was matched with degradation 
products intended to isolate for characterization.  
The mass spectra obtained for Pioglitazone, Degradation Product-1 and 
Degradation Product-2 are shown in Fig. 14, 15 and 16 respectively. The mass 
spectrum, in positive ESI mode was confirmed molecular weight. 
The presence of the different functional group was confirmed by IR 
spectroscopy. The IR bands observed at different wave number are presented in Table 
1. The IR spectra obtained for Pioglitazone, Degradation Product-1 and Degradation 
Product-2 are shown in Fig. 17, 18 and 19 respectively. 
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 Fig. 14: Mass spectrum of Pioglitazone 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 15: Mass spectrum of Degradation Product-1 
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 Fig. 16: Mass spectrum of Degradation Product-2 
 
Table 1: IR bands of at different wave number 
Wave number (cm-1) 
Pioglitazone Degradation Product-1 Degradation Product-2 
3084, 2928, 1744, 
1685, 1508, 1460, 
1313, 1244, 1150 
3414, 3019, 1678, 1521, 
1433, 1384, 1215, 1141 
3416, 3021, 1686, 1512, 
1385, 1215 
 
 
 
 
 
 
 
Degradation Product-2
m/z
200 225 250 27
5
300 325 350 375 400 425 450 475 500 525 550 57
5
600 625 650 675 700 725 750 775 80
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   331.2
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430.96413.35 659.35528.14495.69446.97 571.31580.5
1
631.42
662.2
7
663.25
683.31 705.39
727.20 793.93779.58 814.00
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  Fig. 17: IR spectrum of Pioglitazone 
 
 Fig. 18: Mass spectrum of Degradation Product-1 
 
  Fig. 19: Mass spectrum of Degradation Product-2 
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The widely used and acceptable technique for the structure elucidation and 
confirmation is NMR. The NMR spectra was obtained using 300 MHz instrument for 
1H, 13C and DEPT in deuteriated dimethyl sulphoxide. The peak observed in 1H and 
13C NMR are complied in Table 2 and 3 for Pioglitazone, Table 4 and 5 for 
Degradation Product-1 and Table 6 and 7 for Degradation Product-2 respectively.  
1H-NMR spectra of Degradation Product-1, Degradation Product-2 and 
Pioglitazone are almost comparable for proton position no. 3, 4, 6, 7, 8, 9, 10, 12, 13, 
15, 16 and 17 while, proton at position 18 (-CH) showed multiple signal at 4.87-4.83 
δ ppm in Pioglitazone. The same proton (18) shielded at 3.72-3.51 δ ppm (m) in 
Degradation Product-1 and at 3.72 δ ppm (t) in Degradation Product-2. Therefore, the 
structure of degradation products should be very similar to pioglitazone without 
thiazolidinedione ring.    
13C-NMR spectra of degradation products clearly revealed that there is one 
quaternary carbon less than Pioglitazone, based on preceding discussion on 1H-NMR, 
quaternary carbon might be lost from thiazolidinedione ring i. e. carbonyl group. It is 
also noticed that methylene carbon at position -17 is deshielded to the extend of ~ 4.0 
δ ppm in Degradation Product-1 while methine carbon at position-18 is shielded to the 
extend of ~13 δ ppm, which indicates that electronegativity of the neighboring atoms 
are differed than the pioglitazone, the similar effect is not observed in Degradation 
Product-2. The mass spectrum of Degradation Product-2 showed molecular ion  peak 
at almost double m/z value than the base peak, as well as molecular ion peak of 
Degradation Product-1. Therefore, mass result and 13C NMR observation revealed 
that Degradation product-2 may be dimer of Degradation Product-1. It is also 
supported by chemical evidences.               
The NMR spectra of Pioglitazone for 1H, 13C and DEPT are shown in Fig. 20, 
21 and 22 respectively. The NMR spectra of Degradation Product-1 for 1H, 13C, 
DEPT and HMQC are shown in 23, 24, 25 and 26 respectively. The NMR spectra of 
Degradation Product-2 for 1H, 13C, DEPT and HMQC are shown in 27, 28, 29 and 30 
respectively. 
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Pioglitazone 
N
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8
9
10
11
13
14
15
16
17
18
19
20
21
12
 
 
       Table 2: 1H-NMR of Pioglitazone 
Chemical Shift (  ppm) Proton No. 
12.06 (bs, 1H, NH) 20 
8.70 (d, J=1.23 Hz, 1H, ArH) 6 
8.41 (dd, J=1.65 & 8.28 Hz, 1H, ArH) 4 
7.98 (d, J=8.25 Hz, 1H, ArH) 3 
7.39(d, J=7.92 Hz, 2H, ArH) 12, 16 
7.13(d, J=8.55 Hz, 2H, ArH) 13, 15 
4.87 – 4.83 (m, 1H, CH) 18 
4.40 (t, 2H, CH2) 10 
3.52 (t, 2H, CH2) 9 
3.31 – 3.00 (q, 2H, CH2) 17 
2.77 (q, 2H, CH2) 7 
1.21 (t, 3H, CH3) 8 
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     Table 3: 13C-NMR of Pioglitazone 
Chemical Shift (  ppm) Nature of Carbon Assignment 
175.61, 171.58 
Quaternary 
19, 21 
156.97, 151.05 2, 11 
141.31 5 
129.48 14 
145.22 
Tertiary 
6 
139.90 4 
130.36 12, 16 
127.15 3 
114.41 13, 15 
52.90 18 
65.42 
Secondary 
10 
36.19, 32.12 17, 9 
24.55 7 
14.53 Primary 8 
 
 
 
 Fig. 20: 1H-NMR spectrum of Pioglitazone 
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Fig. 21: 13C-NMR spectrum of Pioglitazone 
 
 
Fig. 22: 13C-DEPT spectrum of Pioglitazone 
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Degradation Product-1 
1
2
3
4
5
6
7
8
9
10
11
13
14
15
16
17
18 19
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21
12N
H3C
O
SH
NH2
O
 
       Table 3: 1H-NMR of Degradation Product-1 
Chemical Shift (  ppm) Proton No. 
8.63 (s, 1H, ArH) 6 
8.17 (d, J=8.04 Hz, 1H, ArH) 4 
7.78 (d, J=8.1 Hz, 1H, ArH) 3 
7.10 (d, J=8.5 Hz, 2H, ArH) 12, 16 
6.80 (d, J=8.5 Hz, 2H, ArH) 13, 15 
4.31 (t, 2H, CH2) 10 
3.72 – 3.51 (m, 1H, CH) 18 
3.35 (t, 2H, CH2) 9 
3.06 – 2.94 (m, 2H, CH2) 17 
2.70 (q, 2H, CH2) 7 
1.18 (t, 3H, CH3) 8 
 
 
Fig. 23: 1H-NMR spectrum of Degradation Product-1 
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        Table 4: 13C-NMR of Degradation Product-1 
Chemical Shift (  ppm) Nature of Carbon Assignment 
173.90 
Quaternary 
19 
157.00, 152.72 2, 11 
140.26 5 
130.90 14 
142.96, 142.67 
Tertiary 
6, 4 
130.30, 126.29 13, 15, 3 
114.46 12, 16 
42.00 18 
65.94 
Secondary 
10 
40.41 17 
33.80 9 
24.88 7 
14.83 Primary 8 
 
 
Fig. 24: 13C-NMR spectrum of Degradation Product-1 
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Fig. 25: 13C-DEPT spectrum of Degradation Product-1 
 
Fig. 26: HMQC spectrum of Degradation Product-1 
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Degradation Product-2 
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        Table 5: 1H-NMR of Degradation Product-2 
Chemical Shift (  ppm) Proton No. 
8.63 (s, 1H, ArH) 6 
8.19 (d, J=6.9 Hz, 1H, ArH) 4 
7.79 (d, J=8.2 Hz, 1H, ArH) 3 
7.09 (d, J=7.9 Hz, 2H, ArH) 12, 16 
6.81 (d, J=8.3 Hz, 2H, ArH) 13, 15 
4.32 (t, 2H, CH2) 10 
3.72 (t, 1H, CH) 18 
3.35 (t, 2H, CH2) 9 
3.04 – 2.95 (m, 2H, CH2) 17 
2.72 (q, 2H, CH2) 7 
1.20 (t, 3H, CH3) 8 
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Fig. 27: 1H-NMR spectrum of Degradation Product-2 
 
 Table 6: 13C-NMR of Degradation Product-2 
Chemical Shift (  ppm) Nature of Carbon Assignment 
172.04, 171.96 
Quaternary 
19 
156.92, 152.54 2, 11 
140.23 5 
130.02 14 
143.07, 142.48 
Tertiary 
6, 4 
130.22 13, 15 
126.13 3 
114.41 12, 16 
53.84 18 
65.82 
Secondary 
10 
35.96 17 
33.66 9 
24.78 7 
14.82 Primary 8 
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Fig. 28: 13C-NMR spectrum of Degradation Product-2 
 
 
Fig. 29: 13C-DEPT spectrum of Degradation Product-2 
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Fig. 30: HMQC spectrum of Degradation Product-2 
 
Form above spectroscopic data of Mass, IR and NMR (1H, 13C, DEPT and 
HMQC) confirmed the structure of both the degradation products and the values of 
spectroscopic data are in total agreement with assigned chemical structure. The 
proposed structures of the degradation products are as below. 
 
 
N
H3C
O
SH
NH2
O  
Degradation Product-1 
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N
H3C
O
S
NH 2
O
N
H3C
O
S
NH 2
O
 
Degradation Product-2 
 
5.4 Proposed Mechanism of Degradation  
 The above assigned structure of both the degradation products is also 
supported by mechanistic possibility of probable degradation of pioglitazone under 
base treatment. The carbonyl group attached to sulphur in pioglitazone is more acidic, 
therefore anion of hydroxyl group will attach on that position and bond between 
sulphur and carbonyl group will break, during work-up carbon dioxide will remove 
and degradation product-1 will form. Additionally, there is obvious possibility of 
dimerization and formation of disulphite bond because of air oxidation. The probable 
mechanism is described below.  
N
H3C
O
S
O
NH2
N
CH3
O
S
H2N
O
N
H3C
O
SH
NH2
O
3-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)-2-
mercaptopropanamide
2,2'-disulfanediylbis(3-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)propanamide)
N
H3C
O
NH
S
O
O
N
H3C
O
N
O
O
S
O
H
H
Na
-CO2
NaOH
PIOGLITAZONE
OH
HCl
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5.5 Chemical Evidences for the Structure of Degradation Products 
The structure of degradation products were assigned by spectroscopic data and 
mechanistic possibility of the base degradation of pioglitazone. To support our 
hypothesis chemical evidence of formation of dimer is illustrated.  
 It is well known that ‘–S-H’ can be oxidize to ‘–S-S-’ by catalytic amount of 
iodine. Therefore, Degradation Product-1 can be converted in Degradation Product-2 
by small pinch of iodine. The chromatogram of the pioglitazone hydrochloride was 
taken for the study is shown in Fig. 31. The experiment was carried out by taking 200 
mg of pioglitazone in 10 mL 5N NaOH and heated for 1 hr at 90° C.  Extend of 
degradation was checked by HPLC. The chromatogram after base degradation is 
shown is Fig. 32. 
 
min0 2.5 5 7.5 10 12.5 15 17.5 20
mAU   
0
200
400
600
800
1000
1200
1400
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96
 
   Fig. 31: Chromatogram of Pioglitazone Hydrochloride (For Retention Time) 
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   Fig. 32: Chromatogram after base dedgradation 
 
 
 It can be seen from the Fir. 32 that Degradation Product-1 (RRT=1.04) was 
formed 87.5 %, Degradation Product-2 (RRT=1.12) formed 1.5 % and Pioglitazone 
remain 11 % by area normalization. The catalytic amount of iodine was added into 
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reaction mixture and stirred at room temperature for half an hour. Extend of formation 
of dimer was checked by HPLC. The chromatogram after addition of iodine is shown 
Fig. 33. 
 
min0 2.5 5 7.5 10 12.5 15 17.5 20
mAU   
0
200
400
600
800
 VWD1 A, Wavelength=225 nm (NOV1309\NOV13006.D)
 7
.6
85
 8
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27
 8
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54
 
   Fig. 33: Chromatogram after addition of iodine 
 
 It can be observed from the Fig. 33 that Degradation Product-2 increased very 
much (52 %) after addition of iodine while peak of Degradation Product-1 is almost 
disappear compare to Fig. 32. It can be concluded that Degradation Product-2 is a 
dimer form of Degradation Product-1.  
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6. Conclusion 
 
The study describes, the isolation and characterization of degradation products 
in Pioglitazone hydrochloride stress studies.  
Systemic degradation of the pioglitazone hydrochloride was studied in five 
different stress conditions (acid, base, peroxide, UV-light and thermal). The 
significant degradation was found in base treatment. Two major degradation products 
were formed at RRT 1.04 and 1.12.  
The condition of base degradation was scaled-up and reaction mixture was 
subjected to preparative HPLC isolation. The degradation products 1 and 2 were 
successfully isolated with HPLC purity greater than 98 %.  
Both degradation products along with pioglitazone was completely 
characterized by 1H, 13C-NMR and DEPT, IR, UV, Mass and HPLC. The 
spectroscopic arguments were advanced to support characterization. 
The mechanistic support for the proof of structure was also discussed, further 
support of structure was derived from the oxidative dimerization of R-S-H to R-S-S-
R. Additionally, under reductive conditions, the conversion of R-S-S-R to R-S-H was 
confirmed, which supports the existence of disulfide bridge in degradation product-
2.ity. The chemical conversion of degradation product-1 into 2 was studied for 
additional evidence.  
The proposed structure of the degradation products of pioglitazone under base 
treatment has been confirmed by spectroscopic, mechanistic and chemical evidence. 
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 FORMULAS 
 
 
Mean:           Sum of all Values 
 
              Number of Values 
 
 
Standard Deviation (SD ( )):   
 
 
 
 
 
 
 
 
 
 
Relative Standard Deviation (RSD ) [%]:              Standard Deviation x 100 
 
                 Mean 
 
  
 
Recovery:           Obtained (Recovered) value X 100 
 
                        True value (Added)  
 
 
 
 
Quantitation from Calibration Curve:           
      y - Intercept 
x = 
  Slope 
 
                                                   3.3   
Limit of Detection (LOD):          =    --------- 
                                                       S 
 
                                                   10   
Limit of Quantification (LOQ):   =    -------- 
                                                       S 
 
 
 LIST OF SYMBOLS AND ABBREVIATIONS 
 
conc : Concentration 
ppm : Parts Per Million 
g : gram 
mg : Milligram 
min : Minute 
mL : Milliliter 
N : Normality 
nm : Nanometer 
No : Number 
UV : Ultraviolet 
µg : Microgram 
µL : Microliter 
 m : Micrometer 
% : Percentage 
° C : Degree Centigrade 
r :  Correlation Coefficient 
  :  Greater Than or Equal to 
≤ :  Less Than or Equal to 
$ : Dollar  
AU : Absorbance Unit 
mAU : Milli Absorbance Unit 
6-MP : 6-Mercaptopurine 
ACN : Acetonitrile 
API : Active Pharmaceutical Ingredient 
Avg : Average 
CEC : Capillary Electrophoresis Chromatography    
cGMP : Current Good Manufacturing Practice 
EP : European Pharmacopoeia 
FDA : Food and Drug Administration 
H2O2 : Hydrogen Peroxide 
HCl : Hydrochloric acid 
HPLC : High Performance Liquid Chromatography 
 ICH : International Conference on Harmonisation 
IR : Infrared 
LOD : Limit Of Detection 
LOQ : Limit Of Quantitation 
MeOH : Methanol 
MS : Mass Spectroscopy 
NaOH : Sodium Hydroxide 
NCE : New Chemical Entity 
NLT : Not Less Than 
NMT : Not More Than 
NMR : Nuclear Magnetic Resonance 
ODS : Octa Decyl Silane 
PDA : Photo Diode Array 
RT : Retention Time 
RRT : Relative Retention Time 
RRF : Relative Response Factor 
RSD : Relative Standard Deviation 
SD : Standard Deviation 
SFC : Supercritical Fluid Chromatography 
TFA : Trifluoro Acetic acid 
TLC : Thin Layer Chromatography 
Temp :  Temperature 
UPLC : Ultra Performance Liquid Chromatography 
US : United State 
USP : United States Pharmacopoeia. 
UV : Ultra Violate 
WHO : World Health Organization 
 
